/Tailin Biotech: 2026 Semi-annual Report

NEWS

Tailin Biotech: 2026 Semi-annual Report

Shenzhen Stock Exchange

2026/08/27

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Zhejiang Tailin Biotechnology Co., Ltd. 2026 Semi-Annual Report 2026-063

[August 2026] Full text of Zhejiang Tailin Biotechnology Co., Ltd.’s 2026 Semi-annual Report

Section 1 Important Tips, Table of Contents and Definitions

The company's board of directors, directors and senior managers guarantee that the contents of the semi-annual report are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability.

The person in charge of the company, Ye Dalin, the person in charge of accounting work, Ye Xingyue, and the person in charge of the accounting department (accounting officer) Zhou Wenqin, declare that they guarantee the authenticity, accuracy and completeness of the financial report in this semi-annual report. All directors have attended the board meeting to review this semi-annual report.

The forward-looking descriptions of the company's future plans and development strategies included in this report do not constitute the company's substantive commitment to investors. Investors and related parties should maintain adequate risk awareness and understand the differences between plans, forecasts and commitments.

The company has described in detail the risks and countermeasures that may exist in the company's operations in the "10. Risks and Countermeasures Facing the Company" section of the third section of this report, "Management Discussion and Analysis". Investors are kindly requested to pay attention to the relevant content.

The company's profit distribution plan reviewed and approved by the board of directors is as follows: based on the total share capital on the equity registration date for equity distribution, a cash dividend of 1 yuan (including tax) will be distributed to all shareholders for every 10 shares, 0 bonus shares (including tax) will be given, and the reserve fund will not be converted into share capital.

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

1. Company Profile

Stock abbreviation Tailin Biotechnology Stock code 300813 Stock Exchange Shenzhen Stock Exchange

The Chinese name of the company: Zhejiang Tailin Biotechnology Co., Ltd.

The company’s Chinese abbreviation (if any) Tailin Biotechnology

The company’s foreign name (if any) ZHEJIANG TAILIN BIOENGINEERING CO.,LTD

The abbreviation of the company’s foreign name (such as

TAILIN BIOTECH

Yes)

The legal representative of the company Ye Dalin

2. Contact person and contact information

Secretary of the Board of Directors Name of securities affairs representative Ye Xingyue Ye Junjun Contact address No. 2930, Nanhuan Road, Binjiang District, Hangzhou City, Zhejiang Province No. 2930, Nanhuan Road, Binjiang District, Hangzhou City, Zhejiang Province Telephone 0571-86589069 0571-86589069 Fax 0571-86689998 0571-86689998 Email [email protected] [email protected]

3. Other situations

Company contact information

Whether the company's registered address, company office address and its postal code, company website, e-mail address, etc. have changed during the reporting period □Applicable Not applicable

The company's registered address, company office address and its postal code, company website, email address, etc. did not change during the reporting period. For details, please refer to the 2025 annual report.

Information disclosure and preparation location

Whether the location of information disclosure and preparation changes during the reporting period

□Applicable Not applicable

The name and URL of the stock exchange website and media where the company discloses its semi-annual report. The company's semi-annual report preparation location did not change during the reporting period. For details, please refer to the 2025 annual report.

Registration changes

Whether the registration status has changed during the reporting period

□Applicable Not applicable

The company's registration status did not change during the reporting period. For details, please refer to the 2025 annual report.

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

4. Main accounting data and financial indicators

Whether the company needs to retroactively adjust or restate previous years’ accounting data

□Yes No

This reporting period The same period last year This reporting period increased or decreased operating income compared with the same period last year (yuan) 165,382,315.28 145,825,607.20 13.41% Net profit attributable to shareholders of listed companies

20,372,823.69 13,542,949.18 50.43% profit (yuan)

Deductions attributable to shareholders of listed companies

Net profit from non-recurring gains and losses 18,252,035.87 13,203,834.73 38.23% (yuan)

Net cash flow from operating activities

21,100,569.48 3,120,686.35 576.15% (yuan)

Basic earnings per share (yuan/share) 0.17 0.11 54.55% Diluted earnings per share (yuan/share) 0.17 0.11 54.55% Weighted average return on equity 2.53% 1.66% 0.87%

End of the reporting period End of the previous year Increase or decrease in total assets at the end of the reporting period compared with the end of the previous year (yuan) 937,764,649.00 958,972,583.39 -2.21% Net assets attributable to shareholders of listed companies

790,725,145.80 804,291,427.29 -1.69% output (yuan)

5. Differences in accounting data under domestic and foreign accounting standards

Differences in net profit and net assets in financial reports disclosed in accordance with both international accounting standards and Chinese accounting standards

□Applicable Not applicable

During the reporting period, there was no difference between the net profit and net assets in the financial reports disclosed in accordance with international accounting standards and Chinese accounting standards.

Differences in net profit and net assets in financial reports disclosed in accordance with both foreign accounting standards and Chinese accounting standards

□Applicable Not applicable

During the reporting period, there was no difference between the net profit and net assets in the financial reports disclosed in accordance with foreign accounting standards and Chinese accounting standards.

6. Non-recurring profit and loss items and amounts

Applicable □Not applicable

Unit: Yuan

Item Amount Description

Gains and losses on disposal of non-current assets (including accrued

-176,221.92

Offset portion of asset impairment provision)

Government subsidies included in current profits and losses (related to the company’s regular

Closely related to regular business operations and in compliance with national policies

1,672,089.34

stipulates, enjoys according to determined standards, and treats the company

Except for government subsidies that have a lasting impact on profits and losses)

Gains and losses from entrusting others to invest or manage assets 961,433.11 Full text of the 2026 Semi-annual Report of Zhejiang Tailin Biotechnology Co., Ltd. "Income from Financial Management Products" in Note 5 (2) 8

Other non-operating income other than the above items and

-86,601.41 expenses

Less: Income tax impact 249,911.30 Total 2,120,787.82

Details of other profit and loss items that meet the definition of non-recurring profits and losses:

□Applicable Not applicable

The company has no other specific circumstances of profit and loss items that meet the definition of non-recurring profits and losses.

Explanation on defining the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Profit and Loss" as recurring profit and loss items

□Applicable Not applicable

The company does not define the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Profit and Loss" as recurring profit and loss items.

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Section 3 Management Discussion and Analysis

1. The main business of the company during the reporting period

The company’s industry status during the reporting period

The company belongs to the pharmaceutical special equipment manufacturing industry, which is a key area where the country actively promotes independent innovation and industrial upgrading. The company mainly focuses on the R&D, production and sales of special instruments and equipment and supporting consumables in this field. Such products play a vital role in new drug development, drug production and quality control, life science research and other fields. They are not only an indispensable part of the pharmaceutical industry, but also the key to technological progress and industrial upgrading of biotechnology and medical and health industries.

The technical level of life science instruments and equipment and pharmaceutical equipment plays an important role in promoting the development of the entire life and health industry chain, and is the cornerstone of the overall development of the pharmaceutical and life and health industries. With the rapid development of fields such as cell medicines, genetic medicines and new vaccines, the demand for related instruments and equipment has also increased. At the same time, new regulatory regulations and updates to pharmaceutical quality standards, such as the formal implementation of EU GMP Appendix I, will greatly promote the development of the instrument and equipment industry. The newly built and expanded vaccine, biopharmaceutical, and chemical production capacity has promoted investment in new equipment, increased industry concentration, and strengthened the research and development and exploration of integrated and automated equipment, thereby stimulating pharmaceutical companies' demand for new, renovated, and expanded facilities, while also increasing the demand for drug quality control and testing equipment. In addition, the development of innovative drugs such as monoclonal antibodies, cell and gene therapy drugs, and radionuclide conjugate drugs heralds the continued growth of investment in the pharmaceutical industry.

The company is a pioneer in the development, promotion and application of microbial detection and pollution control instruments and equipment in the life sciences and pharmaceutical fields, and its capabilities are at the forefront of the industry. In addition to the original product line, the company is actively engaged in the research and development of new products for life sciences and biomedical instruments and equipment, and has obtained a number of patents to further expand its product line. The company's main business is in line with the development direction of emerging industries currently supported by the country. Industry policies have played a positive role in promoting my country's biomedical equipment industry and the company's mid- and long-term business development, creating a good policy environment for the company and conducive to the company's sustainable development and innovation.

2.Main business

The company focuses on microbial detection, pollution control, process analysis and containment protection in the field of life sciences. It integrates R&D, production and sales to provide high-quality products and solutions for biomedicine, food and beverage, medical health, environmental protection and other industries.

3.Main products

The company's product lines are divided according to application categories, covering key technical fields such as microbial detection, contamination control, sterile production, and process analysis. These products are widely used in many important industries such as biopharmaceuticals, medical and health care, experimental animal research, food safety, water quality monitoring and environmental protection.

(1) Microbial detection technology product series

In response to the quality control and testing needs of downstream customers in the production process of pharmaceuticals, food, cosmetics and other fields, the company's microbial testing product line provides customers with a variety of equipment, instruments and consumables. The main application scenarios of products in this segment include: sterility inspection and microbial limit inspection involved in the R&D and production of biological or chemical drugs; food safety microbiological inspection in the food production process; environmental and water quality microbiological testing; cosmetic testing, etc. The current products mainly include sterility testing systems consisting of sterilizers, incubators (culture bottles), culture media, etc.; microbial limit testing systems consisting of homogenizers, microbial limit testers, filter cups, microporous membranes, petri dishes, etc.; microbial verification systems consisting of biological indicators, chemical indicator cards, quality control strains, resistance meters, etc. System; sample microbial sample pre-treatment system consisting of homogenizer, homogenization bag, homogenizer, barreled water sampler, gravimetric diluter, etc.; water ecological detection system consisting of enzyme substrate method detection system, enzyme substrate method intelligent culture counting system, fully automatic "two insects" detection system, etc.; and enzyme substrate method coliform detection system, etc.

The rapid microbial detection equipment, enzyme substrate method microbial detection system and other products developed by the company not only promote the advancement of industry technology, but also play an important role in realizing the automation and intelligence of microbial laboratories in the pharmaceutical industry.

The company has successfully developed a series of NC membrane products. As raw materials for the production of various in vitro diagnostic kits, it can be used in various in vitro diagnostics (such as early pregnancy, COVID-19, AIDS, hepatitis B, etc. detection), and can also be used in various separations, food quality monitoring, environmental monitoring, agriculture and animal husbandry, entry-exit inspection and quarantine, forensic finalization and other fields, such as drug testing, etc.

(2) Sterile production and pollution control equipment series

Using isolators as a technology platform, the company has developed a variety of integrable functional equipment around the GMP sterile production needs of biological, chemical and cell gene therapy drugs, as well as the pollution isolation and pathogenic bacteria disinfecting needs for different application scenarios such as cleanliness, toxicity suppression, biosafety and infection control. The company has formed the following product technology series:

① Sterile production equipment is aimed at the GMP sterile production needs of new drugs such as biology, chemistry and cell gene therapy. It provides customers with integrated equipment based on sterile isolators as the platform, mainly including the following types of products and solutions:

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Aseptic packaging equipment: Provides desktop filling, stoppering, capping and other equipment suitable for different packaging materials, as well as a fully automatic filling workstation using an aseptic isolator platform that integrates material feeding and conveying, aseptic high-precision filling, stoppering, capping and other process steps.

A fully enclosed cell preparation workstation composed of an isolator, functional components, and a honeycomb cell culture system: It realizes the integration of the entire preparation process steps from cell separation, purification, activation, transfection, amplification, observation to collection, etc., and provides strong technical support for the development and production of cell therapy products. The closed design of the system provides a sterile, stable and controlled environment for cell culture, which can significantly improve the quality and safety of cell products.

Live cell imager: used to observe important parameters such as cell morphology, number, and degree of fusion in real time during the culture of suspended cells and adherent cells. It can provide important information about cell growth, provide more powerful and flexible tools for cell biology research, and enable researchers to more accurately monitor and analyze cell characteristics.

Supporting functional equipment: mainly includes isolator-related supporting equipment such as glove integrity testers, rapid transfer devices (RTP) with different interface specifications, and environmental monitoring systems.

②Pollution control equipment

For different application scenarios such as cleanliness, toxicity containment, biosafety and infection control, we provide customers with pollution isolation and disinfection equipment that is suitable for the process. Sterile isolation equipment is mainly used in the R&D, production and inspection process of sterile drugs in the pharmaceutical industry, as well as key process operations such as sterile experimental animal breeding, experiments, and related material processing and transfer. The main products include sterile isolators, sterile transfer cabins, etc.; toxicity suppression is mainly used for the production, deployment, or storage of toxic and highly active drugs in the pharmaceutical industry. It provides barrier protection during the treatment of biosafety and infected pathogenic microorganisms. The main products are negative pressure isolators; environmental biological decontamination is mainly used for high-level disinfection of closed spaces such as clean workshops, biological safety cabinets, biosafety laboratories, medical places, and emergency vehicles. The main products include vaporized hydrogen peroxide generators, hydrogen peroxide atomizing disinfection machines, etc.

(3) Organic matter monitoring and analysis instrument series

A series of analytical instrument products are developed for applications such as organic matter analysis, seal integrity analysis, and gas concentration analysis in analytical laboratories such as pharmaceuticals and environmental protection. The main products of organic analysis include TOC analyzers for pharmaceutical water; solid combustion devices and biodegradation testing systems for solid organic sample detection and analysis. Seal integrity testing instruments mainly include vacuum/pressure decay testers; headspace oxygen analyzers; and filter integrity testers.

The company's main product series are as follows:

Serial number Main product or representative product Function and use

Microbial detection technology product series

It is mainly used for sterility inspection of each batch of injectable preparations. It is used in combination with an incubator to transfer the drugs or reagents to be inspected into the incubator in a non-contact manner through a closed pipeline under pressure to avoid contamination of test samples by environmental microorganisms.

It is mainly used for sterility inspection of injectable preparations or microbial limit inspection of oral and external preparations. It is a disposable consumable and is used to filter and intercept the microorganisms in the sample 2 bacteriological incubator and culture them in situ. It can greatly improve the sensitivity of sterility inspection and prevent contamination from external microorganisms.

Mainly used for microbial count inspection in medicines, food, and water. It is used in conjunction with microbial filter cups and filter membranes to filter the samples to be tested using negative pressure filtration.

Filter to collect microorganisms that may be present in the sample.

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Microporous filter membrane is a pressure-driven membrane separation technology product between coarse filtration and ultrafiltration. It uses microporous media to separate 4 microporous filter membrane components with a diameter of 0.05μm ~ 10μm. It is mainly used to remove micron particles, submicron particles and bacteria in samples.

The overall solution for testing total coliforms, fecal (heat-resistant) coliforms and Escherichia coli enzyme substrate method in water can quickly detect drinking water, source water, waste water, food water, surface water, groundwater, seawater, bottled water, secondary water supply system water, pipe network water, livestock water, medical water, etc.

The company's enzyme substrate method intelligent culture counting system can be used for environmental monitoring single enzyme substrate intelligent units, CDCs, water companies, sewage treatment plants, third-party testing machines 6 culture counting system, universities and scientific research institutes and other units that have system requirements for the detection of microorganisms in water using the enzyme substrate method.

The fully automatic two-worm detection system is mainly used for domestic drinking water and urban water supply.

Detection system

Determination of Giardia cysts and Cryptosporidium oocysts in source water.

Biological indicators are special live microorganisms with established and stable resistance to specific sterilization procedures.

8 Biological indicators can be used to confirm the performance of sterilization equipment, develop, establish and verify the sterilization process of specific items, monitor the sterilization effect of the production process, and can also be used to verify and evaluate the sterilization effect of isolation systems and sterile clean rooms.

Biological indicator resistance meter, used to test the resistance of pressure steam, hydrogen peroxide, and ethylene oxide sterilization biological indicators. It is suitable for the production of biological indicators for drugs and medical devices.

Resistance meter

Manufacturers, Food and Drug Administration, third-party inspection agencies and other fields. The data is authoritative and traceable, and can be observed to verify or determine the sterilization status in real time.

Quality control strains refer to microbial strains that have been specifically screened and identified and are stable, reproducible, standardized and representative. Its main function is for quality control and quality assurance, and it is widely used in pharmaceuticals, food, environment, medical and other fields.

10 quality control strains

The company's quality control strains can be customized according to customer needs, including strain type, bacterial content, etc., and we also provide trace strains that "satisfy the verification of rapid sterility inspection methods."

Sterile production and contamination control equipment series

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Mainly include sterile isolators and containment isolators.

Sterile isolators are mainly used for sterility testing, sub-packaging, sampling, freeze-drying, dispensing, etc. of pharmaceutical injections. They provide a closed sterile operating space for pharmaceutical production and testing operations. The integrated VHPS sterilizer purifies the air inside the cabin to prevent microbial contamination of sterile preparations by the external environment and operators. It can also use its own software system to automatically record operating data to achieve traceability of the pharmaceutical production and testing process.

Repressor isolators are mainly used in the development and production of highly active drugs.

Surface sterilization using VHP is used to transfer utensils, raw materials, etc. from low-level areas to high-level areas.

As a component of the sterile preparation production line, it is generally installed in the wall of the sterile preparation production workshop to construct an independent material channel for transferring production materials from the outside into the sterile preparation clean production workshop. It is generally equipped with a vaporized hydrogen peroxide low-temperature sterilization device, which can carry out microbial sterilization of transferred items and prevent external materials from contaminating the sterile preparation clean workshop.

Negative pressure controlled closed operating system, used for high activity, cytotoxicity

3 blocking isolator

The production process of sexual drugs (such as anti-tumor drugs) can reach the highest protection level of OEB5 for personnel and environmental protection.

The multi-functional cell processing workstation is a multi-functional work platform for in vitro cell processing. Based on the sterile isolator platform, it modularly integrates a variety of equipment required for cellular immunotherapy such as cell centrifuges, CO2 incubators, cell microscopes, constant-temperature metal baths, etc., to provide a continuously controlled multi-functional cell sterile operating environment for in vitro cell processing.

processing workstation

The multifunctional cell processing workstation does not require a B+A clean environment, reducing the construction and operation costs of high-level clean rooms. The workstation software system can not only record system control and environmental monitoring data in real time, but also record and store operation videos to realize data traceability of the entire production operation process.

The honeycomb culture system, based on modular design, can flexibly expand the culture space to meet the requirements of large-scale and different batches of cell culture.

The incubator provides a sterile constant temperature environment for cell culture and has functions such as recording the culture process time, temperature and humidity, and CO2 concentration.

hive culture system

The matching transfer vehicle can be used for multi-functional cell processing workstations and bee systems (transfer vehicles

The rapid docking between 5 nest incubators ensures the complete process from cell operation to culture + honeycomb culture

The process is kept in a sterile environment to prevent cross-contamination.

box)

The honeycomb incubator is equipped with a visual culture process monitoring system, which can monitor the culture data of each culture unit in real time and conduct batch management through monitoring. At the same time, the entire process of cell culture is recorded to achieve traceability of the entire process data.

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

The aseptic dispensing workstation for cells, plasmids, and viral plasmid vectors can be used for automated dispensing, stoppering, and capping of cells, plasmids, and viral vectors; it can meet the needs of aseptic dispensing workers.

work station

Product research and development in the biopharmaceutical and biological products industries and automated packaging of small batch, high-precision products in clinical phase I and phase II.

A vaporized hydrogen peroxide generator is a specialized device that flashes liquid hydrogen peroxide into vaporized hydrogen peroxide and diffuses it into the environment. Vaporized hydrogen peroxide is a broad-spectrum, efficient, safe, low-residue low-temperature disinfectant that can replace traditional disinfectants such as vaporized formaldehyde peroxide. It is mainly used to disinfect the internal spaces of clean room special hydrogen generators in sterile pharmaceutical companies, medical places, biosafety laboratories, and sterile pharmaceutical equipment, thereby controlling biological contamination in specific areas.

Portable and miniaturized design, intelligent operation, one-button start; wireless remote control, can be remotely controlled outside the disinfection space, easy to operate.

Disinfection principle: The equipment uses a micro air pump to provide high-pressure and high-speed air flow, and uses the Venturi effect to spray hydrogen peroxide mist through high-speed air flow and hydrogen peroxide solution through specific atomization.

8 The mouth produces hydrogen peroxide in a dry mist state. Dry mist state hydrogen peroxide rapid diffusion in chemical disinfection machine

In the environment, it can achieve good disinfection effect on the air and objects in the closed environment. It can be widely used in the disinfection of hospital wards, infectious diseases departments, operating rooms, diagnosis and treatment rooms, dressing rooms, negative pressure wards, fever clinics, ambulances, physical examination vehicles, blood donation vehicles, etc.

The fully automatic colony counting workstation is an intelligent workstation that integrates a constant temperature incubator and fully automatic colony counting and interpretation. The product independently develops a high-accuracy AI intelligent algorithm based on the dynamic growth of colonies, fully automatic colony morphology changes, and uses computer visual counting workstation and neural network algorithm technology to achieve batch plate culture and obtain accurate colony counting results.

The fully automatic sterility inspection and culture system is an intelligent instrument dedicated to drug sterility inspection. It consists of a constant temperature culture box, an automated detection unit, a culture container, and a microbial growth signal sensor. The principle is based on the CO2 produced by microbial respiration, which causes the color of the sensor on the culture container to change. Fully automatic sterility

10 Check the culture system

change, the device’s vision camera continuously scans the sensor image and the corresponding 2D

system

The code is visually analyzed by the computer system and converted into a growth signal, and the sterility inspection results are judged based on the change trend analysis and a dedicated algorithm. It is mainly used in rapid sterility inspection of biopharmaceutical production, cell drug quality control, vaccine production, scientific research and service institutions, and can also be used for traditional chemical drug quality control.

Mainly used for packaging integrity testing of sterile injection drugs, mainly used for integrity testing during product development or production process change stages, technical bacterial intrusion testing

test instrument

The method is mainly a microbial challenge method, using high-concentration bacterial suspension as invading microorganisms to evaluate the sterility ability of drug packaging to ensure the drug.

Organic matter monitoring and analysis instrument series

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

It is mainly used for the detection and analysis of pharmaceutical water for sterile preparations. It can be installed at the water inlet of pharmaceutical water in the production line to monitor the water quality online in real time. It can also be used independently in the laboratory to conduct offline sampling analysis of the water quality of pharmaceutical water.

1 TOC analyzer

It can also be widely used in water quality analysis and testing of electronic-grade process water in the chip industry, new energy electrolyte, nuclear power steam water supply, drinking water, environmentally friendly sewage, and chemical process water.

It is mainly used to detect and analyze organic matter in samples from environmental sludge, soil improvement, plastic organic matter content, etc.

Solid combustion device

set

It is mainly used to detect and analyze the biodegradability of materials. It is oriented to the research and development and application fields of new bio-based materials. It serves scientific research institutions of various bio-based new materials, provincial quality supervision and inspection agencies, and laboratories of third-party testing agencies to analyze the biodegradability of various materials.

Biodegradation test

Test system

The principle of pressure change sensor is used to detect product leakage and quality defects.

It is mainly used to detect and analyze the sealing integrity of pharmaceutical packaging. It can perform non-destructive and high-precision vacuum/pressure on pharmaceutical packaging in production workshops and laboratories.

Attenuation tester

, fast offline detection of sealing.

The principle of gas optical spectrum sensor is used to detect changes in target gas concentration in the headspace of product packaging and find quality defects.

Headspace oxygen analysis is mainly used to detect and analyze the sealing integrity of pharmaceutical packaging. It can conduct non-destructive, high-precision and rapid sealing offline testing of pharmaceutical packaging in production workshops and laboratories.

Use the principle of pressure sensor to detect the integrity performance of the filter.

Mainly used in the pharmaceutical industry, it can detect and analyze the integrity of sterilizing filters online, offline, in production workshops and filter integrity laboratories.

sex tester

Tailin spectroscopy technology is used to detect the presence, concentration and other information of the gas through the absorption of specific wavelength laser by hydrogen peroxide gas molecules.

Hydrogen peroxide

Laser hydrogen peroxide gas analysis technology is characterized by its high precision, high sensitivity and 7-body concentration analysis.

The characteristics of non-contact measurement are playing an increasingly important role in many fields.

Use. It is widely used in fields such as biological decontamination in pharmaceutical manufacturing, aseptic filling of food and beverages, and rapid sterilization of medical devices.

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Tailin spectroscopy technology is used to detect the presence, concentration and other information of the gas through the absorption of specific wavelength laser by water gas molecules.

Water gas concentration is widely used in moisture content monitoring in new energy battery manufacturing, water gas control in petrochemical analyzers, and moisture content monitoring in the pharmaceutical and food industry.

Tailin spectroscopy technology is used to detect the presence, concentration and other information of the gas through the absorption of specific wavelength laser by carbon dioxide gas molecules. Widely used in the field of carbon emission control, such as carbon dioxide gas in industrial production

Carbon emission monitoring, monitoring of carbon dioxide in the fermentation process of bio-based materials, energy concentration sensing

Carbon dioxide monitoring of energy recovery systems in the chemical industry.

device

4.Business model

The company adopts a business model integrating R&D, procurement, production and sales. It has established a standard, efficient and sustainable R&D system, which is market-oriented and develops products and solutions that meet market needs. At the same time, it has established a relatively stable customer group through its own marketing system and provided relevant professional services. (1) R&D model

In order to maintain the company's continuous R&D capabilities, the company has established a multi-level, multi-directional R&D institution. The company established Tailin Research Institute to be mainly responsible for the research and development of cutting-edge technologies, and established an experimental testing center covering physical and chemical, microbiological, and electrical safety. The center not only provides routine performance testing of products, but also provides pre-sales testing and after-sales technical testing and analysis for customer samples, playing an active role in product production improvement and customer service. At the same time, based on the research and development, production and sales management needs of various series of products, the company has established life science R&D centers, medical engineering R&D centers, analytical instrument R&D centers and other R&D departments to undertake the R&D work of related product series. In addition, the company has carried out technical cooperation with well-known domestic scientific research institutions, universities and related enterprises such as the Academy of Military Medical Sciences of the Chinese People's Liberation Army, China Institute of Food and Drug Control, Jiangsu Provincial Center for Disease Control and Prevention, Zhejiang University, Hangzhou University of Dianzi Science and Technology, Zhejiang Institute of Metrology, Zhengda Qingchunbao Pharmaceutical Co., Ltd., and leads the technological development of the industry.

(2) Sales model

In terms of sales management, the company fully applies the CRM system. Employees complete the entry of pre-sales and after-sales matters through the CRM system, execute the five major links of arrangement, implementation, reporting, inspection, and evaluation, and incorporate all customers into the CRM system to create a standardized and refined sales management model.

The company's products are mainly sold directly. At the same time, in order to expand sales channels and increase product market share, the company also sells its products to some intermediaries who obtain orders from end users or traders of pharmaceutical machinery and medical products in regional markets.

(3) Production mode

The various series of products produced by the company can be divided into two types: standardized products and customized products. According to the product characteristics, the company has adopted two different production models: stock production and sales-based production, as follows:

Product Category Product Features Production Model Specific Products

Standardized products: The company produces products of fixed specifications and models, and customers purchase products of fixed specifications and models based on product clearance and production of incubators, bacteriometers, microbial testers, and TOC analysis sheets. instrument, sampler, glove integrity tester, solid combustion device, biodegradation analysis system, live cell imager, fully automatic colony counting workstation, etc.

Customized products: According to the specific needs of customers, the appearance, production of sterile isolators, sterile transfer chambers, VHPS sterilizers, cell functions, structures, components and technical parameters of relevant instruments and equipment are specifically designed according to sales. Integrated equipment for the production of cells and gene therapy drugs, etc. Planning and assembly production.

Among standardized products, incubators are disposable consumable products. After making reasonable sales forecasts, the company determines the production plan based on the quantity of inventory goods and products in progress, and maintains a certain safety stock to prepare for customer emergency needs. For other standardized instruments, the company will formulate production plans based on reasonable forecasts of market sales, and timely adjust the production plans based on the actual production progress, inventory volume, and availability of assembly materials in each production workshop.

For customized products such as isolators, sterile transfer chambers, VHPS sterilizers and cell culture equipment, the company organizes production according to customer orders.

(4) Procurement model

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

The company's external procurement of raw materials mainly includes injection molding raw materials, structural parts, electronic components, functional parts, and auxiliary materials. The domestic industry support for related raw materials is complete and the market supply is sufficient. The company purchases according to market prices. The specific procurement models for various types of raw materials are as follows:

Injection molding raw materials: The procurement of injection molding raw materials is mainly based on regular orders. Based on the supplier list, the company selects several suppliers from the list for price inquiry before each order is placed. At the same time, the company arranges specialized personnel to regularly check the real-time price of China Plastics.com, and determines a reasonable current price after a step-by-step review by the company's management.

Structural parts: The company purchases many types of structural parts, which can be divided into conventional structural parts and customized structural parts. Among them, conventional structural parts are general-purpose parts with sufficient supply and convenient procurement; customized structural parts need to be specially customized by suppliers according to the company's design. At the same time, the customized structural parts purchased by the company include some core components independently developed by the company. If such core components are customized externally, suppliers with long-term strategic cooperation relationships with the company will be selected and a "Core Supplier Credit Commitment Letter" will be signed with them to ensure the confidentiality and security of the company's core technology.

Functional components and electronic components: At present, most of the functional components and electronic components purchased by the company are conventional models, mass-produced by professional manufacturers, and the supply is sufficient.

Excipients: At present, the excipients required for the company's production are basically conventional materials and are easier to purchase. For bulk excipients, the company will select at least two suppliers for price inquiry and price comparison to determine the appropriate purchase price for the current period. Some of the auxiliary materials purchased by the company are not only used for production but are also sold externally.

2. Analysis of core competitiveness

Advantages of technology research and development and product innovation

The company has a provincial-level high-tech enterprise R&D center. From the Tailin Research Institute and Experimental Testing Center at the headquarters to the independent R&D departments of each subsidiary, the company has established a multi-level R&D organizational structure. It adheres to the concept of technological innovation-driven product development, builds technical barriers based on industry standards and regulations, and invests relevant talents and technical resources around customer needs to promote the continuous extension of the company's product line and the continuous improvement of product series. The company's main wholly-owned subsidiaries, Tailin Life Sciences, Tailin Medical Engineering, and Tailin Analytical Instruments, are all national-level high-tech enterprises, and all have provincial-level enterprise R&D institutions.

The company's key technical personnel are stable, and more than 50% of the company's R&D team has a bachelor's degree or above. They have deep professional backgrounds and rich practical and R&D experience covering machinery, electronics, chemical engineering, microbiology, biotechnology, pharmaceutical engineering, medical testing, cell therapy and other fields. An influential technical R&D team has been formed in the field of domestic microbial detection and control technology and equipment. Based on a deep and accurate understanding and grasp of industry development, product technology trends and downstream customer needs, it provides strong technical support for the continuous upgrading and innovation of products. The company continues to invest more than 10% of sales revenue into technology research and new product development every year. After years of systematic technical research and product development, as of the end of the reporting period, the company had reserved 472 technology patents, including 70 invention patents, owned 90 software copyrights, and participated in the formulation of 35 national and industry standards, of which 16 standards were the first author and served as a project The leading undertaking unit, sub-project participating units and key equipment R&D units respectively undertook three "13th Five-Year National Science and Technology Innovation Plan-National Key R&D Plan" projects and won the "First Prize for Advanced Collective Award for Technological Innovation in China's Pharmaceutical Equipment Industry" issued by the China Pharmaceutical Equipment Industry Association.

2.Customer resource advantages

The company's business covers the fields of biopharmaceuticals, food and drug inspection and quarantine, inspection and testing, medical and health, ecological environment, hydrology and water conservancy, etc. It provides customers with products including microbial testing equipment and consumables, clean environment control equipment, pharmaceutical water testing equipment, low-temperature disinfection and sterilization equipment, cell and gene therapy GMP production equipment and other products. Focusing on the specific needs of downstream customers, it has carried out a series of product line expansion and development, further improved the company's product line, continuously improved technology and service levels, and accumulated rich customer resources.

After years of intensive industry development, the company's business spans more than 40 countries on five continents, and has served more than 4,000 companies in various industries, covering pharmaceutical companies, food and drug inspection, quarantine and supervision agencies, medical and health institutions, scientific research institutions and other fields. It provides customers with microbial testing, environmental control, cell preparation, disinfection and biosafety protection and other related products. Relying on long-term and stable cooperative relationships with many well-known pharmaceutical companies, inspection and quarantine agencies, medical and health institutions and scientific research institutes in the industry, the company has gained a good reputation in the industry, laying a solid foundation for the sustained and rapid growth of operating performance.

Industry Some domestic customers

More than 1,700 companies, including Sinopharm (Hong Kong stock 01177), WuXi AppTec (603259), GenScript Biotech (Hong Kong stock 01548), Boehringer Ingelheim, Hengrui Pharmaceuticals (600276), Yangtze River Pharmaceuticals, Innovent Biologics (Hong Kong stock) 01801), Chia Tai Tianqing, General Electric Pharmaceuticals, Shanghai Pharmaceuticals (601607), Xiehe Kirin, Sinopharm Group, Fosun Pharma (600196), Kang Pharmaceutical Enterprises Sino (688185), Asymchem (002821), China Resources Shuanghe (600062), Kelun Pharmaceutical (002422), Baiyunshan (600332), Mentholatum Pharmaceuticals, Huadong Pharmaceutical (000963), Yuanda Pharmaceutical (Hong Kong stocks) 00512), Hualan Biotechnology (002007), BGI (300676), Qilu Pharmaceutical, Zhifei Biotechnology (300122), Yunnan Baiyao (000538),

Harbin Pharmaceutical Group Co., Ltd. (600664), CSPC Pharmaceutical Group (Hong Kong stock: 01093), Huizhi Pharmaceutical, etc.

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

800 Yujia, Master Kong (Hong Kong stock 00322), Wahaha, Dayao Beverage, Panpan Food, Bacchus Wine, Yuanqi Forest, Jun Food Industry

Lebao, Yinlu Food, etc.

More than 200, including China Institute of Food and Drug Control, Beijing Institute of Drug Control, Shanghai Institute of Food and Drug Control, and Guangdong Provincial Food and Drug Supervision and Inspection Machinery

Institute of Drug Control, Zhejiang Institute of Food and Drug Control, Sichuan Food and Drug Administration, Gansu Institute of Drug Control, and

Shanghai Food and Drug Packaging Materials Testing Institute, Liaoning Medical Device Inspection and Testing Institute, etc.

There are more than 400 hospitals, including the People's Liberation Army General Hospital, West China Medical College of Sichuan University, Union Hospital Affiliated to Huazhong University of Science and Technology, Tongji Hospital Affiliated to Huazhong University of Science and Technology, Beijing Ditan Hospital Affiliated to Capital Medical University, Beijing You'an Hospital Affiliated to Capital Medical University, the First Affiliated Hospital of Zhejiang University School of Medicine, the Second Affiliated Hospital of Zhejiang University School of Medicine, and Shaoyi Medical and Health Unit Affiliated to Zhejiang University School of Medicine.

Hospital of Obstetrics and Gynecology of Zhejiang University School of Medicine, First Affiliated Hospital of Zhengzhou University, China Center for Disease Control and Prevention, Shanghai Center for Disease Control and Prevention, Sichuan Provincial Center for Disease Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Tianjin Center for Disease Control and Prevention, Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention, etc.

More than 30 companies, including the Institute of Zoology of the Chinese Academy of Sciences, the Military Veterinary Research Institute of the Academy of Military Medical Sciences of the Chinese People's Liberation Army, the Wuhan Institute of Virology of the Chinese Academy of Sciences, and many other scientific research institutes, China Customs Science and Technology Research Center, Yunnan Entry-Exit Inspection and Quarantine Bureau, Fujian Entry-Exit Inspection and Quarantine Bureau, Ningbo Entry-Exit Inspection and Quarantine Bureau, Beijing Customs, Dalian Customs, Quanzhou Customs, etc.

More than 60 universities, Tsinghua University, Peking University, Zhejiang University, Nankai University, West Lake University, Sichuan University, Wuhan University, colleges and universities

Nanjing University, Xiamen University, Zhejiang University of Traditional Chinese Medicine, etc.

Product quality advantage

The company has many years of experience in manufacturing products related to microbial detection and control technology systems, and has a mature production and research and development base. Major wholly-owned subsidiaries such as Tailin Life Sciences, Tailin Medical Engineering, and Tailin Analytical Instruments have all passed ISO9001:2015 quality management system and ISO14001:2015 environmental management system certification. The company has formulated a strict product inspection process to ensure product quality. For example, during the production process of the incubator, the company conducts strict and standardized inspections in terms of ultrasonic welding application, bottle air tightness, sterilization reliability, pump tube material and manufacturing process, etc. to ensure that the product passes sterility testing, microbial recovery growth and other verification and testing, ensuring continuous, stable and reliable quality.

At the same time, the company has created a complete production process technology route for molds, injection molding, sterilization, sheet metal, metalworking, assembly, inspection, and verification. Some structural parts and key functional components of the main instruments and equipment are independently designed by the company and customized and purchased from external units. The core components are processed by themselves. The products are produced through assembly and debugging by professional and technical workers, which improves the reliability of product quality and the ability to provide technical verification services to customers. In addition, in addition to having technical talents for related product software and hardware, the company also reserves professionals with knowledge of sterile inspection operations. Therefore, the company can pay attention to the operating habits of downstream customers in terms of usage details during the product design process, making the company's products have a better user experience in design and use than similar products of competitors.

In order to further improve product quality, the company's R&D department invited the drafters of national reliability design standards and experts in reliability design and testing to conduct multiple rounds of training on reliability design and testing, and introduced the reliability design and testing process into the entire product design and production process. Through reliability design and management, the company has shifted the focus of product quality from quality control at the factory to full-process tracking during the product's service life, extending the company's product quality management to user sites. To this end, the company's main instruments and equipment products have been designed with self-diagnosis systems for product maintenance and faults. When used, users can be proactively reminded to perform routine maintenance on the equipment according to the equipment usage specifications and specific usage conditions, such as proactive reminders to replace consumables, prompting users to pay attention to the status of automatically detected wearing parts and replace them in time. The detection and feedback of fault-prone components are redundantly designed so that once a component runs or detects abnormally, the system can automatically record and remind the system to avoid losses caused to customers due to use in unexpected conditions. The intelligent fault diagnosis system has also greatly improved the efficiency and quality of the company's after-sales service, further improving the user experience.

Product series advantages

The company is the first enterprise in China to develop and produce large-scale microbial testing instruments such as bacteriometers and incubators and supporting consumables for modern microbial testing methods. After long-term industry experience accumulation and continuous R&D innovation, the company has now carried out a series of product line extensions and innovations based on the specific needs of pharmaceutical enterprise customers, forming three major product series: microbial detection technology product series, sterile production and pollution control equipment series, and organic monitoring and analysis instrument series, as well as sterilizers, incubators, sterile isolators, sterile transfer chambers, VHPS sterilizers, TOC Representative products such as analyzers and cell therapy industrialization equipment; in addition to representative products, the company has also developed microbial testers, enzyme substrate method water quality testing systems, fully automatic two-worm detection systems, algae intelligent analyzers, filter membrane pore size testers, filter integrity testers, glove integrity testers, automatic samplers, Quality control strains, biological indicators, chemical indicators, vaporized hydrogen peroxide sterilization process system solutions, medium and high concentration hydrogen peroxide gas analyzers, online and offline microbial rapid test analyzers, centrifuges, water activity meters, carbon enrichment analyzers, biodegradation analysis systems and other supporting instruments and consumables for microbial detection and control technology systems.

The complete product series, on the one hand, enables the company to provide downstream target customers with complete solutions from sterile environment control such as space environment sterilization, aseptic isolation, aseptic transfer, etc. to microbial detection and analysis, creating one-stop purchasing conditions for customers; on the other hand, through software and hardware development, related products can achieve technical standards, data interfaces and information transmission protocols to assist users in efficiently tracking, automatically recording and integrated management of data in all aspects of microbial detection. Full text of Zhejiang Tailin Biotechnology Co., Ltd. 2026 Semi-annual Report

It has built a unified technology system platform for Tailin Biotech's entire product line, which has set up compatibility barriers for other competitors' access to similar products and increased customers' demand for systematic procurement of the company's products.

Regional advantages

The company is located in Hangzhou City within the Yangtze River Delta Economic Region. The Yangtze River Delta Economic Zone is one of the most dynamic economic regions in my country. It has formed a developed manufacturing industry cluster with complete industrial categories, well-developed transportation and logistics, and leading transportation and logistics resources in the country. The company's production and operation activities have the characteristics of complete industrial supporting facilities, timely supply of raw materials, and convenient, efficient, and low-cost logistics and transportation. In addition, the Yangtze River Delta region's rich human resources and the gathering effect of high-tech talents also fully meet the company's demand for management and technical talents. Therefore, the company's production and operations can fully enjoy the regional advantages of the Yangtze River Delta region.

3. Main business analysis

Overview

Please refer to the relevant content of "1. Main businesses engaged in by the company during the reporting period".

Year-on-year changes in major financial data

Unit: Yuan

This reporting period The same period last year Year-on-year increase or decrease Reasons for changes

Operating income 165,382,315.28 145,825,607.20 13.41%

Operating costs 84,317,136.48 70,109,926.46 20.26%

Selling expenses 19,682,491.66 18,594,428.14 5.85%

Management expenses 19,058,147.40 15,885,481.21 19.97%

Mainly due to the financial expenses of purchasing structures in the current period -1,332,824.89 -4,282,977.52 -68.88% The income from financial deposits is included in investment income

Mainly due to the increase in income tax expenses for the current period 1,236,564.32 -244,678.60 605.09% and changes in deferred income tax

R&D investment 25,664,633.42 30,976,719.59 -17.15%

Mainly represents cash generated by sellers’ operating activities in the current period

21,100,569.48 3,120,686.35 576.15% Net flow received from the provision of products and services

due to cash growth

Mainly due to cash received from other investing activities in the current period

91,558,435.60 26,171,397.59 249.84% Net cash flow related to investing activities

due to increase in gold

Cash generated from financing activities is mainly due to share repurchase in the current period -35,885,014.98 -28,295,156.53 26.82%

Net flow due to payment

Mainly represents the net cash and cash equivalents received from sales of goods and provision of services in the current period.

76,318,056.21 899,984.83 8,379.93% Cash increase, other increases received

Due to an increase in cash related to investing activities;

Mainly due to the growth of operating income in the current period and net profit under R&D expenses 20,372,823.69 13,342,711.07 52.69%

due to the decrease in credit impairment losses.

There are significant changes in the company's profit composition or profit sources during the reporting period

□Applicable Not applicable

There were no major changes in the company's profit composition or profit sources during the reporting period.

Products or services accounting for more than 10%

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Applicable □Not applicable

Unit: Yuan

Operating income compared to the previous year Operating costs compared to the previous year Gross profit margin compared to the previous year’s operating income Operating costs Gross profit margin

Increase/decrease in the same period of the year Increase/decrease in the same period of the year Increase/decrease in the same period of the year by product or service

Aseptic production and pollution

62,608,294.1 39,626,987.4

Dyeing control equipment system 36.71% 7.66% 25.54% -9.01%

2 0

List of products

Microbial detection technology 69,722,059.9 31,257,700.8

55.17% 18.92% 20.63% -0.64% Technology series products 6 2

Organic matter analysis technology 16,902,081.0

5,902,158.33 65.08% 6.32% 3.46% 0.97% Technology series products 1

13,550,274.8

Others 7,410,138.87 45.31% 36.69% 9.16% 13.79%

4. Analysis of non-main business

Applicable □Not applicable

Unit: Yuan

Amount Proportion of total profit Explanation of reasons Whether it is sustainable

Purchase structured deposit financial management

Investment income 1,641,315.01 7.60% No

product revenue

Asset impairment -886,249.41 -4.10% Provision for inventory decline in value No

Carry forward unpaid payables

Non-operating income 3,141.73 0.01% No amount

Mainly fixed asset liquidation

Non-operating expenses 265,965.06 1.23% No carryover and late payment fees

The company develops, produces and sells by itself

The software products for sale are in process

After registration procedures, you can enjoy the increase

Other income 4,400,416.82 20.36% is due to the value tax refund policy upon collection.

Enjoy tax incentives in this period

Amount of 2.6477 million yuan;

5. Analysis of assets and liabilities

Major changes in asset composition

Unit: Yuan End of the reporting period End of the previous year

Increase or decrease in proportion Amount explained for major changes Proportion to total assets Amount Proportion to total assets

155,451,865. 149,088,376.

Monetary funds 16.58% 15.55% 1.03% 25 64

55,441,771.8 55,073,932.7

Accounts receivable 5.91% 5.74% 0.17% 1 7

Mainly due to the increase in contract assets at the end of the period 6,904,907.97 0.74% 4,967,260.85 0.52% 0.22%

Resulting inventories 136,452,748. 14.55% 126,535,071. 13.19% 1.36% Full text of the 2026 Semi-annual Report of Zhejiang Tailin Biotechnology Co., Ltd.

10 63

Investment real estate 8,399,509.00 0.90% 8,551,355.56 0.89% 0.01%

11,104,836.6 10,549,721.8

Long-term equity investment 1.18% 1.10% 0.08% 3 5

244,342,116. 250,792,052.

Fixed assets 26.06% 26.15% -0.09% 18 78

Mainly due to the investment in high-performance filtration in this period

39,161,752.0

Construction in progress 4.18% 9,259,817.63 0.97% 3.21% Due to the industrialization project of devices and supporting functional films

72,340,074.7 65,727,476.6

Contract liabilities 7.71% 6.85% 0.86%

7 1

Major overseas assets

□Applicable Not applicable

Assets and liabilities measured at fair value

□Applicable Not applicable

Restrictions on asset rights as of the end of the reporting period

Item Closing amount Opening amount Reasons and reasons for limited scope of use Raised funds account 13,045,461.36 1,542,658.02 Raised funds supervision account guarantee deposit 577,505.51 495,826.51 ETC deposit cannot be withdrawn at any time 11,000.00 11,000.00 Cannot be withdrawn at any time

Subtotal 13,633,966.87 2,049,484.53

6. Investment status analysis

Overall situation

□Applicable Not applicable

Major equity investments obtained during the reporting period

□Applicable Not applicable

Major non-equity investments ongoing during the reporting period

□Applicable Not applicable

Financial assets measured at fair value

□Applicable Not applicable

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Usage of raised funds

Applicable □Not applicable

(1) Overall use of raised funds

Applicable □Not applicable

Unit: Report in 10,000 yuan

End of term

Report Cumulative

Already collected, accumulated, not yet

Changes in current period Changes in idle budget funds Not yet used

Raising has been used to change the purpose of raising securities for two years. Raising. Used. Purpose. Raising.

Raising funds Raised funds raised for the purpose of raising funds raised above listed funds Raising ratio of raised funds

Year Method Net Amount of Fund Raising Date of Raising Total Funds Total (3) Purpose of Fund Raising Funds

(1) The total amount of funds raised by the total fund = the total amount of funds raised by the total fund and go

Amount to total amount ratio Amount (2) (2) Amount to

amount example

(1)

Xiang no

store

specific

Yu Li

Object 2022

Raise funds

2021 Issue Year 01 21,00 20,41 606.0 15,57 76.31 20,06 98.29 6,704

0 Financial College 0 years Transferable Month 19 0 2.11 1 5.51 % 2.34 % .55

Towa

Change of public relations day

Cash

Secretary debt

management

coupon

21,00 20,41 606.0 15,57 76.31 20,06 98.29 6,704

Total -- -- 0 -- 0

0 2.11 1 5.51 % 2.34 % .55

Description of the overall use of raised funds:

On December 28, 2021, the company raised 210 million yuan through the issuance of convertible corporate bonds, and the net amount raised after deducting issuance expenses was 204.1211 million yuan. The company held the 21st meeting of the third board of directors on December 12, 2023, and reviewed and approved the "Proposal on Using Raised Funds to Increase Capital in Wholly-Owned Subsidiaries" for the implementation of the investment project "Cell Therapy Industrialization Equipment Manufacturing Base Project" of Tailin Medical Engineering. The company held the seventh meeting of the fourth session of the Board of Directors on April 24, 2025, and the seventh meeting of the fourth session of the Board of Supervisors on May 19, 2025. The Annual General Meeting of Shareholders reviewed and approved the "Proposal on the Closing of Investment Projects Raised by the Issuance of Convertible Corporate Bonds to Unspecified Objects in 2021 and the Investment of the Surplus Raised Funds into New Projects and Permanent Replenishment of Working Capital", which concluded the company's convertible bond-raised investment project "Cell Therapy Industrialization Equipment Manufacturing Base Project" and used the remaining raised funds for the new project "High-Performance Filter and Supporting Functional Membrane Industrialization Project" and permanent replenishment of working capital. The company held the eighth meeting of the fourth board of directors on June 13, 2025, and reviewed and approved the "Proposal on Using Raised Funds to Increase Capital in Wholly-Owned Subsidiaries" for Tailin New Materials to implement a new project "High-Performance Filter and Supporting Functional Membrane Industrialization Project". As of the end of the reporting period, the unused raised funds were RMB 67.0455 million, of which RMB 54 million was used to purchase certificates of deposit, structured deposits, and bank financial products that have not yet expired. The remainder were deposited in the company's special account for raised funds.

(2) Project status of fund-raising commitments

Applicable □Not applicable

Unit: RMB 10,000 Commitment Whether Raising Adjustment This newspaper As of As of project This newspaper As of whether Project financing Securities

Investment project Changed funds Post-investment Reporting period End of period Period-end Reached Reporting period Report Reached Feasible projects Listed

Project Nature Update Commitment Total Capital Investment Cumulative Investment Scheduled Realization End of Period Estimated Nature Name Date

Hechao project investment amount, investment progress, cumulative benefits, whether to publish the full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Raising funds (including total amount (1) amount (3) using state profits to achieve significant investment in life Part (2) = major changes in status (2)/period benefits

more) (1)

Commitment to investment projects

2021

cells

year direction

treatment

Not special

2022 Industry 2025

Definitely right

Year 01 Cosmetic production 9,79 9,79 9,72 99.3 Year 04 80.5 247. Xiangfa Yes 0 No No Month 19 Preparation and construction 2.51 2.51 4.11 0% Month 24 5 16 OK

foundation day

Convert

land item

company

Head

bond

2021 high sex

Can pass the year

No special filter

2022 2028

Fixed pairing and matching 10,9 10,9

Year 01 Production 606. 4,47 40.9 Year 12 Uncomfortable operation No 36.8 36.8 No Month 19 Construction 01 4.19 1% Month 31 May 8 8

daily note

conversion industry

Corporate items

bond item

2021

year direction

Not special

2022 permanent 2025

Definitely right

Year 01 Supplementary 1,37 1,37 1,37 100. Year 05 Uncomfortable symptoms Replenish flow No 0 No Month 19 Flow 7.21 7.21 7.21 00% Month 19 OK

day funds day

Convert

company

bond

15,5

22,1 22,1 606. 80.5 247. Subtotal of committed investment projects -- 75.5 -- -- -- --

06.6 06.6 01 5 16

Investment direction of super-raised funds

2026 2026

Discomfort Year 06 Discomfort Discomfort 0.00 Year 06 Discomfort

No 0 0 0 0 0 0 No Use on the 30th of the month. Use % on the 30th of the month. Use the day.

15,5

22,1 22,1 606. 80.5 247.Total -- 75.5 -- -- -- --

06.6 06.6 01 5 16

Description of sub-projects

The company held the fifth meeting of the fourth board of directors on December 31, 2024, and reviewed and approved the "Plan on Issuance of Convertible Unfulfilled Assets to Unspecified Objects"

"Proposal on Extension of Investment Projects Raised by Corporate Bonds" adjusts the time when the project reaches its intended usable state to June 30, 2025. progress, estimate

The company held the seventh meeting of the fourth board of directors on April 24, 2025, and the 2024 annual shareholder returns on May 19, 2025.

The meeting reviewed and approved the "About the completion of investment projects with funds raised from the issuance of convertible corporate bonds to unspecified objects in 2021 and the remaining proceeds and reasons (including

"Proposal to invest funds in new projects and permanently replenish working capital", close the project, and use the remaining raised funds and net interest income to "whether it reaches

An amount of 123.1409 million yuan will be used to invest in the "High-Performance Filter and Supporting Functional Membrane Industrialization Project" project and permanently replenish working capital. "Public expected benefits"

Through the purchase of industrial plants and investment in key production equipment, the cell therapy industrialization equipment manufacturing base project reached the "unsuitable" capacity selection level in April 2025.

Construction goals and reach usable status, but because cell therapy is a cutting-edge treatment technology, the downstream market in the field of cell therapy is in the early stage of development.

In the development stage, market demand needs to be gradually released, so the project benefits have not met expectations.

(because)

Project feasibility

Major changes occur Not applicable

transformational situation

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Ming

over-funded

Amount, purpose

Not applicable

and usage progress

situation

There is unauthorized change

Raise more funds

Purpose, violation Not applicable

Taking up the raised funds

gold situation

Applicable

Raise funds to invest

occurred in previous years

capital project implementation

According to the resolution of the 20th meeting of the company’s third board of directors on November 24, 2023, the company changed the “change of cell therapy location” for the raised funds investment project.

The implementation entity, implementation method and implementation location of the "Industrial Equipment Manufacturing Base Project". The implementation entity was adjusted from the company to Tailin Kuang, a subsidiary of the company.

In medical engineering, the implementation methods and implementation locations have changed.

Applicable

Raise funds to invest

occurred in previous years

capital project implementation

According to the resolution of the 20th meeting of the company's third board of directors on November 24, 2023, the company changed the "Adjustment of Cell Therapy Methods" for the investment project with raised funds.

In medical engineering, the implementation methods and implementation locations have changed.

Raise funds to invest

Investment projects in advance

Not applicable

Investment and replacement

situation

Recruit with idle time

Funds temporarily replenished

Not applicable

Replenish working capital

situation

Applicable

According to the resolution of the seventh meeting of the fourth session of the Board of Directors on April 24, 2025, the resolution of the seventh meeting of the fourth session of the Supervisory Board, and the resolution of the 2024 Annual General Meeting of Shareholders on May 19, 2025, the company will close the "Cell Therapy Industrialization Equipment Manufacturing Base Project" and use the remaining raised funds of 109.3688 million yuan for the new project "High Performance Filter and Supporting Functional Membrane Industrialization Project" and 13.7721 million yuan for project implementation. Used to supplement working capital.

The reasons for the balance of raised funds currently being raised are as follows: 1. The raised funds originally planned to be used for land purchase and production base construction were adjusted to the remaining amount for plant purchase and decoration project costs, thus resulting in a surplus of raised funds originally planned to be invested. 2. The company solved the bottleneck problem of production space and causes by purchasing industrial plants. At the same time, cell therapy is a cutting-edge treatment technology. The downstream market in the field of cell therapy is in the early development stage, and market demand is gradually released. The company’s cumulative investment in convertible bond investment projects so far has been able to meet the current production capacity needs. From a strategic perspective, the company adjusted the investment scale of convertible bond investment projects, so there was a certain degree of savings in the funds originally planned to be invested.

The company used part of the temporarily idle raised funds for cash management and obtained certain investment income, as well as current interest while the raised funds were stored in the bank account.

Not yet used

As of the end of the reporting period, the unused raised funds were RMB 67.0455 million, which were used to purchase certificates of deposit, structured deposits, and bank raised funds.

The bank's wealth management products have not expired for 54 million yuan, and the remainder are deposited in the company's special account for raised funds. journey and destination

Raise funds to make

In use and disclosed

Not applicable

Problems

or other situations

Note: During the implementation process of the "High Performance Filter and Supporting Functional Membrane Industrialization Project", the total investment and corresponding investment details, project construction cycle, project economic benefit forecast and other matters were adjusted based on the actual situation. This matter has been reviewed and approved by the company at the 14th meeting of the fourth board of directors held on July 1, 2026.

(3) Project changes with raised funds

Applicable □Not applicable

Unit: RMB 10,000 Full text of Zhejiang Tailin Biotechnology Co., Ltd.’s 2026 Semi-annual Report

After change Deadline after change Deadline Project reaches

Project proposed Project for this report

Corresponding to the actual end of investment to the scheduled end of this report, whether the financing amount has been reached, the actual feasibility of the investment period after the change of the fund raising party.

The cumulative investment progress of the original commitment can be realized within the expected project period. The amount of capital raised and the investment amount of the project will be released. (3) = (2) The total benefit amount on the status date will be significant.

(2) )/(1) issue

(1) Change

cell therapy

2021

Xiangbute Cell Therapy Industry

Xiang Bute

Targeted therapeutic industrial equipment in 2025

Targeted 9,792. 9,724.

Issuance of chemical equipment Manufacturing base 99.30% April 80.55 No No Issuance of possible 51 11

Conversion of public manufacturing base project 24th

conversion public

Corporate Bond Land Project (Change

corporate bonds

before)

9,792. 9,724.

Total -- -- -- 0 -- -- 80.55 -- -- 51 11

According to the resolution of the 20th meeting of the company's third board of directors on November 24, 2023, the company changed the reasons, decision-making procedures and information for the change of investment projects with raised funds.

The implementation entity, implementation method and implementation location of the "Cell Therapy Industrialization Equipment Manufacturing Base Project". Explanation of disclosure status of implementation entities (divided into specific projects)

It was adjusted from the company to Tailin Medical Engineering, a subsidiary of the company, and the implementation method and implementation location were also changed. For failure to achieve the planned progress or expected benefits, please refer to the aforementioned "Project Situation of Raised Fund Commitments" - "Details of the failure to achieve the planned progress and expected benefits by project, as well as the original situation and reasons (by specific projects)".

The feasibility of the project after the change has changed significantly

Not applicable

Description of big changes

Entrusted financial management and derivatives investment

(1) Entrusted financial management situation

Applicable □Not applicable

Overview of entrusted financial management during the reporting period

Unit: 10,000 yuan

Product Category Risk Characteristics Balance of entrusted financial management during the reporting period Overdue amount not recovered Bank financial management products Low risk 19,590 0 The company entrusts a financial institution to carry out asset management as a single client, or invests in high-risk entrusted financial management with low security and poor liquidity. Specific circumstances □Applicable Not applicable

(2) Derivatives investment situation

□Applicable Not applicable

The company had no derivative investments during the reporting period.

7. Sale of major assets and equity

Sale of major assets

□Applicable Not applicable

The company did not sell any major assets during the reporting period.

Sale of major equity interests

□Applicable Not applicable

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

8. Analysis of major holding and participating companies

Applicable □Not applicable

Information about major subsidiaries and joint-stock companies that affect the company's net profit by more than 10%

Unit: yuan Company name Company type Main business Registered capital Total assets Net assets Operating income Operating profit Net profit

life sciences

Zhejiang Tailin Technology Research

50,000,00 193,043,4 162,017,4 77,369,54 19,117,71 17,209,74 Life Sciences Subsidiary Production, Production

0.00 77.61 47.26 9.94 6.95 6.76 Co., Ltd. Production and sales

and services etc.

Analytical instruments

Zhejiang Tailin Technology Research

10,000,00 38,051,95 29,548,89 19,173,44 6,511,362 6,455,100 Analytical instruments Subsidiary Production, production

0.00 2.56 0.13 4.33 .39 .55 Co., Ltd. Production and sales

and services etc.

medical device

Zhejiang Tailin R&D, production -

10,000,00 4,375,801 2,850,693 2,327,469 2,327,469Medical device subsidiary production and sales 1,316,436

0.00 .88 .69 .93 .93Co., Ltd. and Services .47

etc;

Acquisition and disposal of subsidiaries during the reporting period

Applicable □Not applicable

Company name How to acquire and dispose of subsidiaries during the reporting period Impact on overall production operations and performance

It will not have any significant impact on the overall production, operation and performance. Zhejiang Tailinkeda Medical Technology Co., Ltd. plans to cancel and is in progress.

influence

Description of major holding and joint-stock companies

As of the end of the reporting period, the company had 6 wholly-owned subsidiaries and 1 holding subsidiary:

Zhejiang Tailin Life Sciences Co., Ltd.: Date of establishment: March 31, 2016; Registered capital 5,000 RMB 10,000; registered address: No. 33, No. 7 Road, Dongzhou Industrial Function Zone, Dongzhou Street, Dongzhou Street, Fuyang District, Hangzhou City, Zhejiang Province, etc.; Business scope: General projects: technical services, technology development, technical consultation, technology exchange, technology transfer, technology promotion; production of first-class medical devices; sales of first-class medical devices; manufacturing of instruments and meters; sales of intelligent instruments and meters; sales of second-class medical devices; research and development of industrial enzyme preparations; manufacturing of special chemical products (excluding hazardous chemicals); sales of special chemical products (not including hazardous chemicals) Containing hazardous chemicals); engineering and technological research and experimental development; manufacturing of plastic products; sales of plastic products; manufacturing of special equipment for environmental protection; sales of special equipment for environmental protection; Internet sales (except for sales of goods requiring licenses); production of daily masks (non-medical); sales of daily masks (non-medical); manufacturing of maternal and infant products; sales of maternal and infant products; sales of daily necessities; sales of sanitary products and disposable medical supplies; sales of disinfectants (excluding hazardous chemicals); import and export of goods. (Except for projects that require approval according to law, business activities can be carried out independently with a business license in accordance with the law) Licensed projects: production of sanitary products and disposable medical supplies; production of disinfectants (excluding hazardous chemicals); production of disinfection equipment; sales of disinfection equipment. (Projects that require approval according to law can only be carried out with the approval of relevant departments. Specific business projects shall be subject to the approval documents or licenses of relevant departments)

For details on the operation during the reporting period, please refer to the aforementioned "Main Subsidiaries and Joint Stock Companies that Impact More than 10% of the Company's Net Profit".

Zhejiang Tailin Analytical Instrument Co., Ltd.: Date of establishment: August 8, 2018; Registered capital 10 million yuan; Registered address: 2nd Floor, Building 2, No. 2930, South Ring Road, Puyan Street, Binjiang District, Hangzhou City, Zhejiang Province; Business scope: technology development, technical services, technical consulting, transfer of results: laboratory analytical instruments, computer software and hardware, computer system integration, laboratory equipment; manufacturing: laboratory analytical instruments; sales: laboratory analytical instruments, computer software and hardware, instrumentation, laboratory equipment. (Projects that require approval according to law can only carry out business activities after approval from relevant departments).

For details on the operation during the reporting period, please refer to the aforementioned "Main Subsidiaries and Joint Stock Companies that Impact More than 10% of the Company's Net Profit".

Zhejiang Tailin Medical Engineering Co., Ltd.: Date of establishment: August 30, 2019; Registered capital 100 million yuan; Registered address: No. 1, No. 2, No. 9 Road, Dongzhou Industrial Functional Zone, Dongzhou Street, Fuyang District, Hangzhou City, Zhejiang Province Building; licensed items: production of disinfection equipment; sales of disinfection equipment; inspection and testing services; production of disinfection products for the prevention and treatment of infectious diseases; import and export of goods (items that require approval according to law, business activities can only be carried out after approval by relevant departments, and specific business projects are subject to approval. Full text of the 2026 Semi-annual Report of Zhejiang Tailin Biotechnology Co., Ltd.

The result shall prevail). General projects: engineering and technology research and experimental development; medical research and experimental development; production of Class I medical devices; sales of Class I medical devices; sales of Class II medical devices; manufacturing of special pharmaceutical equipment; sales of special pharmaceutical equipment; manufacturing of special equipment (excluding manufacturing of licensed professional equipment); gas and liquid separation and purification equipment manufacturing; gas, liquid separation and purification equipment sales; technical services, technology development, technical consultation, technology exchange, technology transfer, and technology promotion; professional cleaning, cleaning, and disinfection services; conference and exhibition services (except for projects that require approval according to law, business activities can be carried out independently with a business license in accordance with the law). Operate with the following branches: Licensed items: Hazardous chemical operations (items that require approval according to law can only be carried out with the approval of relevant departments, and specific operating items are subject to the approval results).

During the reporting period, Tailin Medical Engineering achieved operating income of RMB 67,098,594.32 and net profit of RMB 805,470.92.

Zhejiang Tailin Science and Technology Co., Ltd.: Date of establishment: January 29, 2021; Registered capital 10 million yuan; Registered address: Building 12, Building 3, No. 2930, South Ring Road, Puyan Street, Binjiang District, Hangzhou, China (Zhejiang) Free Trade Pilot Zone Building; business scope: general projects: technical services, technology development, technical consultation, technology exchange, technology transfer, technology promotion; sales of new membrane materials; sales of special equipment for environmental protection; sales of gas and liquid separation and purification equipment; sales of special chemical products (excluding hazardous chemicals); sales of chemical products (excluding licensed chemical products); sales of daily masks (non-medical); sales of medical personnel Wholesale of personal care products; sales of second-class medical equipment; production of labor protection products; sales of disinfectants (excluding hazardous chemicals); sales of maternal and infant products; sales of daily necessities; sales of personal hygiene products; sales of sanitary products and disposable medical products; professional cleaning, cleaning, and disinfection services; conference and exhibition services (except for projects that require approval according to law, business activities can be carried out independently with a business license and in accordance with the law). Licensed items: import and export of goods; import and export of technology; sales of disinfection equipment; import and export agency (items that require approval according to law can only be carried out with the approval of relevant departments, and specific business items are subject to the approval results).

During the reporting period, Tailin Science and Technology achieved an operating income of 25,457,506.62 yuan and a net profit of -56,667.32 yuan.

Zhejiang Tailin Medical Devices Co., Ltd.: Date of establishment: July 1, 2022; Registered capital 10 million yuan; Registered address: No. 1, No. 4, No. 9 Road, Dongzhou Industrial Functional Zone, Dongzhou Street, Fuyang District, Hangzhou City, Zhejiang Province Building; Business scope: General projects: Production of Class I medical devices; Manufacturing of special pharmaceutical equipment; Sales of special pharmaceutical equipment; Research and development of new material technology; Manufacturing of general equipment (excluding manufacturing of special equipment); Manufacturing of new membrane materials; Sales of new membrane materials; Manufacturing of high-performance fibers and composite materials; Sales of high-performance fibers and composite materials; Manufacturing of medical packaging materials; Surface functional materials Sales; manufacturing of bio-based materials; sales of bio-based materials; sales of new catalytic materials and additives; manufacturing of synthetic materials (excluding hazardous chemicals); sales of plastic products; manufacturing of ecological environment materials; sales of ecological environment materials; manufacturing of special equipment for environmental protection; sales of special equipment for environmental protection; manufacturing of special equipment for semiconductor devices; sales of special equipment for semiconductor devices; mechanical equipment research and development Development; manufacturing of metal products for safety and fire protection; processing of mechanical parts and components; mold manufacturing; sales of molds; sales of metal materials; metal cutting and processing services; manufacturing of metal structures; sales of metal structures; technical services, technology development, technical consultation, technology exchange, technology transfer, technology promotion; import and export of goods; engineering and technology research and experimental development; medical research and experiments Development; sales of first-class medical devices; sales of second-class medical devices; manufacturing of special equipment (excluding manufacturing of licensed professional equipment); manufacturing of gas, liquid separation and purification equipment; sales of gas, liquid separation and purification equipment; professional cleaning, cleaning and disinfection services; conference and exhibition services (except for projects that require approval according to law, business activities can be carried out independently with a business license and in accordance with the law).

For details on the operation during the reporting period, please refer to the aforementioned "Main Subsidiaries and Joint Stock Companies that Impact More than 10% of the Company's Net Profit".

Zhejiang Tailin New Materials Co., Ltd.: Date of establishment: March 25, 2025; Registered capital 100 million yuan; Registered address: 578, Building 17, No. 2723, Fuchunwan Avenue, Chunjiang Street, Fuyang District, Hangzhou City, Zhejiang Province No.; Business scope: General projects: manufacturing of new membrane materials; sales of new membrane materials; research and development of new material technology; manufacturing of high-performance fibers and composite materials; sales of high-performance fibers and composite materials; manufacturing of plastic products; sales of plastic products; manufacturing of special equipment for environmental protection; sales of special equipment for environmental protection; manufacturing of gas, liquid separation and purification equipment; sales of gas, liquid separation and purification equipment; instrument manufacturing Manufacturing; sales of instruments and meters; sales of second-class medical devices; sales of sanitary products and disposable medical supplies; import and export of goods; technical services, technology development, technical consultation, technology exchange, technology transfer, and technology promotion; research and development of industrial enzyme preparations; research and development of fermentation process optimization technology; engineering and technology research and experimental development (except for projects that require approval according to law, business activities can be carried out independently with a business license and in accordance with the law). Licensed projects: production of disinfectants (excluding hazardous chemicals); production of sanitary products and disposable medical supplies (projects that require approval according to law can only be carried out with the approval of relevant departments, and specific business projects are subject to the approval results). During the reporting period, Tailin New Materials achieved operating income of 7,922,174.17 yuan and net profit of -205,264.40 yuan.
Zhejiang Tailinkeda Medical Technology Co., Ltd. (controlled subsidiary): As of the disclosure date of this report, Tailinkeda Medical has not carried out business activities. Currently, the company is negotiating with relevant shareholders regarding the cancellation of Telinkoda Medical.

9. Structured entities controlled by the company

□Applicable Not applicable

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

10. Risks faced by the company and countermeasures

Risks of industry policy changes

The company's pharmaceutical equipment manufacturing industry and its downstream pharmaceutical manufacturing industry are sunrise industries encouraged by national macro-control and industrial policies. However, due to the regulatory nature of the pharmaceutical manufacturing industry, industry development is greatly affected by national laws and regulations, industrial policies, especially the Chinese Pharmacopoeia and GMP supervision. The "Chinese Pharmacopoeia" contains drug quality standards and corresponding raw materials, excipients, finished product inspection requirements and inspection methods. Its important features are legality and normativeness; GMP is a system to achieve the drug standards and specifications specified in the Pharmacopoeia and ensure the continuous production of drugs under controlled conditions. It requires pharmaceutical companies to continuously control raw materials, personnel, facilities and equipment, production processes, packaging and transportation, quality control and other aspects to form a complete drug production quality assurance system to minimize the risk of non-conformity in the drug production process. Pharmaceutical equipment companies whose products comply with the test methods or test conditions of the Chinese Pharmacopoeia and meet the requirements of the new version of GMP implementation guidance will see significant growth in sales revenue during the implementation of the Pharmacopoeia revision and GMP verification, while pharmaceutical equipment companies that do not meet the requirements will be eliminated. At the same time, as a highly regulated industry, the regulatory authorities of the pharmaceutical manufacturing industry include national and local drug regulatory authorities at all levels. These regulatory authorities formulate relevant policies and regulations to supervise the pharmaceutical manufacturing industry. At present, our country is actively promoting the development of medical and health services, deepening the reform of the medical and health care system, and will gradually introduce corresponding reform measures to address existing problems in the pharmaceutical management system and operating mechanism, medical and health security system, and pharmaceutical supervision. As the supervision of the pharmaceutical manufacturing industry becomes increasingly strict, once the medical reform plan changes, it is likely to further intensify competition in the domestic pharmaceutical manufacturing industry. These will have an impact on the new and expanded production capacity of industry-related enterprises, which will in turn affect their investment in the field of fixed assets. Therefore, although the standardization process of my country's pharmaceutical industry is sustainable and long-term, and the fixed asset investment in the industry will maintain a growth trend, in the process of industry standardization, industry regulatory policies are always in a process of dynamic adjustment and change. During this period, it will have an impact on the market demand for pharmaceutical equipment, the efficiency of technology research and development of production companies, and the product life cycle. The demand for fixed asset investment in the pharmaceutical industry will often be concentrated before the rectification time node required by regulations, and there will be a short-term drop in demand after the time node, showing the characteristics of cyclical fluctuations and upward trends. On the one hand, this will cause certain fluctuations in fixed asset investment in the industry in the short term, which will have an impact on the operating performance of pharmaceutical equipment manufacturing companies; on the other hand, if pharmaceutical equipment manufacturing companies cannot deeply understand the guidance of industry regulations, correctly grasp the direction of industry supervision, and promptly improve technology research and development levels and improve product function development in accordance with regulatory policy requirements, it will weaken the vitality of the company's products and market competitiveness, which may in turn have an adverse impact on the company's production, operation and development.

Countermeasures: The company will strengthen market research, pay attention to national macro policies, economic situations and market trends, adjust development strategies in a timely manner, actively turn risks into opportunities, and actively respond to the risks of policy changes through flexible and proactive sales policies. At the same time, on the premise of consolidating existing markets, the company will take measures such as increasing market development efforts and diversifying market strategies to increase overseas market development, disperse local risks by increasing the breadth and depth of market coverage, and continuously improve the application areas and market share of existing products to create new profit growth points for the company.

Risks of loss of technical personnel and technical confidentiality

The pharmaceutical equipment manufacturing industry is a technology-intensive industry. The production and processing of enterprise products require high technical levels. For this reason, the company has established a large-scale and strong R&D team with strong technical strength, and invests more resources in technology R&D and product development every year. Key technical personnel play an important role in the company's product innovation and sustainable development, and the stability of technical personnel also has an important impact on the company's development. Although the company has established a relatively complete technology research and development management mechanism and adopted a series of incentive measures to attract and stabilize technical personnel. However, as the competition in the industry becomes increasingly fierce, the competition for technical talents among competitors in the industry will also intensify. If the company cannot effectively avoid the loss of core technical personnel, or the product technology secrets are leaked, the company's technical advantages will be weakened, and even a certain degree of economic loss will be caused to the company.

Countermeasures: The company has taken a series of measures, including improving the working environment, providing development opportunities, and opening up recruitment channels, to maintain the stability of core technical backbones from the aspects of talent introduction, retention, training, and incentives. By establishing and improving the company's long-term incentive mechanism, it attracts and retains outstanding talents, and fully mobilizes the enthusiasm and creativity of employees to ensure that the company's technology research and development capabilities maintain its leading position.

Risks in the development of new products and new technologies

Pharmaceutical equipment manufacturing products are characterized by rapid upgrading due to technological development and customer demand, and production technology is changing with each passing day. With the advancement of technology and the continuous changes in downstream market demand, new technologies, new processes, and new products developed by pharmaceutical equipment manufacturers are also constantly emerging. Maintaining continuous technological innovation and new product development, and adapting them to changes in market demand and industry development trends, is the key to the long-term and healthy development of pharmaceutical equipment industry companies. The company has always attached great importance to investment in technology research and development and focused on improving the company's independent innovation capabilities. It is at the forefront of the industry in terms of technological upgrading and new product development, and has formed a relatively mature technological innovation mechanism. However, the development of new products and new technologies requires a large amount of human and financial resources, a certain research and development cycle, and there are many uncertain factors in the development process. There is still a question of whether the new products and new technologies that have been developed can be industrialized and produced in a timely manner and make profits. Therefore, the company faces the risk of developing new products and new technologies. Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Countermeasures: The company will continue to increase investment in research and development, continue to develop new products and new technologies on the premise of meeting customer and market needs, and transform and upgrade the company's products. At the same time, it will continue to explore cutting-edge technologies in the industry and achieve industrialization to achieve continued growth of the company's business.

Risks of insufficient market expansion of new products and intensified market competition

The company focuses on technology research and development, has accumulated and reserved a number of patented technologies over the years, and has always maintained a leading edge in the industry. The company has recently launched products targeting the industrialization of cell therapy, biodegradation testing and other fields. There is a possibility that the market development of downstream customers will not be as expected, the downstream customers will not have sufficient recognition of the company's new business and products, and the brand acceptance will be low, thus affecting the realization of the expected benefits of the project. With the gradual improvement and further implementation of national regulations in the fields of food, drug safety, medical and health, and environmental protection, the demand for sterilizers, incubators, sterile isolators, sterile transfer chambers, VHPS sterilizers, cell culture equipment, TOC analyzers and other products in market segments such as microbial detection and control and water organic analysis will further increase, and will also attract more competitors. The number of manufacturers of similar products of the company is increasing day by day. Although the overall market share of competitors is small and the product market recognition is not high, through means such as imitating expired patent products and low-price competition, it will still have an impact on the market order of related products, leading to increasingly fierce market competition. Although the company will continue to put technology first, enhance core competitiveness, actively develop and reserve new technologies, and gradually expand overseas markets on the basis of the original domestic market, facing a rapidly developing sunrise industry, the company will still face the risk of gradually intensifying competition in the product market in the future.

Countermeasures: The company has formulated a precise marketing strategy to actively expand customers in epidemic prevention institutions, medical and health care, scientific research institutions, vaccine development units and other fields. Based on the original direct sales-based sales model, it has vigorously developed dealer channels in various regions to improve product coverage. Actively participate in industry exhibitions such as Pharmaceutical Machinery Exhibition and Cell Industry Conference to showcase the company's products and technical strength, enhance the company's visibility and brand influence, and actively expand overseas markets.

Risks controlled by the actual controller

The actual controllers of the company are Mr. Ye Dalin and Ms. Ni Weiju. As of the end of the reporting period, they directly held 52.91% of the company's shares. At the same time, Mr. Ye Dalin is the executive partner of Gaode Investment and indirectly controls 4.51% of the company's shares through Gaode Investment. Mr. Ye Dalin serves as the company's chairman and general manager. The actual controller has a relatively high shareholding ratio and has the ability to have a greater impact on the company's operating and management activities; if the company's actual controller uses its control power to improperly control the company's operating decisions, personnel, finance, etc., it may bring risks to the company's operations and other shareholders.

Countermeasures: The company's board of directors will strengthen the training and management of actual controllers, directors, and senior managers, establish and improve the company's legal person governance structure and internal control systems and procedures, improve standard operation levels in accordance with the company's articles of association, and perform information disclosure obligations in a timely manner in accordance with relevant laws and regulations.

The above tips do not include other risks that may occur to the company but are not listed. Investors are advised to invest with caution.

11. Registration form for reception of research, communication, interviews and other activities during the reporting period

Applicable □Not applicable

The main topic of discussion

Basic information of the survey: reception time, reception location, reception method, type of reception objects, reception objects, content and information provided.

condition index information

For details, please see Juchao Information Network

Panorama Network "Investment"

(http://www

interactive relationship

The network platform will be online on April 8, 2026. For details, please see cninfo.com 2025 annual results.cninfo.com.

Taiwan” Others

Briefing session on content disclosed on Japan Exchange Network. cn)《2026（https://ir

Invested on April 8th.p5w.net)

investor relations activities

Record sheet》

12. Formulation and implementation of market value management system and valuation improvement plan

Whether the company has formulated a market value management system.

□Yes No

Whether the company has disclosed plans to increase its valuation.

□Yes No

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Implementation of the “Double Improvement of Quality and Return” action plan. Whether the company has disclosed an announcement of the “Dual Improvement of Quality and Return” action plan.

□Yes No

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Section 4 Corporate Governance, Environment and Society

1. Changes in directors and senior managers of the company

Applicable □Not applicable

Name Position held Type Date Reason

Dong Ming Independent Director Resigned on expiration of term of office June 1, 2026 Dismissed

2. Profit distribution and conversion of capital reserve funds into share capital during the reporting period

Applicable □Not applicable

Number of bonus shares for every 10 shares (shares) 0 Number of dividends for every 10 shares (yuan) (tax included) 1 Base number of share capital of the distribution plan (shares) 119,981,249 Amount of cash dividends (yuan) (tax included) 11,998,124.90 Amount of cash dividends in other ways (such as share repurchase) (yuan) 0.00 Total cash dividends (including other ways) (yuan) 11,998,124.90 Distributable profit (yuan) 109,117,142.75 Total cash dividends (including other methods) as a proportion of total profit distribution 100.00%

Cash dividend distribution this time

If the company's development stage is difficult to distinguish but there are major capital expenditure arrangements, when distributing profits, the proportion of cash dividends in this profit distribution should be at least 20%

Detailed explanation of profit distribution or capital reserve conversion plan

The company held the 16th meeting of the fourth session of the Board of Directors on August 26, 2026, and reviewed and approved the "Proposal on the Profit Distribution Plan for the Half-Year 2026": It was agreed that based on the total share capital on the equity registration date for equity distribution, a cash dividend of 1 yuan (including tax) will be distributed to all shareholders for every 10 shares, and no bonus shares will be given; no capital reserve will be converted into share capital. Based on the calculation based on the company's existing total share capital of 121,199,219 shares as of August 26, 2026, excluding the 1,217,970 shares that have been repurchased and the 119,981,249 shares that participated in profit distribution, the company is expected to distribute cash dividends of RMB 11,998,124.90 in the first half of 2026. This proposal still needs to be submitted to the company's second extraordinary shareholders' meeting in 2026 for review. If the company's total share capital changes before the implementation of the distribution plan due to convertible bond conversion, share repurchase, exercise of equity incentives, listing of new shares through refinancing, etc., the total distribution amount will be adjusted based on the principle that the distribution ratio remains unchanged.

The formulation of this distribution plan comprehensively considered the characteristics of the company's industry, development stage, profitability level, shareholder return needs and other factors, complied with relevant regulations such as the "Articles of Association" and the actual situation of the company, and effectively safeguarded the legitimate rights and interests of all shareholders. This distribution plan has been reviewed and approved at a special meeting of the company’s independent directors.

3. Implementation of the company’s equity incentive plan, employee stock ownership plan or other employee incentive measures

Applicable □Not applicable

Equity incentives

Not applicable

Implementation of employee stock ownership plan

Applicable □Not applicable

All effective employee stock ownership plans during the reporting period

Scope of employees Number of employees Total number of stocks held Changes Share capital of listed companies Funds to implement the plan Full text of Zhejiang Tailin Biotechnology Co., Ltd.'s 2026 Semi-annual Report

(Share) Proportion of Total Source

Directors (excluding independent

Legal remuneration of employees, establishment of directors), senior management

Self-raised funds and legal personnel, core skills 112 1,208,000 Not applicable 1.00%

Legal and administrative regulations personnel; 2. Core

Xu's key personnel in other ways. Note 1

Directors (excluding independent

Legal remuneration of employees, establishment of directors), senior management

Self-raised funds and legal personnel; 2. Core 102 1,218,000 Not applicable 1.00%

Legal and administrative regulations allow technical personnel and core

Xu's key personnel in other ways. Note 2

Note 1: 2025 employee stock ownership plan.

Note 2: 2026 employee stock ownership plan.

Shareholdings of directors and senior managers in employee stock ownership plans during the reporting period

Number of shares held at the beginning of the reporting period Number of shares held at the end of the reporting period Total share capital of listed companies Name Position

(share) (share) ratio

Shen Zhilin Deputy General Manager, Director 100,000 200,000Note 0.17% Xia Xinqun Deputy General Manager, Director 100,000 200,000Note 0.17% Financial Director, Secretary of the Board of Directors

Ye Xingyue 50,000 100,000 note 0.08% book

Ni Xiaolu Director 30,000 60,000 Note 0.05% Note: Includes the number of shares allocated by the employee stock ownership plan in 2026. As of the end of the reporting period, the non-transaction transfer of the 2026 Employee Stock Ownership Plan has not been completed.

Changes in asset management institutions during the reporting period

□Applicable Not applicable

Changes in equity caused by holders’ disposal of shares during the reporting period

□Applicable Not applicable

Exercise of shareholders’ rights during the reporting period

According to the company's "2025 Employee Stock Ownership Plan (Draft)" and its summary, "the holders of this employee stock ownership plan voluntarily give up the voting rights of the company's stocks indirectly held by participating in the stock ownership plan, and only retain the dividend rights and investment income rights of these shares." During the reporting period, the company's "2025 Employee Stock Ownership Plan" exercised the shareholder rights to participate in the 2025 cash dividend and did not participate in the voting of the company's shareholders' meeting or exercise other shareholder rights.

Other relevant situations and explanations of the employee stock ownership plan during the reporting period

Applicable □Not applicable

The first lock-in period of the 2025 Employee Stock Ownership Plan expires on May 5, 2026. The company-level performance assessment target for the first lock-up period of this employee stock ownership plan has been achieved, and the company-level unlocking coefficient corresponding to this employee stock ownership plan is 100%; at the individual level, there are 3 holders whose performance assessment results are C, corresponding to this individual-level unlocking ratio of 60%; the remaining holders' performance assessments are all A or B, corresponding to this individual-level unlocking ratio is 100%. To sum up, the number of shares unlocked this time is 476,480 shares, accounting for 0.39% of the company’s total share capital. The stock shares that cannot be unlocked for holders with the aforementioned assessment result of C will be handled by the Management Committee in accordance with the relevant provisions of the "2025 Employee Stock Ownership Plan (Draft)".

During the reporting period, some participants in the company's "2025 Employee Stock Ownership Plan" resigned. According to the relevant provisions of the company's "2025 Employee Stock Ownership Plan Management Measures", the 2025 Employee Stock Ownership Plan Management Committee took back the corresponding shares of the employee stock ownership plan held by these participants and redistributed them in accordance with relevant regulations. There is no related relationship or concerted action relationship between the redistribution objects and the shareholders, controlling shareholders and actual controllers holding more than 5% of the company's shares.

Changes in the membership of the Employee Stock Ownership Plan Management Committee

□Applicable Not applicable

The financial impact of employee stock ownership plans on listed companies during the reporting period and related accounting treatments

Applicable □Not applicable

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

According to the provisions of "Accounting Standards for Business Enterprises No. 11 - Share-based Payment": equity-settled share-based payment that is exchanged for employee services upon completion of services within the waiting period or exercisable upon meeting specified performance conditions, on each balance sheet date during the waiting period, the services obtained in the current period shall be included in the relevant costs or expenses and capital reserves based on the best estimate of the number of exercisable equity instruments and the fair value on the date of grant of the equity instrument.

For the amortization amount of the company's 2025 employee stock ownership plan during the reporting period, please refer to the relevant content of "Section 8 Financial Report" - "15. Share-based Payment". Termination of employee stock ownership plans during the reporting period

□Applicable Not applicable

Other notes:

Regarding matters related to the 2026 Employee Stock Ownership Plan:

The company held the 11th meeting of the fourth session of the Board of Directors on March 25, 2026, and held the 2025 annual shareholders' meeting on April 16, 2026, which reviewed and approved the "Proposal on the Company's 2026 Employee Stock Ownership Plan (Draft)" and its Summary, the "Proposal on the Company's 2026 Employee Stock Ownership Plan Management Measures" and other related proposals. For details, please refer to the company's announcement on March 27, 2026. The "Zhejiang Tailin Biotechnology Co., Ltd. 2026 Employee Stock Ownership Plan (Draft)" and other relevant announcements were disclosed on the Juchao Information Network (http://www.cninfo.com.cn).

The company's 2026 Employee Stock Ownership Plan securities account has been opened at the Shenzhen Branch of China Securities Depository and Clearing Co., Ltd. For details, please refer to the "Announcement on the Completion of the 2026 Employee Stock Ownership Plan Account Opening" (Announcement Number: 2026-035) disclosed by the company on April 30, 2026 on cninfo.com (http://www.cninfo.com.cn).

The company held the 13th meeting of the fourth session of the Board of Directors on May 15, 2026, and reviewed and approved the "Proposal on Adjusting the Purchase Price of the 2026 Employee Stock Ownership Plan", and agreed that the company would adjust the stock purchase price of the employee stock ownership plan from 14.13 yuan/share to 14.10 yuan/share based on the implementation of equity distribution in 2025 and the "2026 Employee Stock Ownership Plan (Draft)" and other relevant regulations. For details, please refer to the company's The "Announcement on Adjusting the Purchase Price of the Employee Stock Ownership Plan in 2026" (Announcement No.: 2026-040) and other related announcements were disclosed on the cninfo.com (http://www.cninfo.com.cn) on May 16, 2026.

As of the end of the reporting period, the non-transaction transfer of the 2026 Employee Stock Ownership Plan has not been completed.

Other employee incentives

□Applicable Not applicable

4. Environmental information disclosure

Whether listed companies and their major subsidiaries are included in the list of companies that disclose environmental information in accordance with the law

□Yes No

5. Social Responsibility

The company adheres to the enterprise spirit of "pioneering, innovative, pragmatic and efficient" and takes "serving human health, benefiting the world, and serving human health with advanced technology and high-quality products" as its purpose. While promoting its own development, it actively fulfills its social responsibilities and effectively coordinates economic and social benefits, short-term and long-term interests, and its own development and social development to achieve healthy and harmonious development of enterprises and employees, enterprises and society, and enterprises and the environment. 1. Protection of the rights and interests of shareholders and creditors

The company's profit distribution policy attaches great importance to reasonable investment returns for investors, takes into account the company's actual operating conditions and sustainable development, and maintains continuity and stability.

Protection of employees’ rights and interests

The company respects and protects the rights and interests of employees and provides employees with a healthy and safe working environment. In accordance with the provisions of the Labor Law of the People's Republic of China, the Labor Contract Law of the People's Republic of China and other national and local laws and regulations, we sign labor contracts with employees to provide them with necessary social security. In accordance with relevant national and local regulations, we pay social insurance and housing provident funds for all eligible employees. At the same time, the company continues to improve its employee welfare system and regularly distributes labor protection supplies, holiday gifts, and related allowances. The company has a trade union organization that carries out work in accordance with the requirements of the Trade Union Law to ensure the legitimate rights and interests of employees.

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Protection of the rights and interests of suppliers, customers and consumers

The company adheres to the quality policy of "customer-centered, building the core competitiveness of the enterprise with innovation capabilities and product quality, and becoming the first choice of customers", with the purpose of meeting market and customer needs, continuing to provide customers with high-quality products and services, and gaining long-term trust and support from customers. The company attaches great importance to maintaining good relationships with suppliers, fully respects and protects the legitimate rights and interests of suppliers, and strives to promote each other and grow together. Through mutual exchanges and learning in technology, quality, and services, the company develops hand in hand for mutual benefit and win-win results.

Environmental protection and sustainable development

In accordance with national regulations on environmental protection and resource conservation, and based on the company's actual situation, the company has established an environmental protection and resource conservation system to reduce pollutant emissions and improve the efficiency of comprehensive utilization of resources. The company continuously invests manpower, material and financial resources to improve processes and reduce energy consumption and pollutant emission levels; it conducts regular supervision and inspections to identify problems and take timely measures to correct them.

The company signed a distributed photovoltaic cooperation agreement with Hangzhou Hehan New Energy Co., Ltd., and Hehan New Energy funded the construction of a distributed photovoltaic power station at the company's Dongzhou production base. The project adopts the form of building integrated photovoltaic (BIPV), which not only generates green energy, but also effectively utilizes idle roofs. The project capacity is 610Kw. It has been put into use and connected to the grid for power generation. It is expected to generate more than 600,000 kWh of electricity annually. This project will not only save the company's electricity, waterproofing and roof maintenance costs, but is also expected to save more than 200 tons of standard coal and reduce emissions of more than 600 tons of carbon dioxide, as well as a considerable amount of sulfur dioxide, carbon dust, etc. every year.

The enzyme substrate method intelligent culture counting system developed by the company can be used by environmental testing units, centers for disease control and prevention, water companies, sewage treatment plants and other units and institutions to culture and determine the results of fecal coliforms, total coliforms, and Escherichia coli in water samples, assisting the comprehensive management of the domestic water environment.

5.Investor relations

The company strictly complies with the provisions of the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the GEM Stock Listing Rules of the Shenzhen Stock Exchange and other laws and regulations, departmental regulations, normative documents and the company's articles of association. The company continuously improves internal control management and corporate governance structure, convenes shareholders' meetings in accordance with the law, strictly fulfills its information disclosure obligations, and communicates with investors through various methods such as investor phone calls and investor relations interactive platforms to protect shareholders' rights to know and participate.

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Section 5 Important Matters

Commitments made by the company’s actual controller, shareholders, related parties, acquirers, the company and other relevant parties that have been fulfilled during the reporting period and have been overdue as of the end of the reporting period □ Applicable  Not applicable

During the reporting period of the company, there were no commitments made by the company's actual controller, shareholders, related parties, acquirers, the company and other relevant parties that were fully fulfilled during the reporting period and that were overdue and unfulfilled as of the end of the reporting period.

Non-operating capital occupation of listed companies by controlling shareholders and other related parties □Applicable Not applicable

During the company's reporting period, there was no non-operational occupation of funds by the listed company's controlling shareholders and other related parties.

3. Illegal external guarantees

□Applicable Not applicable

The company had no illegal external guarantees during the reporting period.

4. Appointment and dismissal of accounting firms

Has the semi-annual financial report been audited?

□Yes No

The company's semi-annual report has not been audited.

Explanations of the Board of Directors and the Audit Committee on the accounting firm’s “non-standard audit report” for this reporting period □ Applicable  Not applicable
Explanation of the Board of Directors on the “Non-standard Audit Report” of the previous year □Applicable Not applicable

7. Matters related to bankruptcy and reorganization

□Applicable Not applicable

The company had no bankruptcy or reorganization related matters during the reporting period.

8. Litigation matters

Major litigation and arbitration matters

□Applicable Not applicable

During the reporting period, the Company had no major litigation or arbitration matters.

Other litigation matters

Applicable □Not applicable

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Litigation (Arbitration) Litigation (Arbitration)

Litigation (Arbitration) Amount involved Whether a pre-litigation (arbitration) has been formed

Trial results and execution of judgment Disclosure date Basic information on disclosure index (10,000 yuan) Liability calculation progress

Influence situation

Company and subsidiaries

Not to the company

as plaintiff

financial status

less than significant

719.88 No In Progress and Going Concern /

Other litigation

Ability constitutes a heavy

Litigation Matters Collection

big adverse impact

total

Subsidiaries act as

Defendant’s financial situation fell short of

77.49 of major litigation No In progress and going concern /

Other litigation matters, capacity constitutes important

Summary of items Large adverse impact

9. Punishment and Rectification

□Applicable Not applicable

There were no penalties or rectifications during the company's reporting period.

10. Integrity status of the company, its controlling shareholders and actual controllers

□Applicable Not applicable

11. Major related transactions

Related transactions related to daily operations

Applicable □Not applicable

approved

Related sharing can be obtained

Is the related intersection related?

Related, related, related, related, transaction, quasi-transaction

Related party transaction amount exceeds transaction disclosure disclosed transaction transaction transaction transaction amount Yijin similar

Relationship Pricing Approval Settlement Date Indexer Type Content Price (10,000 Amount Transaction

Principle (10,000 amount method

Yuan) Ratio Market Price

Yuan)

Hongzhong Company Baide Yu Juweigong Chaozi Division Information Network Zizi (htt Company p://w Jiangsu Tailin ww.cn Hongzhong Life Press and Information.

Xiangguan 2026

Bai De Science According to the contract, com.c

Lianren Procurement Market 100.0 Discomfort Year 03

Biology Shareholding Same price 177.9 450 No Final settlement n) Disclosure

Purchase Product Pricing 0% Use Month 27

The publicity of science and technology is revealed

product day

Co., Ltd., Form "Related Company Company Director Yu 2026, Deputy General Manager Daily Manager Related Shen Zhi Transaction Lin Xian Full text of the expected 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

"Annual public notice of fellow students" Ren Hong (public notice number: Director 2026. 016) Hongzhong Company Baide Yu Juwei Chaozi Company Information Network (htt Company p://wtailinww.cn lifeinfo.science.com.c shareholding n) Phi Jiangsu

Public exposure to the public

Division, Xiang Guan 2026 "Guan Baide" according to the contract

Company associate sales market discomfort Year 03 Yu Biology Same price 3.8 0.94% 250 Negative settlement

Dong Sales Product Pricing Using Month 27 2026 Technology Grid Calculation

Things, products, day, year, limited form

Vice President Daily Company

Manager associated with Shen Zhi's transactions Mr. Lin's expected public announcement of colleagues "Ren Hong" (Public Report No. 2026-Director. 016) Total -- -- 181.7 -- 700 -- -- -- -- --

Details of large sales returns Not applicable

Daily correlations that will occur in this period by category

The total amount of transactions carried out is estimated, as reported N/A

Actual performance during the period (if any)

The difference between the transaction price and the market reference price is relatively

Not applicable

Big reason (if applicable)

Related transactions arising from asset or equity acquisition and sale

□Applicable Not applicable

The company had no related transactions involving acquisition or sale of assets or equity during the reporting period.

Related transactions related to joint external investment

□Applicable Not applicable

The company had no related transactions involving joint external investments during the reporting period.

Related credit and debt transactions

□Applicable Not applicable

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

The company had no related creditor's rights or debts during the reporting period.

Dealings with related financial companies

□Applicable Not applicable

There are no deposits, loans, credit or other financial business between the company and its related financial companies, or between the company's financial companies and related parties.

The transactions between the financial company controlled by the company and related parties

□Applicable Not applicable

There are no deposits, loans, credit or other financial business between the financial companies controlled by the company and related parties.

Other major related transactions

□Applicable Not applicable

The company had no other major related transactions during the reporting period.

12. Major contracts and their performance

Custody, contracting and leasing matters

(1) Custody situation

□Applicable Not applicable

There was no custody situation during the company's reporting period.

(2) Contracting situation

□Applicable Not applicable

There was no contracting situation during the reporting period of the company.

(3) Leasing situation

Applicable □Not applicable

Rental situation description

Serial number Lessor Lessee Address Lease period Rent Area (m2) 1 Tailin Biotechnology Binjiang District, Hangzhou Nanhuan Road, Binjiang District, Hangzhou 2025.12.01- December 1, 2025 to November 30, 2026 1303.46 1/2 Floor, Building 3, No. 2930, Pudong People's Government 2035.11.30 The cost is 444,045 yuan. From December 1, 2030, the rent for services along the street will increase by 8%.

2 Tailin Biotech Hangzhou Xingchuangling Nanhuan Road, Binjiang District, Hangzhou City 2025.07.15- Adjust the area, 6745.9 Pao Technology Co., Ltd. No. 2930, Building 3, 2027.07.14 Amount and term adjustment for the agreement signed on March 2, 2025, to the company's 4/5/6/7/8/10/11th floor on July 15, 2025 As of July 14, 2027, the rent is 3,939,605 yuan. Nanhuan Road, Binjiang District, Hangzhou City. 2025.07.15- The amount of the agreement signed on November 1, 2023, 1,060 2930, Building 2, East 4th Floor, 2027.07.14 Period adjustment, from July 15, 2025 to July 2027.

As of March 14, the rent is 619,040 yuan3 Tailin Biology Hangzhou An Yuansheng Nanhuan Road, Binjiang District, Hangzhou 2022.03.01- Rent from March 1, 2022 to February 28, 2027 952.50

No. 2930, Building 3, 9th Floor, Biomedical Technology 2027.02.28 Gold 2,953,259.88 yuan

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Ltd.

4 Tailin Bio Luckin Coffee Nanhuan Road, Binjiang District, Hangzhou 2024.10.20- October 20, 2024 to October 19, 2027 75 (Hangzhou) No. 2930, Building 3, 1st Floor, 101 2027.10.19 The annual rent is 266,907 yuan

Co., Ltd. Room

5 Tailin Biology Hangzhou Rendaohou Nanhuan Road, Binjiang District, Hangzhou 2026.2.3- February 3, 2026 to February 2, 2027 Rent 1,100 Qin Service Co., Ltd. 1F West, Building 2, No. 2930 2029.2.2 562,100 yuan, no increase thereafter

company

6 Tailin Biotech Hangzhou Zhou'anwen Nanhuan Road, Binjiang District, Hangzhou 2024.06.01- The first year's rent-free period is 3 months, and the annual rent is charged for 9 months in total 830hua Media Co., Ltd. 3F South, Building 2, No. 2930 2027.05.31 249,933.75 yuan, with an annual increase of 5% starting from the next year

Company Room 306

7 Tailin Biotech Hangzhou Fujin Electric Nanhuan Road, Binjiang District, Hangzhou 2025.06.01- First-year rent-free period of 2 months, first-year rent 104,691 298 Sub-Business Co., Ltd. 3F South, Building 2, No. 2930 2027.05.31 yuan, with an annual increase of 5% starting from the following year

Company Room 308

8 Tailin Biotech Hangzhou Weitong Construction Nanhuan Road, Binjiang District, Hangzhou City 2025.09.01- September 1, 2025 to August 31, 2026, 5.36 Construction Engineering Co., Ltd. Building 3, No. 2930 2026.08.31 Rent 2,400 yuan

Company 2025.07.14 B1

Room 102

Projects that bring profits and losses to the company exceeding 10% of the company's total profit during the reporting period

□Applicable Not applicable

During the company's reporting period, there were no leasing projects that brought profits or losses to the company that accounted for more than 10% of the company's total profits during the reporting period.

Major guarantee

□Applicable Not applicable

The company had no major guarantees during the reporting period.

Major contracts for daily operations

Unit: yuan with significant impact

Contract performance Whether there is a contract? Recognition in the current period Recognition cumulatively

The conclusion of the contract, the total amount of the contract, the performance of the contract, the various terms of accounts receivable, the contract cannot be the company's name, the sales revenue, the sales revenue

The name of the counterparty, the progress of the amount, the status of the payment, whether the package has been issued, the re-weighing of the performance, the amount of the deposit, the amount of the deposit.

Big risk of major changes

ization

Other major contracts

Applicable □Not applicable

contract contract

involve involve

Asset Asset As of Contract Valuation Valuation

Evaluation of Contract Accounts Transaction Report Contract Forming Organization Basis Whether

Enter into a contract Face price Valuation Pricing Price Relevance Period-end disclosure Disclosure Company Signing Name Date Relevance

Counterparty Target Value Value Principle (10000 Relationship Execution Date Index Party Name Date (such as (such as Transaction

Name (Ten thousand (ten thousand yuan) Quote: Yes) Yes)

yuan) yuan) condition (such as (such as

Yes) Yes)

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

The company is on Juchao Information Network (http://www in Hangzhou

.cnizhoufu

nfo.Spring Bay

com.New Town

cn) Construction

Disclosure based on

of high sex

"Guan Neng Gong"

Yu pseudo-energy membrane

Yu Hangcai

State rich material,

Spring Bay Bio

Xincheng Medical

Zhejiang Hangzhou Management Materials

Tailin Fuchun 2025 2025 Member materials, this item

New Material Bay New Year 05 Discomfort Discomfort 30,0 Year 04 Countersigned Membrane Group No No Project Construction

The information is that the urban management department will use it on October 15th to order height parts and equipment on October 28th.

Limited to Congregational Committee Day Day Performance Filter

Division Committee Filter Production

Utensils and goods,

Complete sets

Functional equipment

Film yield level

Industrial additional

Item worth new

contract materials

books cum products

external research

Investment occurs

public property base

"report" place

(Announcement No.: 2025 -

)

13. Description of other major matters

Applicable □Not applicable

Matters related to the repurchase of company shares

The company held the 11th meeting of the fourth board of directors on March 25, 2026, and reviewed and approved the "Proposal on the Plan to Repurchase the Company's Shares". For details, please refer to the company's announcement on March 27, 2026. The "Announcement on the Plan to Repurchase the Company's Shares" (Announcement Number: 2026-020) and the "Repurchase Report" (Announcement Number: 2026-024) were disclosed on the Juchao Information Network (http://www.cninfo.com.cn).

As of April 22, 2026, the company's share repurchase plan has been completed. For details, please refer to the "Announcement on the Repurchase of Shares Reaching 1% and the Completion of the Repurchase" (Announcement Number: 2026-030) disclosed by the company on April 24, 2026 on the cninfo website (http://www.cninfo.com.cn).

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Regarding matters related to the 2026 employee stock ownership plan

As of the end of the reporting period, the non-transaction transfer of the 2026 Employee Stock Ownership Plan has not been completed.

Matters related to the company’s issuance of convertible corporate bonds to unspecified objects

The company held the 11th meeting of the fourth session of the Board of Directors on March 25, 2026, and reviewed and approved the relevant proposals for the company to issue convertible corporate bonds to unspecified objects. For details, please refer to the "Plan for Issuing Convertible Corporate Bonds to Unspecified Objects" disclosed by the company on the cninfo.com (http://www.cninfo.com.cn) on March 27, 2026 and other relevant announcements.

The company held the 2025 annual shareholders' meeting on April 16, 2026, and reviewed and approved the relevant resolutions on the company's issuance of convertible corporate bonds to unspecified objects, and authorized the board of directors to handle all matters related to the issuance of convertible corporate bonds. For details, please refer to the relevant announcement disclosed by the company on the cninfo.com (http://www.cninfo.com.cn) on April 16, 2026.

On April 27, 2026, the company received the "Notice on Acceptance of Application Documents for Zhejiang Tailin Biotechnology Co., Ltd. to issue convertible corporate bonds to unspecified objects" (Shenzhen Stock Exchange [2026] No. 90) issued by the Shenzhen Stock Exchange (hereinafter referred to as the "Shenzhen Stock Exchange"). The Shenzhen Stock Exchange checked the application documents submitted by the company for the issuance of convertible corporate bonds to unspecified objects, deemed the application documents to be complete, and decided to accept the application. For details, please refer to the relevant announcement disclosed by the company on the cninfo.com (http://www.cninfo.com.cn) on April 28, 2026.

On May 19, 2026, the company received the "Audit Inquiry Letter Regarding Zhejiang Tailin Biotechnology Co., Ltd.'s Application for Issuing Convertible Corporate Bonds to Unspecified Objects" (Audit Letter [2026] No. 020044) (hereinafter referred to as the "Audit Inquiry Letter") issued by the Shenzhen Stock Exchange. In accordance with the requirements of the audit inquiry letter, the company has worked with relevant intermediaries to implement the procedures one by one and submitted responses to the audit inquiry letter in a timely manner. For details, please refer to the relevant announcement disclosed by the company on the cninfo.com (http://www.cninfo.com.cn) on June 3, 2026.

The company held the 14th meeting of the fourth session of the Board of Directors on July 1, 2026, and reviewed and approved the "Proposal on the Company's Plan for Issuing Convertible Corporate Bonds to Unspecified Objects (Revised Draft)", the "Proposal on the "Company's Plan for Issuing Convertible Corporate Bonds to Unspecified Objects (Revised Draft)"" and "On The company issued a convertible corporate bond to unspecified objects to raise funds to use the feasibility analysis report (revised draft)" and other proposals. For details, please refer to the relevant announcement disclosed by the company on the cninfo.com (http://www.cninfo.com.cn) on July 1, 2026.

On July 13, 2026, the Shenzhen Stock Exchange Listing Review Committee held the 42nd Listing Review Committee review meeting in 2026, and reviewed the company's application for issuance of convertible corporate bonds to unspecified objects. The review result of the meeting was to suspend review. For details, please refer to the company's July 13, 2026 The "Announcement on the Review Results of the Shenzhen Stock Exchange's Listing Review Committee for the Issuance of Convertible Corporate Bonds to Unspecified Objects" was disclosed on the Juchao Information Network (http://www.cninfo.com.cn) (Announcement No.: 2026-051).

On July 14, 2026, the company received the "Implementation Letter on the Deliberation Opinions of the Listing Review Committee" (Audit Letter [2026] No. 020058) issued by the Shenzhen Stock Exchange Listing Review Center (hereinafter referred to as the "Implementation Letter"). In accordance with the requirements of the implementation letter, the company has provided explanations and responses one by one with relevant intermediaries. For details, please refer to the relevant announcement disclosed by the company on July 20, 2026 on the cninfo.com (http://www.cninfo.com.cn).

The company held the 15th meeting of the fourth board of directors on August 14, 2026, and reviewed and approved the "Proposal on Terminating the Issuance of Convertible Corporate Bonds to Unspecified Objects and Withdrawing the Application Documents", and agreed that the company would terminate the issuance of convertible corporate bonds to unspecified objects and withdraw the application documents. For details, please refer to the relevant announcement disclosed by the company on the cninfo.com (http://www.cninfo.com.cn) on August 14, 2026.

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

On August 21, 2026, the company received the "Decision on Terminating the Review of Zhejiang Tailin Biotechnology Co., Ltd.'s Application for the Issuance of Convertible Corporate Bonds to Unspecified Objects" issued by the Shenzhen Stock Exchange (Shenzhen Stock Exchange [2026] No. 259). According to the relevant provisions of Article 20 of the Shenzhen Stock Exchange’s Review Rules for the Issuance and Listing of Securities by Listed Companies (Revised in 2025) and Article 62 of the Shenzhen Stock Exchange’s Review Rules for the Issuance and Listing of Stocks (Revised in 2024), the Shenzhen Stock Exchange decided to terminate the review of the company’s application for the issuance of convertible corporate bonds to unspecified objects. For details, please refer to the relevant announcement disclosed by the company on August 24, 2026 on the cninfo network (http://www.cninfo.com.cn).

14. Major events of the company’s subsidiaries

□Applicable Not applicable

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Section 6 Share changes and shareholder status

1. Changes in shares

Changes in shares

Unit: Before the change in share capital Increase or decrease in this change (+, -) After this change, transfer of reserve fund

Quantity Proportion Issuance of new shares Bonus shares Others Subtotal Quantity Proportion

1. Limited

36,073,1 36,073,1 Conditional shares 29.76% 29.76%

46.00 46.00 copies

Country

Home holdings

Country

A legal person holds

36,073,1 36,073,1 Held by other domestic investors 29.76% 29.76%

46.00 46.00 shares

its

Middle: within the territory

Legal person holdings

within the territory

36,073,1 36,073,1 Held by natural persons 29.76% 29.76%

46.00 46.00 shares

outside

Capital holdings

its

Chinese: overseas

Legal person holdings

overseas

natural person

2. Unlimited

85,126,0 85,126,0 Conditional shares 70.24% 70.24%

73.00 73.00 copies

People

85,126,0 85,126,0 RMB Ordinary 70.24% 70.24%

73.00 73.00 shares

Environment

listed within

foreign stocks

Environment

Off the market

foreign stocks

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

him

3. Shares 121,199, 121,199,

100.00% 100.00%Total 219.00 219.00

Reasons for share changes

□Applicable Not applicable

Approval status of share changes

□Applicable Not applicable

Transfer status of changes in shares

□Applicable Not applicable

Implementation progress of share buybacks

Applicable □Not applicable

The company held the 11th meeting of the fourth session of the Board of Directors on March 25, 2026, and reviewed and approved the "Proposal on the Plan to Repurchase the Company's Shares", agreeing that the company will use its own funds and/or self-raised funds to repurchase some of the company's RMB A ordinary shares in a centralized bidding transaction for the implementation of the employee stock ownership plan. For details, please refer to the "Announcement on the Plan to Repurchase the Company's Shares" (Announcement No.: 2026-020) and the "Repurchase Report" (Announcement No.: 2026-024) disclosed by the company on the cninfo.com (http://www.cninfo.com.cn) on March 27, 2026 and March 30, 2026 respectively.

On April 17, 2026, the company implemented share repurchase for the first time through centralized bidding transactions through a special securities account for repurchase; as of April 22, 2026, the company had repurchased a total of 1,217,970 shares of the company through centralized bidding transactions through a special securities account for share repurchases, accounting for 1.00% of the current total share capital of the company. The highest transaction price was 26.84 yuan/share, and the lowest transaction price was 26.00. Yuan/share, the total transaction amount is 32,282,907.30 Yuan (excluding transaction fees). So far, the share repurchase plan has been completed. For details, please refer to the "Announcement on the First Repurchase of the Company's Shares" (Announcement Number: 2026-028) and the "Announcement on the Repurchase of Shares Reaching 1% and the Completion of the Repurchase" (Announcement Number: 2026-030) disclosed by the company on April 18, 2026 and April 24, 2026 on the cninfo.com.cn (http://www.cninfo.com.cn).

Implementation progress of using centralized bidding method to reduce and repurchase shares

□Applicable Not applicable

The impact of share changes on financial indicators such as basic earnings per share and diluted earnings per share in the most recent year and period, net assets per share attributable to the company’s common shareholders Applicable □Not applicable

In April 2026, the company reduced the number of shares by 1,217,970 shares due to repurchase, and the weighted average number of ordinary shares outstanding was 120,793,229 shares. After the change in shares in this period, the basic earnings per share was 0.17 yuan, and the diluted earnings per share was 0.17 yuan; the net assets per share attributable to the company's common shareholders were 6.66 yuan.

Other content that the company deems necessary or required to be disclosed by securities regulatory authorities

□Applicable Not applicable

Changes in restricted shares

□Applicable Not applicable

2. Securities issuance and listing

□Applicable Not applicable

3. Number of shareholders and shareholding status of the company

Unit: Share

Voting rights were restored at the end of the reporting period.

Common shares at the end of the reporting period

10,852 Total preferred shareholders 0 votes 0 total shareholders

Number (if any) (see registered shares

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Total number of shareholders (if any)

Shareholding status of shareholders holding more than 5% of the shares or the top 10 shareholders (excluding shares lent through refinancing)

Reporting period: Held: No: Pledged, marked or frozen

reporting period

Name of shareholder, nature of shareholder, shareholding ratio, increase or decrease during the period, sales restriction clause, shareholding at the end of the sales restriction clause

Example of change in the quality of the shares, the status of the shares, the number of shares, the number of shares

Condition Quantity of copies Quantity of copies

Domestic 45,724, 34,293, 11,431, Ye Dalin 37.73% 0.00 Not applicable 0 Random person 000.00 000.00 000.00 18,402,

Within the territory from 18,402,

Ni Weiju 15.18% 0.00 0.00 400.00 Not applicable 0 Ranren 400.00

Note

Qingdao High

Gotta invest

Domestic non-

Partnership 5,466,3 5,466,3

State-owned law 4.51% 0.00 0.00 Not applicable 0 industries (yes 00.00 00.00

people

Limited combination

Guy)

Zhejiang Tai

forest biology

technology stocks

Limited copies 1,208,0 1,208,0

Others 1.00% 0.00 0.00 Not applicable 0 Company - 00.00 00.00 2025

Employees hold

stock plan

Domestic self 1,171,2 878,466 292,822Xia Xinqun 0.97% 0.00 Not applicable 0 natural person 88.00 .00 .00

Domestic 912,496 684,372 228,124Shen Zhilin 0.75% 0.00 Not applicable 0 natural person .00 .00 .00

Domestic since 791,500 791,500 791,500Song Caisheng 0.65% 0.00 Not applicable 0

Ranren .00 .00 .00Beijing Xi

Jinhui Investment

Asset management

limited company

673,467 673,467 Si-Xi Others 0.56% 0.00 0.00 Not applicable 0

.00 .00Jin Hui

Sichuan Securities

private equity

gold

Chinese farmers

industrial bank

Shares are

Ltd.

-China

617,500 617,500 617,500 China Securities Others 0.51% 0.00 Not applicable 0

.00 .00 .00 500 points

digital enhancement

securities

investment base

gold

Domestic from 609,700 609,700 609,700Luo Xiangchun 0.50% 0.00 Not applicable 0

Ranren .00 .00 .00Full text of 2026 Semi-annual Report of Zhejiang Tailin Biotechnology Co., Ltd.

strategic investor or general

The legal person's profit due to the placement of new shares

For the top 10 shareholders Not applicable

condition (if any) (see note

Mr. Ye Dalin and Ms. Ni Weiju are husband and wife. They are the company’s controlling shareholders and actual controllers. Mr. Ye Dalin serves as the company’s chairman and general manager. Mr. Ye Dalin serves as the executive partner of Gaode Investment. Gaode Investment has a related relationship with the company’s controlling shareholder and actual controller.

It constitutes a relationship of acting in concert; Mr. Xia Xinqun and Mr. Shen Zhilin are directors and senior managers of the company, and they are partners or acting in concert of Gaode Investment.

He is a participant in the "Zhejiang Tailin Biotechnology Co., Ltd. - 2025 Employee Stock Ownership Plan". In addition, the company does not know whether there is any related relationship or concerted action relationship between other shareholders.

The above shareholders are involved in entrustment/

Fiduciary voting rights, waiver Not applicable

Explanation of voting rights

Among the top 10 shareholders

As of the end of the reporting period, the number of shares held in the special repurchase securities account of Zhejiang Tailin Biotechnology Co., Ltd. was 1,217,970.00 shares, accounting for 1,217,970.00 shares of the special repurchase account.

1.00% of the company's total share capital.

Ming (see Note 11)

Shareholdings of the top 10 shareholders without sales restrictions (excluding shares lent through refinancing and shares locked by executives)

Share type

Name of shareholder Number of shares without selling restrictions held at the end of the reporting period

Type of shares Quantity Ni Weiju 18,402,400.00 RMB ordinary shares 18,402,400.00 Ye Dalin 11,431,000.00 RMB ordinary shares 11,431,000.00 Qingdao Gaode Investment Partnership

5,466,300.00 RMB ordinary shares 5,466,300.00 Enterprise (limited partnership)

Zhejiang Tailin Biotechnology

Co., Ltd. -

1,208,000.00 RMB ordinary shares 1,208,000.00 2025 employee stock ownership plan

row

Song Caisheng 791,500.00 RMB ordinary shares 791,500.00 Beijing Xijinhui Investment Management

Management Co., Ltd.-Xi Jin

673,467.00 RMB ordinary shares 673,467.00 Huichuan Securities Private Equity Fund

gold

Agricultural Bank of China Co., Ltd.

Co., Ltd. - Hua Xia Zhong

617,500.00 RMB ordinary shares 617,500.00 Securities 500 Index Enhanced

securities investment funds

Luo Xiangchun 609,700.00 RMB ordinary shares 609,700.00 Shen Lihua 600,000.00 RMB ordinary shares 600,000.00 China Construction Bank shares

Co., Ltd.-Noando

517,900.00 RMB ordinary shares 517,900.00 Strategic mixed securities investment

capital fund

Unlimited sales conditions for the top 10

Mr. Ye Dalin and Ms. Ni Weiju are husband and wife. They are the controlling shareholders and actual controllers of the company. Mr. Ye Dalin is the director of the company, shareholders, and former shareholders.

Chairman and General Manager; Mr. Ye Dalin serves as the executive partner of Gaode Investment. Gaode Investment and 10 controlling shareholders and actual controllers of the company have unrestricted shares.

constitute a concerted action relationship; Mr. Xia Xinqun and Mr. Shen Zhilin serve as directors and senior managers of the company, and are among the top 10 shareholders of Gaode Investment’s partnership in Donghe.

He is a participant in the "Zhejiang Tailin Biotechnology Co., Ltd. - 2025 Employee Stock Ownership Plan". Apart from this, the companies are not related or consistent

Know whether there is any related relationship or concerted action relationship between other shareholders.

description of action

Song Caisheng, the top 10 ordinary shareholders, holds 441,500 shares through ordinary securities accounts and 350,000 shares through credit securities accounts. The actual total holdings are 791,500 shares participating in margin trading and securities lending business. Beijing Xijinhui Investment Management Co., Ltd. - Xijinhui Hechuan Securities Private Equity Fund holds 0 shares through ordinary securities accounts (for example, 491,667 shares, 181,800 shares are held through credit securities accounts, and the actual total is 673,467 shares held. Luo Xiangchun holds 0 shares through ordinary securities accounts, and 609,700 shares are held through credit securities accounts, and the actual total is 609,700 shares.

Note: Including the 12.1 million shares that Ms. Ni Weiju voluntarily locked and transferred in the "Share Transfer Agreement" signed with Mr. Ye Dalin on May 30, 2025. According to the "Letter of Commitment on Share Locking" issued by Ms. Ni Weiju, she promised not to actively reduce the shareholding in any way within 12 months from the date of completion of the transfer. Full text of the 2026 Semi-annual Report of Zhejiang Tailin Biotechnology Co., Ltd. Zhejiang Tailin Biotechnology Co., Ltd.

shares obtained. As of the disclosure date of this report, this commitment has been fulfilled. Situation of shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of unrestricted tradable shares participating in the refinancing business and lending shares □Applicable Not applicable

The top 10 shareholders and the top 10 shareholders of unrestricted tradable shares have changed from the previous period due to refinancing lending/returning □Applicable Not applicable

Whether the company has differential voting rights arrangements

□Yes No

Whether the company's top 10 common shareholders and the top 10 common shareholders without selling restrictions have conducted agreed repurchase transactions during the reporting period Yes  No

The company's top 10 common shareholders and the top 10 common shareholders without selling restrictions did not conduct agreed repurchase transactions during the reporting period.

4. Changes in shareholdings of directors and senior managers

□Applicable Not applicable

The shareholdings of the company's directors and senior managers did not change during the reporting period. For details, please refer to the 2025 annual report.

5. Changes in controlling shareholders or actual controllers

If the company has previously disclosed that the actual controller is planning a change of control but has not yet completed it, please explain the progress of the change of control. □Applicable Not applicable

Changes in controlling shareholders during the reporting period

□Applicable Not applicable

The company's controlling shareholder did not change during the reporting period.

Changes in actual controller during the reporting period

□Applicable Not applicable

The actual controller of the company did not change during the reporting period.

6. Relevant information on preference shares

□Applicable Not applicable

There were no preferred shares in the company during the reporting period.

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Section 7 Bond-related situations □Applicable Not applicable

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Section 8 Financial Report

1. Audit report

Has the semi-annual report been audited?

□Yes No

The company's semi-annual financial report has not been audited.

2. Financial statements

The unit of statements in the financial notes is: Yuan

Consolidated balance sheet

Prepared by: Zhejiang Tailin Biotechnology Co., Ltd.

June 30, 2026

Unit: Yuan

Item Ending balance Beginning balance

Current assets:

Monetary funds 155,451,865.25 149,088,376.64 Settlement reserves

Loan funds

Trading financial assets 37,100,000.00 61,120,441.21 Derivative financial assets

Notes receivable

Accounts receivable 55,441,771.81 55,073,932.77 Accounts receivable financing 8,764,689.34 12,778,553.43 Prepayments 6,081,493.14 4,101,853.88 Premiums receivable

Reinsurance accounts receivable

Receivable reinsurance contract reserves

Other receivables 7,654,832.04 7,403,136.38 Including: interest receivable

Dividends receivable

Buy financial assets under resale agreements

Inventory 136,452,748.10 126,535,071.63

Among them: data resources

Contract assets 6,904,907.97 4,967,260.85 Assets held for sale

Non-current assets due within one year

Other current assets 109,666,354.22 128,781,141.12 Total current assets 523,518,661.87 549,849,767.91 Full text of the 2026 Semi-annual Report of Zhejiang Tailin Biotechnology Co., Ltd.

Non-current assets:

Grant loans and advances

debt investment

Other debt investments 55,819,673.98 55,452,627.40 Long-term receivables

Long-term equity investment 11,104,836.63 10,549,721.85 Other equity instrument investments

Other non-current financial assets

Investment real estate 8,399,509.00 8,551,355.56 Fixed assets 244,342,116.18 250,792,052.78 Construction in progress 39,161,752.01 9,259,817.63 Productive biological assets

oil and gas assets

right-of-use assets

Intangible assets 26,994,622.93 27,392,503.39

Among them: data resources

development expenditure

Among them: data resources

goodwill

Long-term deferred expenses 28,112,311.40 29,069,749.33 Deferred income tax assets 158,565.00 169,460.81 Other non-current assets 152,600.00 17,885,526.73 Total non-current assets 414,245,987.13 409,122,815.48 Total assets 937,764,649.00 958,972,583.39 Current liabilities:

short term borrowing

Borrow from the central bank

borrowing funds

Trading financial liabilities

Derivative financial liabilities

Notes payable

Accounts payable 30,769,872.42 15,858,863.20 Advance payments

Contract liabilities 72,340,074.77 65,727,476.61 Financial assets sold and repurchased

Taking deposits and placing deposits with other banks

Agent for buying and selling securities

Agent underwriting securities funds

Employee benefits payable 16,424,180.01 28,000,225.11 Taxes payable 3,210,820.51 5,069,396.07 Other payables 13,710,705.20 30,935,912.34 Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Among them: interest payable

Dividends payable

Handling fees and commissions payable

Reinsurance accounts payable

Liabilities held for sale

Non-current liabilities due within one year

Other current liabilities 8,399,483.37 6,543,946.12 Total current liabilities 144,855,136.28 152,135,819.45 Non-current liabilities:

insurance contract reserves

long term borrowing

bonds payable

Among them: preferred shares

perpetual bond

Lease liability

long-term payables

Long-term employee benefits payable

Estimated liabilities

deferred income

Deferred income tax liabilities 2,184,366.92 2,545,336.65

Other non-current liabilities

Total non-current liabilities 2,184,366.92 2,545,336.65 Total liabilities 147,039,503.20 154,681,156.10 Owners’ equity:

Share capital 121,199,219.00 121,199,219.00 Other equity instruments

Among them: preferred shares

perpetual bond

Capital reserve 414,449,343.70 412,503,433.90 Less: treasury shares 32,285,577.51

other comprehensive income

special reserve

Surplus reserve 31,190,070.38 27,628,568.73 General risk reserve

Undistributed profits 256,172,090.23 242,960,205.66 Total owners’ equity attributable to the parent company 790,725,145.80 804,291,427.29

minority interests

Total owners’ equity 790,725,145.80 804,291,427.29 Total liabilities and owners’ equity 937,764,649.00 958,972,583.39 Legal representative: Ye Dalin Person in charge of accounting work: Ye Xingyue Person in charge of accounting department: Zhou Wenqin

Balance sheet of the parent company

Unit: Yuan

Item Ending balance Beginning balance

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Current assets:

Monetary funds 107,401,692.58 83,642,174.79 Trading financial assets 20,100,000.00 56,103,090.25 Derivative financial assets

Notes receivable

Accounts receivable 2,290,253.40 2,726,360.06 Accounts receivable financing 63,000.00 532,000.00 Prepayments 131,856.35 383,445.37 Other receivables 2,422,634.44 3,216,862.63 Including: interest receivable

Dividends receivable

Inventory

Among them: data resources

Contract assets 522,202.00 129,852.00 Assets held for sale

Non-current assets due within one year

Other current assets 80,726,259.68 95,872,047.56 Total current assets 213,657,898.45 242,605,832.66 Non-current assets:

debt investment

Other debt investments 10,013,863.01

long-term receivables

Long-term equity investment 424,426,309.36 419,811,823.52 Other equity instrument investments

Other non-current financial assets

Investment real estate 8,399,509.00 8,551,355.56 Fixed assets 4,083,071.85 4,371,714.46 Construction in progress

productive biological assets

oil and gas assets

right-of-use assets

Intangible assets 1,668,152.25 1,775,989.23

Among them: data resources

development expenditure

Among them: data resources

goodwill

Long-term deferred expenses 1,961,295.45 1,885,522.60 Deferred income tax assets

Other non-current assets

Total non-current assets 450,552,200.92 436,396,405.37 Total assets 664,210,099.37 679,002,238.03 Full text of the 2026 Semi-annual Report of Zhejiang Tailin Biotechnology Co., Ltd.

Current liabilities:

short term borrowing

Trading financial liabilities

Derivative financial liabilities

Notes payable

Accounts payable 1,093,975.40 2,480,404.43 Advance payments

Contract liabilities 4,301,852.50 4,059,554.85 Employee benefits payable 1,458,369.34 3,411,963.39 Taxes payable 651,123.03 654,114.50 Other payables 12,538,624.21 26,112,081.44 of which: interest payable

Dividends payable

Liabilities held for sale

Non-current liabilities due within one year

Other current liabilities 559,240.82 312,726.04 Total current liabilities 20,603,185.30 37,030,844.65 Non-current liabilities:

long term borrowing

bonds payable

Among them: preferred shares

perpetual bond

Lease liability

long-term payables

Long-term employee benefits payable

Estimated liabilities

deferred income

Deferred income tax liability

Other non-current liabilities

Total non-current liabilities

Total liabilities 20,603,185.30 37,030,844.65 Owners’ equity:

Share capital 121,199,219.00 121,199,219.00 Other equity instruments

Among them: preferred shares

perpetual bond

Capital reserve 414,386,059.45 412,480,540.25 Less: treasury shares 32,285,577.51

other comprehensive income

special reserve

Surplus reserve 31,190,070.38 27,628,568.73 Undistributed profits 109,117,142.75 80,663,065.40 Total owners’ equity 643,606,914.07 641,971,393.38 Full text of the 2026 Semi-annual Report of Zhejiang Tailin Biotechnology Co., Ltd.

Total liabilities and owners’ equity 664,210,099.37 679,002,238.03

Consolidated income statement

Unit: Yuan

Project Half-year 2026 Half-year 2025

Total operating income 165,382,315.28 145,825,607.20 Including: operating income 165,382,315.28 145,825,607.20 Interest income

Premiums earned

Fee and commission income

Total operating costs 148,978,158.00 132,729,520.40 Including: operating costs 84,317,136.48 70,109,926.46 Interest expenses

Handling fees and commission expenses

surrender deposit

Net compensation expenses

Net withdrawal of insurance liability reserves

policy dividend payout

Reinsurance cost

Taxes and surcharges 1,588,573.93 1,445,942.52 Sales expenses 19,682,491.66 18,594,428.14 Management expenses 19,058,147.40 15,885,481.21 Research and development expenses 25,664,633.42 30,976,719.59Financial expenses -1,332,824.89 -4,282,977.52Including: interest expenses

Interest income 2,062,233.89 4,462,895.95 plus: other income 4,400,416.82 2,660,840.59 investment income (losses are filled in with "-"

1,641,315.01 -5,502.22 columns)

Of which: for associates and joint ventures

555,114.78 -5,502.22 Enterprise investment income

Measured at amortized cost

Income from derecognition of financial assets

Exchange gains (losses are filled in with "-"

column)

Net exposure hedging gains (losses expressed as “—

"Fill in the column)

Gains from changes in fair value (losses calculated as

Fill in the column with "—" sign)

Credit impairment losses (losses are preceded by “—”

No. 312,571.64 -2,090,608.33 (please fill in the list)

Asset impairment losses (losses are represented by “—”

-886,249.41 -27,112.65 (fill in the numbers)

Gains from asset disposals (losses are marked with “—”

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

(Fill in the number)

Operating profit (loss should be filled in with “—”

21,872,211.34 13,633,704.19 columns)

Add: non-operating income 3,141.73 19,066.82

Less: Non-operating expenses 265,965.06 554,738.54

Total profits (total losses are marked with “—”

21,609,388.01 13,098,032.47 fill in the column)

Less: Income tax expense 1,236,564.32 -244,678.60

Net profit (net loss is filled in with "-"

20,372,823.69 13,342,711.07 columns)

(1) Classification by business continuity

Net profit from continuing operations (net loss divided by

20,372,823.69 13,342,711.07 (Fill in “—”)

Net profit from discontinued operations (net loss is listed with “—”)

(2) Classification according to ownership ownership

Net profit attributable to shareholders of the parent company

20,372,823.69 13,542,949.18 (Net loss is listed with "—")

Profit and loss of minority shareholders (net loss is represented by “—

-200,238.11 "Fill in the number)

6. Net amount of other comprehensive income after tax

Other comprehensive income, net of tax, attributable to owners of the parent company

(1) Other comprehensive income that cannot be reclassified into profit or loss

Remeasure the changes in defined benefit plan
Other comprehensive income that cannot be transferred to profit or loss under the equity method
Changes in fair value of other equity instrument investments
Changes in the fair value of the company’s own credit risk

5.Others

(2) Other comprehensive income that will be reclassified into profit and loss

Other comprehensive income that can be converted to profit or loss under the equity method
Changes in fair value of other debt investments 3. Amount of financial assets reclassified and included in other comprehensive income
Credit impairment provisions for other debt investments 5. Cash flow hedging reserves
Translation differences of foreign currency financial statements

7.Others

Other comprehensive income, net of tax, attributable to minority shareholders

Total comprehensive income 20,372,823.69 13,342,711.07 Total comprehensive income attributable to owners of the parent company

20,372,823.69 13,542,949.18

Total comprehensive income attributable to minority shareholders -200,238.11

8. Earnings per share:

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

(1) Basic earnings per share 0.17 0.11

(2) Diluted earnings per share 0.17 0.11 If a business merger under the same control occurs in this period, the net profit realized by the merged party before the merger is: 0.00 yuan, and the net profit realized by the merged party in the previous period is: 0.00 yuan. Legal representative: Ye Dalin Person in charge of accounting work: Ye Xingyue Person in charge of accounting department: Zhou Wenqin

Income statement of the parent company

Unit: Yuan

Project Half-year 2026 Half-year 2025

Operating income 5,311,398.18 4,326,116.36 Less: Operating costs 1,938,793.45 438,543.93 Taxes and surcharges 458,854.54 494,638.73 Sales expenses 32,494.62 128,238.42 Management expenses 8,883,540.81 8,216,235.87 Research and development expenses 399,594.52 539,370.70 Financial expenses -1,750,183.99 -3,832,890.09 Including: interest expenses

Interest income 1,760,644.15 -3,849,158.27 plus: other income 115,175.30 34,776.14 investment income (losses are filled in with "-"

40,249,783.78 -2,714,606.40 columns)

Of which: for associates and joint ventures

investment income

Money measured at amortized cost

Income from derecognition of financial assets

Net exposure hedging gains (losses expressed as “—

"Fill in the column)

Gains from changes in fair value (losses calculated as

Fill in the column with "—" sign)

Credit impairment losses (losses are preceded by “—”

-15,226.06 -2,497,736.72 (fill in the numbers)

Asset impairment losses (losses are represented by “—”

-20,650.00 82,909.00 (please fill in the numbers)

Gains from asset disposals (losses are marked with “—”

(Fill in the number)

2. Operating profit (loss should be filled in with “—”

35,677,387.25 -6,752,679.18 columns)

Add: Non-operating income 20.13 9,100.02 Less: Non-operating expenses 62,390.91 4,300.92

3. Total profit (total loss is marked with “—”

35,615,016.47 -6,747,880.08 fill in the column)

Less: Income tax expense -3,628.70

4. Net profit (net loss is filled in with "—"

35,615,016.47 -6,744,251.38 columns)

(1) Net profit from continuing operations (net loss divided by

35,615,016.47 -6,744,251.38 (Fill in “—”)

(2) Net profit from discontinued operations (net loss equal to

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Fill in the column with "—" sign)

5. Net amount of other comprehensive income after tax

(1) Other comprehensive income that cannot be reclassified into profit or loss

Remeasure the changes in defined benefit plan
Other comprehensive income that cannot be transferred to profit or loss under the equity method
Changes in fair value of other equity instrument investments
Changes in the fair value of the company’s own credit risk

5.Others

(2) Other comprehensive income that will be reclassified into profit and loss

Other comprehensive income that can be converted to profit or loss under the equity method
Changes in fair value of other debt investments
The amount of financial assets reclassified and included in other comprehensive income
Credit impairment provisions for other debt investments 5. Cash flow hedging reserves
Translation differences of foreign currency financial statements

7.Others

Total comprehensive income 35,615,016.47 -6,744,251.38

7. Earnings per share:

(1) Basic earnings per share

(2) Diluted earnings per share

Consolidated cash flow statement

Unit: Yuan

Project Half-year 2026 Half-year 2025

1. Cash flow generated from operating activities:

Cash received from sales of goods and provision of services 191,499,433.14 144,693,583.98 Net increase in customer deposits and interbank deposits

Net increase in borrowing from the central bank

The net increase in funds borrowed from other financial institutions is the cash obtained from premiums received from the original insurance contract.

Net cash received from reinsurance business

Net increase in policyholders’ savings and investment funds

Net increase in cash borrowing funds collected from interest, handling fees and commissions

Net increase in repurchase business funds

Net cash received from buying and selling securities on behalf of agents

Tax returns received 4,539,251.74 3,650,225.75 Other cash received related to operating activities 5,639,562.49 8,514,128.53 Subtotal of cash inflows from operating activities 201,678,247.37 156,857,938.26 Cash paid for purchasing goods and receiving services 76,247,301.01 45,460,508.04

Net increase in loans and advances to customers

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Net increase in deposits with central banks and inter-banks

Cash used to pay compensation from the original insurance contract

Net increase in lending funds

Cash payments for interest, fees and commissions

Cash payment for policy dividends

Cash paid to and for employees 80,701,070.47 75,307,420.36 Various taxes and fees paid 12,915,916.82 13,306,346.33

Other cash payments related to operating activities 10,713,389.59 19,662,977.18 Subtotal cash outflow from operating activities 180,577,677.89 153,737,251.91 Net cash flow generated from operating activities 21,100,569.48 3,120,686.35

2. Cash flow generated from investing activities:

Recover cash received on investment

Cash received from investment income

Disposal of fixed assets, intangible assets and other long-term

Net cash received from period assets

Received from disposal of subsidiaries and other business units

net cash

Other cash received related to investing activities 817,940,739.86 596,652,600.71 Subtotal of cash inflows from investing activities 817,940,739.86 596,652,600.71 Purchase and construction of fixed assets, intangible assets and other long-term assets

24,582,304.26 17,581,203.12 Cash paid for assets

Cash paid for investments

Net increase in mortgage loans

Obtain payment from subsidiaries and other business units

net cash

Payment of other cash related to investing activities 701,800,000.00 552,900,000.00 Subtotal cash outflow from investing activities 726,382,304.26 570,481,203.12 Net cash flow generated from investing activities 91,558,435.60 26,171,397.59

3. Cash flow generated from financing activities:

Cash received from investment 11,174,000.00

Among them: subsidiaries absorb investment income from minority shareholders

Cash arrived

Obtain cash received from borrowing money

Other cash received related to financing activities

Subtotal of cash inflows from financing activities 11,174,000.00 Cash paid to repay debts 3,669,656.41

Distribution of dividends, profits or repayment of interest payments

3,599,437.47 12,125,603.81 cash

Including: shares paid by subsidiaries to minority shareholders

Profit, profit

Payment of other cash related to financing activities 32,285,577.51 23,673,896.31 Subtotal of cash outflows from financing activities 35,885,014.98 39,469,156.53 Net cash flow generated from financing activities -35,885,014.98 -28,295,156.53

4. The impact of exchange rate changes on cash and cash equivalents

-455,933.89 -96,942.58 impact

Net increase in cash and cash equivalents 76,318,056.21 899,984.83

Add: Balance of cash and cash equivalents at the beginning of the period 78,545,303.53 69,878,082.46

Balance of cash and cash equivalents at the end of the period 154,863,359.74 70,778,067.29
Cash flow statement of the parent company

Unit: Yuan Zhejiang Tailin Biotechnology Co., Ltd. Full text of 2026 semi-annual report

Project Half-year 2026 Half-year 2025

1. Cash flow generated from operating activities:

Cash received from selling goods and providing services 3,300,343.44 2,008,924.79 Tax refunds received 20,830.94 Cash received from other operating activities 4,293,411.68 4,540,916.03 Subtotal of cash inflows from operating activities 7,593,755.12 6,570,671.76 Cash paid for purchasing goods and receiving services 3,460,139.40 429,640.00 Cash paid to and for employees 6,986,888.65 7,967,435.27 Various taxes and fees paid 694,773.44 910,901.95 Other cash payments related to operating activities 15,270,814.59 1,982,067.93 Subtotal cash outflow from operating activities 26,412,616.08 11,290,045.15 Net cash flow generated from operating activities -18,818,860.96 -4,719,373.39

2. Cash flow generated from investing activities:

Recover cash received on investment

Cash received from investment income 40,000,000.00

Disposal of fixed assets, intangible assets and other long-term

Net cash received from period assets

Received from disposal of subsidiaries and other business units

net cash

Other cash received related to investing activities 762,521,491.30 615,379,634.38 Subtotal of cash inflows from investing activities 802,521,491.30 615,379,634.38 Purchase and construction of fixed assets, intangible assets and other long-term assets

221,850.97 508,060.00 Cash paid for assets

Cash paid for investment 3,000,000.00 45,840,000.00 Cash paid for acquisition of subsidiaries and other business units

net cash

Other cash payments related to investing activities 650,800,000.00 525,898,000.00 Subtotal cash outflow from investing activities 654,021,850.97 572,246,060.00 Net cash flow generated from investing activities 148,499,640.33 43,133,574.38

3. Cash flow generated from financing activities:

Cash received from investment 11,174,000.00 Cash received from borrowing

Other cash received related to financing activities

Subtotal of cash inflows from financing activities 11,174,000.00 Cash paid to repay debts

Distribution of dividends, profits or repayment of interest payments

3,599,437.47 12,125,603.81 cash

Cash payments related to other financing activities 32,285,577.51 23,509,544.31 Subtotal cash outflows from financing activities 35,885,014.98 35,635,148.12 Net cash flow generated from financing activities -35,885,014.98 -24,461,148.12

4. The impact of exchange rate changes on cash and cash equivalents

influence

Net increase in cash and cash equivalents 93,795,764.39 13,953,052.87 Plus: opening balance of cash and cash equivalents 13,516,528.19 5,729,061.10
Balance of cash and cash equivalents at the end of the period 107,312,292.58 19,682,113.97
Consolidated statement of changes in owners’ equity

Amount of current period

Unit: Yuan

Project 2026 Half Year

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Less equity attributable to owners of the parent company

Other equity instruments Part 1 There is a decrease and there is no amount

He who specializes in making money

: shares

Equity Preferred Shares Perpetual Bonds Other Capital Reserves Treasury Shares Comprehensive Income Reserves Reserves Risk Reserved Profit Other Subtotal Owners’ Equity Total Equity

Profit plan 121 412 27, 242 804 804,19,50 628,96,29,29

1. Previous year

9,2 3,4 ,56 0,2 1,4 1,4 balance at the end of

1. 8.7 05. 27. 27. 00 90 3 66 29 29 plus: yes

Changes in accounting policies

before

period error correction

its

him

121 412 27, 242 804 804 ,19 ,50 628 ,96 ,29 ,29

2. Current year

9,2 3,4 ,56 0,2 1,4 1,4 Beginning balance

1. 8.7 05. 27. 27. 00 90 3 66 29 29

3. This issue adds 32, 13,

1,9 3,5 13, 13, less changes 285 211

45, 61, 566 566 (reduced to ,57,88

909 501 ,28 ,28 Fill in “-” 7.5 4.5

.80 .65 1.4 1.4 columns) 1 7

9 9 20, 20, 20,

372 372 372

(1) Comprehensive

,82 ,82 ,82Total income

3.6 3.6 3.6 9 9 9 - - 32,

1,9 30, 30,

(2) All 285

45, 339 339 input and reduction, 57

909,66,66 less capital 7.5

.80 7.7 7.7

1 1 1. owner

ordinary investment

Other rights

beneficial instruments held

investors invest capital

3． Share-based payment 1.9 1.9 1.9 Payment included in equity of all shareholders 909 909 909 .80 .80 .80 32, - -

285 32, 32, 4. Others ,57 285 285 7.5 ,57 ,57

1 7.5 7.5 Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

1 1

- - 3,5

7,1 3,5 3,5

(3) Profit 61,

60, 99, 99, distribution 501

939 437 437 .65

.12 .47 .47

3,5

1． Withdraw profit 61,

61,

Surplus reserve 501

.65

Extract one

General risk preparation

- - 1. Distribution to all 3,5 3,5 3,5 (or 99, 99, 99, shareholders) 437 437 437 .47 .47 .47 4. Others

(4) All

Inside the investor’s rights

carry forward

1． capital company

Convert accumulated assets to capital

(or equity)

surplus public

Convert accumulated assets to capital

(or equity)

3． surplus public

Accumulate to make up for losses

4． Settings subject to

Changes in benefit plan

Amount carried forward and retained

income

Other comprehensive

Consolidated income carried forward

retained earnings

6． Others

(5) Special projects

reserve

1． This issue mentions

take

This issue makes

use

(6) Others

121 414 32, 31, 256 790 790,19,44 285 190,17,72,72

4. This issue

9,2 9,3 ,57 ,07 2,0 5,1 5,1 Ending balance

1. 7.5 0.3 90. 45. 45. 00 70 1 8 23 80 80

Amount of previous year

Unit: Yuan Zhejiang Tailin Biotechnology Co., Ltd. Full text of 2026 semi-annual report

2025 half year

Less equity attributable to owners of the parent company

Other equity instruments One has

minus the number

Project capital: Other shareholders' equity, preferred shares, perpetual bonds, other capital reserves, treasury shares, comprehensive income, reserves, surplus reserves, risks, quasi-allocated profits, other subtotal shareholders' equity, equity

Provision for profit 121 420 27, 250 820 820 ,19 ,50 628 ,71 ,05 ,72

1. Last year, 19

9,2 7,9 ,56 4,6 0,3 Balance at the end of 9,5 6.5

1. 8.7 03. 45. 41. 00 91 3 67 31 82 plus: yes

Changes in accounting policies

before

period error correction

its

him

121 420 27, 250 820 820 ,19 ,50 628 ,71 ,05 ,72

2. Current year, 19

9,2 7,9 ,56 4,6 0,3 9,5 Beginning balance 6.5

1. 8.7 03. 45. 41. 00 91 3 67 31 82

3. Added in this issue - -

11, 1,4 10, less changes 9,8 679

258 23, 514 (reduced to 35, ,19

,51 027 ,68 Fill in "-" 484 6.5

1.5 .28 0.7 columns) .24 1

2 5 13, 13, - 13,

542 542 200 342

(1) Comprehensive

,94 ,94 ,23 ,71Total income

9.1 9.1 8.1 1.0 8 8 1 7 - - - -

11, 11, 11,

(2) All 478

258 258 737 investors input and minus ,95

,51 ,51 ,46 less capital 8.4

1.5 1.5 9.9 2 2 2

- 1. Owner 478 478 invested common ,95 ,95 shares 8.4 8.4

0 0 2. Other rights

beneficial instruments held

investors invest capital

3． Share-based payment 1.0 1.0 1.0 payment is included in the equity of all shareholders 032 032 032 .79 .79 .79

- - 1. Others

12, 12, 12, Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

335 335 335 ,54 ,54 ,54 4.3 4.3 4.3 1 1 1

- - 12, 12, 12,

(3) Profit 119 119 119 Distribution ,92 ,92 ,92 1.9 1.9 1.9

0 0 0 1． Withdraw profit

surplus public space

Extract one

General risk preparation

- - 12, 12, 12, 3. to all

119 119 119 persons (or shares

,92,92,92 East) distribution

1.9 1.9 1.9

0 0 0 4. Others

(4) All

Inside the investor’s rights

carry forward

1． capital company

Convert accumulated assets to capital

(or equity)

surplus public

Convert accumulated assets to capital

(or equity)

3． surplus public

Accumulate to make up for losses

4． Settings subject to

Changes in benefit plan

Amount carried forward and retained

income

Other comprehensive

Consolidated income carried forward

retained earnings

6． Others

(5) Special projects

reserve

1． This issue mentions

take

This issue makes

use

(6) Others

121 409 27, 252 810 810 ,19 ,24 628 ,13 ,21 ,21

4. This issue

9,2 9,4 ,56 7,6 4,8 4,8 Ending balance

1. 8.7 30. 61. 61. 00 39 3 95 07 07 Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.
Statement of changes in owner’s equity of the parent company

Amount of current period

Unit: Yuan

2026 half year

Other equity instruments All less: Others Undivided

Project Capital Special Surplus Owner's Equity Priority Perpetual Inventory Comprehensive Distribution Others

Other public reserves, reserves, equity joint ventures, bonds, shares, profits

plan

121,1 412,4 27,62 80,66 641,9

1. Previous year

99,21 80,54 8,568 3,065 71,39 Ending balance

9.00 0.25 .73 .40 3.38

Add: yes

Changes in accounting policies

before

period error correction

its

him

121,1 412,4 27,62 80,66 641,9

2. Current year

99,21 80,54 8,568 3,065 71,39Initial balance

9.00 0.25 .73 .40 3.38

3. Added in this issue

Less change amount 1,905 32,28 3,561 28,45 1,635 (decreases are filled in with ,519. 5,577 ,501. 4,077 ,520. "-" in column 20.51 65.35 69)

35,61 35,61

(1) Comprehensive

5,016 5,016Total income

.47 .47

(2) All 1,905 32,28

30,38 people invested and reduced ,519. 5,577

0,058 less capital 20.51

.31 1. owner

ordinary investment

Other rights

beneficial instruments held

investors invest capital

3． Share branch

1,905 1,905 paid included in all

,519. ,519. Funds for investors’ rights and interests

20 20 amount

32,28

32,28 4. Others 5,577

5,577.51

.51 - -

3,561

(3) Profit 7,160 3,599

,501.

Distribution ,939. ,437.

12 47 1. Withdrawal profit 3,561 -

Yu Gong Gong ,501. 3,561

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

65,501.

- 1. to all

3,599 3,599 (or shares

,437. ,437.East) distribution

47 47 3． Others

(4) All

Inside the investor’s rights

carry forward

1． capital company

Convert accumulated assets to capital

(or equity)

surplus public

Convert accumulated assets to capital

(or equity)

3． surplus public

Accumulate to make up for losses

4． Settings subject to

Changes in benefit plan

Amount carried forward and retained

income

Other comprehensive

Consolidated income carried forward

retained earnings

6． Others

(5) Special projects

reserve

1． This issue mentions

take

This issue makes

use

(6) Others

121,1 414,3 32,28 31,19 109,1 643,6

4. This issue

99,21 86,05 5,577 0,070 17,14 06,91 Ending balance

9.00 9.45 .51 .38 2.75 4.07 Amount of last period

Unit: Yuan

2025 half year

Other equity instruments All

Less: Others not divided

Items Capital Special Surplus Owners' Rights Equity Priority Perpetual Inventory Comprehensive Dividends Others Other Reserves Reserves Equity Partnership Debt Shares Income Profit

Total 121,1 420,5 27,62 115,6 685,0

1. Previous year

99,21 07,95 8,568 85,72 21,46 Ending balance

9.00 3.91 .73 1.27 2.91 plus: yes

Changes in accounting policies

before

period error correction

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

its

him

121,1 420,5 27,62 115,6 685,0

2. Current year

99,21 07,95 8,568 85,72 21,46Initial balance

9.00 3.91 .73 1.27 2.91

3. Added in this issue

- -Minus change amount

11,25 18,86 30,12 (reduced to

8,511 4,173 2,684 Fill in the “-” sign

.52 .28 .80 columns)

(1) Comprehensive 6,744 6,744Total income ,251. ,251. 38 38

(2) All

11,25 11,25 people input and minus

8,511 8,511 less capital

.52 .52 1. owner

ordinary investment

Other rights

beneficial instruments held

investors invest capital

3． Share branch

1,077 1,077 paid included in all

,032. ,032. Funds for investors’ rights and interests

79 79 amount

- 12,33 12,33 4. Others

5,544 5,544 .31 .31

(3) Profit 12,11 12,11 Distribution 9,921 9,921

.90 .90 1. Withdraw profit

surplus public space

- 1. to all

12,11 12,11 (or shares

9,921 9,921 East) allocation

.90 .90 3. Others

(4) All

Inside the investor’s rights

carry forward

1． capital company

Convert accumulated assets to capital

(or equity)

surplus public

Convert accumulated assets to capital

(or equity)

3． surplus public

Accumulate to make up for losses

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd. 4. Settings subject to

Changes in benefit plan

Amount carried forward and retained

income

Other comprehensive

Consolidated income carried forward

retained earnings

6． Others

(5) Special projects

reserve

1． This issue mentions

take

This issue makes

use

(6) Others

121,1 409,2 27,62 96,82 654,8

4. This issue

99,21 49,44 8,568 1,547 98,77 Ending balance

9.00 2.39 .73 .99 8.11

3. Basic situation of the company

Zhejiang Tailin Biotechnology Co., Ltd. (hereinafter referred to as the company or the company) is a joint-stock company established by the overall change of the original Hangzhou Tailin Biotechnology Equipment Co., Ltd. It was registered with the Hangzhou Municipal Administration for Market Regulation on April 30, 2015, and is headquartered in Hangzhou, Zhejiang Province. The company currently holds a business license with a unified social credit code of 91330100735254191Q, a registered capital of 121.1992 million yuan, and a total of 121,199,219 shares (face value 1 yuan per share). Among them, there are 36,073,146 shares with trading restrictions and 85,126,073 shares with no selling conditions. The company's shares were listed for trading on the Shenzhen Stock Exchange on January 14, 2020.

The company belongs to the pharmaceutical special equipment manufacturing industry. The main business activities are the research and development, production and sales of sterile production and pollution control equipment, microbial testing and organic analysis products.

4. Basis for preparation of financial statements

Basics of preparation

The company's financial statements are prepared on a going concern basis.

Continued operations

The Company has no events or circumstances that would cause significant doubts about its ability to continue operating within 12 months from the end of the reporting period.

5. Important accounting policies and accounting estimates

Specific accounting policies and accounting estimation tips:

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

The Company has formulated specific accounting policies and accounting estimates based on the actual production and operation characteristics for transactions or matters such as impairment of financial instruments, inventories, depreciation of fixed assets, construction in progress, intangible assets, and revenue recognition.

Statement on compliance with corporate accounting standards

The financial statements prepared by the company comply with the requirements of the Accounting Standards for Business Enterprises and truly and completely reflect the company's financial status, operating results, cash flow and other relevant information.

Accounting period

The fiscal year begins on January 1 and ends on December 31 of the Gregorian calendar.

Business cycle

The company's operating business has a short operating cycle, and 12 months is used as the liquidity classification standard for assets and liabilities.

Accounting standard currency

RMB is adopted as the standard accounting currency.

Determination method and selection basis of importance standards

Applicable □Not applicable

Item Materiality criteria Important write-off accounts receivable More than 0.5% of total assets, important prepayments with an aging of more than 1 year Important construction projects in progress that exceed 0.5% of total assets Total investment in a single project exceeds 0.5% of total assets, important accounts payable with an age of more than 1 year More than 0.5% of total assets, important other payables with an age of more than 1 year Important contract liabilities with an age of more than 1 year, exceeding 0.5% of total assets Cash flows from important investing activities that exceed 0.5% of total assets. Significant investment and financing activities that do not involve cash receipts and payments exceeding 5% of total assets. Cash flows that exceed 5% of total assets.

Subsidiaries and non-wholly owned subsidiaries whose total assets/total income/total profits exceed the group's total assets/total income/profit

15% of total profit

Important associates whose investment income calculated using the individual equity method exceeds 5% of the group’s total profits

Matters that the company has an important impact on investors' decision-making are identified as important commitments.

item

The company will report the profit distribution after the balance sheet date and other post-balance sheet matters that are crucial to investors.

Events that have a significant impact on policy decisions are identified as important post-balance sheet events.

Accounting treatment methods for business combinations under the same control and those not under the same control
Accounting treatment for business combinations under common control

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

The assets and liabilities acquired by the company in a business merger are measured according to the book value of the merged party in the consolidated financial statements of the ultimate controlling party on the merger date. The company adjusts the capital reserve based on the difference between the book value share of the owner's equity of the merged party in the final controlling party's consolidated financial statements and the book value of the merger consideration paid or the total face value of the shares issued; if the capital reserve is insufficient for offset, the company adjusts the retained earnings.

Accounting treatment for business combinations not under common control

On the acquisition date, the company recognizes the difference between the merger cost and the fair value share of the acquiree's identifiable net assets acquired in the merger as goodwill; if the merger cost is less than the fair value share of the acquiree's identifiable net assets acquired in the merger, the difference is first recognized as goodwill. The fair value of the acquiree's identifiable assets, liabilities and contingent liabilities and the measurement of merger costs are reviewed. After review, if the merger cost is still less than the fair value share of the acquiree's identifiable net assets obtained in the merger, the difference is included in the current profit and loss.

Judgment standards for control and preparation methods of consolidated financial statements
Judgment of control

If it has power over the investee, enjoys variable returns by participating in the relevant activities of the investee, and has the ability to use its power over the investee to affect the amount of its variable returns, it is deemed to be control.

Preparation method of consolidated financial statements

The parent company includes all subsidiaries it controls in the consolidated financial statements. The consolidated financial statements are based on the financial statements of the parent company and its subsidiaries, and based on other relevant information, are prepared by the parent company in accordance with the "Accounting Standards for Business Enterprises No. 33 - Consolidated Financial Statements".

Classification of joint arrangements and accounting treatment of joint operations
Determination standards for cash and cash equivalents

The cash shown in the cash flow statement refers to cash on hand and deposits that can be used for payment at any time. Cash equivalents refer to investments held by an enterprise that have short maturities, are highly liquid, are easily convertible into known amounts of cash, and have little risk of changes in value.

Foreign currency business and foreign currency statement conversion
Foreign currency business conversion

When foreign currency transactions are initially recognized, they are converted into RMB amounts using the approximate exchange rate of the spot exchange rate on the date of the transaction. On the balance sheet date, foreign currency monetary items are translated using the spot exchange rate on the balance sheet date. Exchange differences arising from different exchange rates, except for foreign currency special borrowings related to the acquisition and construction of assets that meet capitalization conditions. Full text of the 2026 Semi-annual Report of Zhejiang Tailin Biotechnology Co., Ltd.

Exchange differences in addition to payment and interest are included in the current profit and loss; foreign currency non-monetary items measured at historical cost are still converted at the approximate exchange rate of the spot exchange rate on the date of the transaction, and their RMB amounts are not changed; foreign currency non-monetary items measured at fair value are converted at the spot exchange rate on the date when the fair value is determined, and the difference is included in the current profit and loss or other comprehensive income.

Translation of foreign currency financial statements

Assets and liability items in the balance sheet are translated using the spot exchange rate on the balance sheet date; owners' equity items, except for "undistributed profits" items, are translated using the spot exchange rate on the date of the transaction; income and expense items in the income statement are translated using the approximate exchange rate of the spot exchange rate on the date of the transaction. The translation difference of foreign currency financial statements arising from the above translation shall be included in other comprehensive income.

Financial instruments
Classification of financial assets and financial liabilities

Financial assets are divided into the following three categories upon initial recognition: (1) Financial assets measured at amortized cost; (2) Financial assets measured at fair value with changes included in other comprehensive income; (3) Financial assets measured at fair value with changes included in current profits and losses.

Financial liabilities are divided into the following four categories upon initial recognition: (1) Financial liabilities measured at fair value and whose changes are included in current profits and losses; (2) Financial liabilities formed when the transfer of financial assets does not meet the conditions for derecognition or continued involvement in the transferred financial assets; (3) Financial guarantee contracts that do not belong to the above (1) or (2), and loan commitments that do not belong to the above (1) and provide loans at lower than market interest rates; (4) Financial liabilities measured at amortized cost.

Recognition basis, measurement method and derecognition conditions of financial assets and financial liabilities

(1) Recognition basis and initial measurement method of financial assets and financial liabilities

When a company becomes a party to a financial instrument contract, it recognizes a financial asset or financial liability. When financial assets or financial liabilities are initially recognized, they are measured at fair value; for financial assets and financial liabilities measured at fair value and whose changes are included in current profits and losses, relevant transaction costs are directly included in current profits and losses; for other types of financial assets or financial liabilities, relevant transaction costs are included in the initial recognition amount. However, if the company's initial recognition of accounts receivable does not contain a significant financing component or the company does not consider the financing component of a contract that does not exceed one year, the initial measurement shall be based on the transaction price defined in "Accounting Standards for Business Enterprises No. 14 - Revenue".

(2) Subsequent measurement method of financial assets

Financial assets measured at amortized cost

The actual interest rate method is adopted and subsequent measurement is carried out based on amortized cost. Gains or losses arising from financial assets that are measured at amortized cost and are not part of any hedging relationship are included in the current profit and loss when derecognized, reclassified, amortized according to the effective interest method, or impairment is recognized.

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Debt instrument investments measured at fair value and changes included in other comprehensive income

Fair value is used for subsequent measurement. Interest, impairment losses or gains and exchange gains and losses calculated using the effective interest rate method are included in the current profit and loss, and other gains or losses are included in other comprehensive income. When derecognition is terminated, the accumulated gains or losses previously included in other comprehensive income will be transferred out of other comprehensive income and included in the current profit and loss.

Equity instrument investments measured at fair value and changes included in other comprehensive income

Fair value is used for subsequent measurement. Dividends received (except for the recovery part of investment costs) are included in the current profits and losses, and other gains or losses are included in other comprehensive income. Upon derecognition, the accumulated gains or losses previously included in other comprehensive income will be transferred out of other comprehensive income and included in retained earnings.

Financial assets measured at fair value and changes included in current profits and losses

Fair value is used for subsequent measurement, and the resulting gains or losses (including interest and dividend income) are included in the current profit or loss, unless the financial asset is part of a hedging relationship.

(3) Subsequent measurement method of financial liabilities

Financial liabilities measured at fair value and changes included in current profits and losses

Such financial liabilities include trading financial liabilities (including derivatives that are financial liabilities) and financial liabilities designated as measured at fair value with changes included in current profits and losses. Such financial liabilities are subsequently measured at fair value. The amount of changes in the fair value of financial liabilities designated as at fair value through profit or loss due to changes in the company's own credit risk is included in other comprehensive income, unless such treatment would cause or expand accounting mismatches in profit or loss. Other gains or losses arising from such financial liabilities (including interest expenses, excluding changes in fair value caused by changes in the company's own credit risk) are included in the current profits and losses, unless the financial liabilities are part of a hedging relationship. Upon derecognition, the accumulated gains or losses previously included in other comprehensive income will be transferred out of other comprehensive income and included in retained earnings.

Financial liabilities arising from the transfer of financial assets that do not meet the conditions for derecognition or continued involvement in the transferred financial assets

Measurement shall be carried out in accordance with the relevant provisions of "Accounting Standards for Business Enterprises No. 23 - Transfer of Financial Assets".

Financial guarantee contracts that do not fall under 1) or 2) above, and loan commitments that do not fall under 1) above and provide loans at lower than market interest rates

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

After initial recognition, subsequent measurement shall be based on the higher of the following two amounts: ① The amount of loss provision determined in accordance with the impairment regulations of financial instruments; ② The balance after the initial recognition amount deducts the accumulated amortization amount determined in accordance with the relevant provisions of "Accounting Standards for Business Enterprises No. 14 - Revenue".

Financial liabilities measured at amortized cost

Measured at amortized cost using the effective interest method. Gains or losses arising from financial liabilities that are measured at amortized cost and are not part of any hedging relationship are included in the current profit and loss when they are derecognized and amortized according to the effective interest method.

(4) Derecognition of financial assets and financial liabilities

Financial assets are derecognised when one of the following conditions is met:

① The contractual right to receive cash flows from financial assets has terminated;

② The financial assets have been transferred, and the transfer meets the provisions of "Accounting Standards for Business Enterprises No. 23 - Transfer of Financial Assets" regarding the derecognition of financial assets.

When the current obligation of a financial liability (or part thereof) has been discharged, the financial liability (or part thereof) shall be derecognised accordingly.

Recognition basis and measurement method of financial asset transfer

If the company transfers almost all the risks and rewards of the ownership of the financial asset, it shall terminate the recognition of the financial asset, and separately recognize the rights and obligations arising or retained in the transfer as assets or liabilities; if it retains almost all the risks and rewards of the ownership of the financial asset, it shall continue to recognize the transferred financial asset. If the company neither transfers nor retains substantially all the risks and rewards of ownership of a financial asset, the following situations will apply: (1) If it does not retain control over the financial asset, the financial asset will be derecognised, and the rights and obligations arising or retained in the transfer will be separately recognized as assets or liabilities; (2) If it retains control over the financial asset, the relevant financial assets will be recognized to the extent of its continued involvement in the transferred financial assets, and the relevant liabilities will be recognized accordingly.

If the overall transfer of a financial asset meets the conditions for derecognition, the difference between the following two amounts will be included in the current profit and loss: (1) The book value of the transferred financial asset on the date of derecognition; (2) The sum of the consideration received for the transfer of the financial asset and the amount corresponding to the derecognition part of the cumulative amount of changes in fair value that was originally directly included in other comprehensive income (the financial assets involved are debt instrument investments measured at fair value and their changes are included in other comprehensive income). If a part of a financial asset is transferred, and the transferred part as a whole meets the conditions for derecognition, the entire book value of the financial asset before transfer will be apportioned between the derecognized part and the continued recognition part according to their respective relative fair values on the date of transfer, and the difference between the following two amounts shall be included in the current profit and loss: (1) The book value of the derecognized part; (2) The consideration for the derecognition part is the sum of the amount corresponding to the derecognition part of the cumulative amount of changes in fair value that was originally directly included in other comprehensive income (the financial assets involved in the transfer are debt instrument investments that are measured at fair value and their changes are included in other comprehensive income).

Determination method of fair value of financial assets and financial liabilities

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

The company determines the fair value of relevant financial assets and financial liabilities using valuation techniques that are applicable under the current circumstances and supported by sufficient available data and other information. The company divides the input values used in the valuation technology into the following levels and uses them in sequence:

(1) The first level input value is the unadjusted quoted price in an active market for the same asset or liability that can be obtained on the measurement date;

(2) The second level input value is the directly or indirectly observable input value of the relevant assets or liabilities in addition to the first level input value, including: quotations of similar assets or liabilities in active markets; quotations of the same or similar assets or liabilities in inactive markets; other observable input values other than quotations, such as interest rates and yield curves that are observable during normal quotation intervals; market verification input values, etc.;

(3) The third level input value is the unobservable input value of the relevant assets or liabilities, including interest rates that cannot be directly observed or cannot be verified by observable market data, stock volatility, future cash flows of abandonment obligations assumed in business combinations, financial forecasts made using its own data, etc.

Impairment of financial instruments

Based on expected credit losses, the company calculates financial assets measured at amortized cost, debt instrument investments measured at fair value with changes included in other comprehensive income, contract assets, lease receivables, and financial liabilities classified as measured at fair value with changes included in current profits and losses. Other than loan commitments, financial liabilities that are not measured at fair value through profit or loss, or financial guarantee contracts that are not financial liabilities arising from the transfer of financial assets that do not meet the conditions for derecognition or that continue to be involved in the transferred financial assets are subject to impairment treatment and loss provisions are recognized.

Expected credit losses refer to the weighted average of the credit losses of financial instruments with the risk of default as the weight. Credit loss refers to the difference between all contractual cash flows receivable under the contract and all cash flows expected to be received by the company, discounted at the original effective interest rate, that is, the present value of all cash shortfalls. Among them, credit-impaired financial assets purchased or originated by the company are discounted according to the credit-adjusted actual interest rate of the financial assets.

For purchased or originated financial assets that have suffered credit impairment, the company will only recognize the cumulative change in expected credit losses during the entire duration since initial recognition as loss provisions on the balance sheet date.

For lease receivables, receivables and contract assets formed by transactions regulated by "Accounting Standards for Business Enterprises No. 14 - Revenue" and contract assets, the company uses simplified measurement methods to measure loss provisions based on an amount equivalent to the expected credit losses during the entire duration.

For financial assets other than the above measurement methods, the company evaluates at each balance sheet date whether its credit risk has increased significantly since initial recognition. If the credit risk has increased significantly since the initial recognition, the company will measure the loss provision based on the amount of expected credit losses during the entire duration; if the credit risk has not increased significantly since the initial recognition, the company will measure the loss provisions based on the amount of expected credit losses of the financial instrument in the next 12 months.

The Company uses reasonable and evidence-based information available, including forward-looking information, to determine whether the credit risk of a financial instrument has increased significantly since initial recognition by comparing the risk of default on the financial instrument on the balance sheet date with the risk of default on the initial recognition date.

On the balance sheet date, if the company determines that a financial instrument has only low credit risk, it is assumed that the credit risk of the financial instrument has not increased significantly since initial recognition.

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

The company assesses expected credit risk and measures expected credit losses on the basis of a single financial instrument or a combination of financial instruments. When based on a portfolio of financial instruments, the company divides financial instruments into different portfolios based on common risk characteristics.

The company remeasures expected credit losses on each balance sheet date, and the resulting increase or reversal of loss provisions is included in the current profit and loss as impairment losses or gains. For financial assets measured at amortized cost, the loss provision is deducted from the book value of the financial asset listed in the balance sheet; for debt investments measured at fair value with changes included in other comprehensive income, the company recognizes its loss provision in other comprehensive income and does not deduct the book value of the financial asset.

Offset of financial assets and financial liabilities

Financial assets and financial liabilities are presented separately in the balance sheet and do not offset each other. However, if the following conditions are met at the same time, the company will present the net amount after offsetting each other in the balance sheet: (1) The company has the legal right to offset the recognized amount, and the legal right is currently enforceable; (2) The company plans to settle on a net basis, or realize the financial assets and pay off the financial liabilities at the same time.

For transfers of financial assets that do not meet the conditions for derecognition, the company will not offset the transferred financial assets and related liabilities.

(11) Recognition standards and accrual methods for expected credit losses on accounts receivable and contract assets

Accounts receivable and contract assets with expected credit losses based on combinations of credit risk characteristics

Portfolio category Basis for determining portfolio Method for measuring expected credit losses

Refer to historical credit loss experience and combine the current status of bank acceptance bills receivable

conditions and forecasts of future economic conditions, by note type

Default risk exposure and expected credit loss rate of commercial acceptance bills throughout the duration to calculate expected credit losses

Prepare accounts receivable-account aging portfolio with reference to historical credit loss experience, combined with current conditions and predictions of future economic conditions.

Comparison table of accounts receivable aging and expected credit loss rate to calculate expected credit losses

Prepare other receivables - aging portfolio with reference to historical credit loss experience, combined with current conditions and predictions of future economic conditions.

Comparison table of aging of other receivables and expected credit loss rate to calculate expected credit losses

With reference to historical credit loss experience, combined with the current status of contract assets/other non-current assets-warranty funds and predictions of future economic conditions, we use the nature of the payment to

Combine the default risk exposure and the expected credit loss rate throughout the duration to calculate the expected credit loss

Comparison table of aging and expected credit loss rate of aging portfolio

Accounts receivable Other receivables

Account age

Expected credit loss rate (%) Expected credit loss rate (%)

Within 1 year (inclusive, the same below) 5.00 5.00

1-2 years 10.00 10.00

2-3 years 20.00 20.00

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

3-4 years 30.00 30.00 4-5 years 50.00 50.00 More than 5 years 100.00 100.00 The aging of accounts receivable/other receivables is calculated from the initial recognition date.

Recognition standards for accounts receivable and contract assets for which expected credit losses are to be calculated individually

For receivables and contract assets whose credit risk is significantly different from the combined credit risk, the company accrues expected credit losses on an individual basis.

Notes receivable
Accounts receivable
Accounts receivable financing
Other receivables

Determination method and accounting treatment method of expected credit losses of other receivables

Contract assets

Companies present contract assets or contract liabilities on their balance sheets based on the relationship between the fulfillment of performance obligations and payments from customers. The company will present the net amount after offsetting contract assets and contract liabilities under the same contract.

The Company presents the right to receive consideration from customers that is unconditional (i.e., dependent only on the passage of time) as receivables and the right to receive consideration for goods transferred to the customer (that right is dependent on factors other than the passage of time) as a contract asset.

The Company presents obligations to transfer goods to customers for consideration received or receivable from customers as contract liabilities.

Inventory
Classification of inventory

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Inventories include finished products or commodities held for sale in daily activities, work-in-progress in the production process, materials and supplies consumed in the production process or in the process of providing services, etc.

Valuation method for issued inventory

Inventories are issued using the weighted average method at the end of the month.

Inventory inventory system

The inventory system of inventories is the perpetual inventory system.

Amortization method for low-value consumables and packaging materials

(1) Low value consumables

Amortization is carried out according to the one-time write-off method.

(2) Packaging

Amortization is carried out according to the one-time write-off method.

Provision for inventory decline

(1) Recognition standards and accrual methods for inventory depreciation provisions

On the balance sheet date, inventories are measured at the lower of cost and net realizable value, and inventory depreciation provisions are made based on the difference between cost and net realizable value. For inventories that are directly used for sale, the net realizable value is determined by the estimated selling price of the inventory minus the estimated sales expenses and related taxes in the normal production and operation process; for inventories that need to be processed, the estimated selling price of the finished products produced during the normal production and operation process is deducted by the estimated costs to be incurred upon completion. The amount after the estimated sales expenses and related taxes is determined to determine its net realizable value; on the balance sheet date, if part of the same inventory has a contract price and other parts do not have a contract price, its net realizable value is determined separately and compared with its corresponding cost to determine the amount of provision or reversal of inventory depreciation provisions.

(2) Provision for inventory decline in value on a group basis

Assets held for sale
Debt investment
Other debt investments
Long-term receivables
Long-term equity investment
Judgment of joint control and significant influence

If there is shared control over an arrangement in accordance with relevant agreements, and the relevant activities of the arrangement must be decided with the unanimous consent of the parties sharing control rights, it is deemed to be joint control. Having the power to participate in decision-making on the financial and operating policies of the investee, but not being able to control or jointly control the formulation of these policies with other parties, is deemed to have significant influence.

Determination of investment costs

(1) Formed through a merger of enterprises under common control, if the merging party pays cash, transfers non-cash assets, assumes debts or issues equity securities as the merger consideration, the initial investment cost shall be the share of the book value of the owner's equity of the merged party in the consolidated financial statements of the ultimate controlling party on the date of merger. The difference between the initial investment cost of the long-term equity investment and the book value of the merger consideration paid or the total face value of the shares issued is adjusted to the capital reserve; if the capital reserve is insufficient for offset, the retained earnings are adjusted.

The company realizes the long-term equity investment formed by the merger of enterprises under the same control step by step through multiple transactions to determine whether it is a "package transaction". If it belongs to a "package transaction", each transaction shall be accounted for as a transaction that obtains control. If it does not belong to a "package deal", on the merger date, the initial investment cost will be determined based on the share of the book value of the combined party's net assets in the ultimate controlling party's consolidated financial statements that should be enjoyed after the merger. The difference between the initial investment cost of the long-term equity investment on the merger date and the book value of the long-term equity investment before the merger plus the book value of the new payment for further shares acquired on the merger date is adjusted to the capital reserve; if the capital reserve is insufficient for offset, the retained earnings are adjusted.

(2) If it is formed by a business combination not under the same control, the fair value of the merger consideration paid on the purchase date shall be regarded as its initial investment cost.

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

The company realizes the long-term equity investment formed by the merger of enterprises not under common control step by step through multiple transactions, and distinguishes individual financial statements and consolidated financial statements for relevant accounting treatment:

In individual financial statements, the sum of the book value of the original equity investment plus the new investment cost is regarded as the initial investment cost that is calculated according to the cost method.
In the consolidated financial statements, determine whether it is a "package deal". If it belongs to a "package transaction", each transaction shall be accounted for as a transaction that obtains control. If it does not belong to a "package transaction", the equity of the purchased party held before the purchase date will be remeasured according to the fair value of the equity on the purchase date, and the difference between the fair value and its book value will be included in the investment income of the current period; if the equity of the purchased party held before the purchase date involves other comprehensive income under equity method accounting, the other comprehensive income related to it will be converted into the current period income on the purchase date. However, other comprehensive income arising from changes in the net liabilities or net assets of the defined benefit plan due to the remeasurement of the investee is excluded.

(3) Except for the formation of a business merger: if it is obtained by paying cash, the actual purchase price paid will be used as its initial investment cost; if it is obtained by issuing equity securities, its initial investment cost will be based on the fair value of the equity securities issued; if it is obtained by debt restructuring, its initial investment cost will be determined according to "Accounting Standards for Business Enterprises No. 12 - Debt Restructuring"; if it is obtained by exchanging non-monetary assets, its initial investment cost will be determined according to "Accounting Standards for Business Enterprises No. 7 - Exchange of Non-monetary Assets".

Subsequent measurement and profit and loss recognition methods

Long-term equity investments that control the invested unit are accounted for using the cost method; long-term equity investments in associates and joint ventures are accounted for using the equity method.

Methods for disposing of investments in subsidiaries step by step through multiple transactions until loss of control

(1) Principles for judging whether it is a “package deal”

If the equity investment in a subsidiary is disposed of in stages through multiple transactions until it loses control, the company shall determine whether the step-by-step transaction is a "package transaction" based on the transaction agreement terms of each step of the step-by-step transaction, the disposal consideration obtained respectively, the object of the equity sale, the disposal method, the time of disposal, and other information. If the terms, conditions and economic impact of each transaction meet one or more of the following conditions, it usually indicates that multiple transactions are a "package deal":

These transactions are entered into at the same time or with consideration of mutual effects;
These transactions as a whole can achieve a complete business result;
The occurrence of one transaction depends on the occurrence of at least one other transaction;
A transaction is uneconomical on its own but is economical when considered together with other transactions.

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

(2) Accounting treatment that does not belong to “package deal”

Individual financial statements

For the equity disposed of, the difference between its book value and the actual price obtained shall be included in the current profit and loss. For the remaining equity, if it still has a significant influence on the invested unit or exercises joint control with other parties, it will be converted to equity method accounting; if it can no longer exercise control, joint control or significant influence on the invested unit, it will be accounted for in accordance with the relevant provisions of "Accounting Standards for Business Enterprises No. 22 - Recognition and Measurement of Financial Instruments".

Consolidated financial statements

Before the loss of control, the difference between the disposal price and the share of the subsidiary's net assets corresponding to the disposal of the long-term equity investment continuously calculated from the date of purchase or merger will be adjusted to the capital reserve (capital premium). If the capital premium is insufficient to offset, the retained earnings will be offset.

When control over the atomic company is lost, the remaining equity will be remeasured according to its fair value on the date of loss of control. The difference between the sum of the consideration obtained for disposing of the equity and the fair value of the remaining equity, minus the share of the original subsidiary's net assets calculated continuously from the date of purchase or merger based on the original shareholding ratio, shall be included in the investment income for the period when control is lost, and goodwill shall be offset at the same time. Other comprehensive income related to the equity investment in the original subsidiary shall be converted into investment income for the current period when control is lost.

(3) Accounting treatment for “package transactions”

Individual financial statements

Each transaction is accounted for as a transaction in which a subsidiary is disposed of and control is lost. However, the difference between the price of each disposal before the loss of control and the book value of the long-term equity investment corresponding to the disposal investment is recognized as other comprehensive income in individual financial statements, and is transferred to the profit and loss of the current period when control is lost.

Consolidated financial statements

Each transaction is accounted for as a transaction in which a subsidiary is disposed of and control is lost. However, before the loss of control, the difference between the price of each disposal and the share of the subsidiary's net assets corresponding to the disposal investment is recognized as other comprehensive income in the consolidated financial statements, and is transferred to the profits and losses of the current period when the control is lost.

Investment real estate

Investment real estate measurement model

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Cost method measurement

Depreciation or amortization method

Investment real estate includes leased land use rights, land use rights held and prepared to be transferred after appreciation, and leased buildings.
Investment real estate is initially measured according to cost, and subsequently measured using the cost model, and depreciation or amortization is calculated using the same methods as fixed assets and intangible assets.
Fixed assets

(1) Confirmation conditions

Fixed assets refer to tangible assets held for the production of goods, provision of labor services, leasing or operation and management, and with a useful life of more than one accounting year. Fixed assets are recognized when it is likely that economic benefits will flow in and the cost can be measured reliably.

(2) Depreciation method

Category Depreciation method Depreciation life Residual value rate Annual depreciation rate Houses and buildings Straight-line method 10-40 5.00 2.38-9.50 Machinery and equipment Straight-line method 5, 10 5.00 19.00, 9.50 Transportation means Straight-line method 5, 8 5.00 19.00, 11.88 Office and electronic equipment Straight-line method 5 5.00 19.00

Projects under construction
Construction in progress is recognized when it is likely that economic benefits will flow in and the cost can be measured reliably. Construction in progress is measured based on the actual costs incurred before the asset reaches its intended usable condition.
When the project under construction reaches the intended usable state, it will be transferred to fixed assets according to the actual cost of the project. If the asset has reached the intended usable state but has not yet completed the final settlement, the estimated value will be transferred to fixed assets first. After the final settlement is completed, the original temporary estimated value will be adjusted according to the actual cost, but the originally accrued depreciation will not be adjusted. Category Standards and timing for transferring construction in progress to fixed assets

Houses and buildings meet construction completion acceptance standards and reach the intended usable state

After installation and commissioning, the machinery and equipment meet the design requirements or standards stipulated in the contract.

Borrowing costs
Recognition principles for capitalization of borrowing costs

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

If the borrowing costs incurred by the company can be directly attributed to the purchase, construction or production of assets that meet the capitalization conditions, they shall be capitalized and included in the cost of the relevant assets; other borrowing costs shall be recognized as expenses when incurred and included in the current profits and losses.

Borrowing cost capitalization period

(1) Capitalization begins when borrowing costs meet the following conditions at the same time: 1) Asset expenditures have occurred; 2) Borrowing costs have been incurred; 3) The purchase, construction or production activities necessary to bring the asset to its intended usable or salable state have begun.

(2) If an asset that meets the capitalization conditions is abnormally interrupted during the acquisition, construction or production process, and the interruption lasts for more than 3 months, the capitalization of borrowing costs is suspended; the borrowing costs incurred during the interruption are recognized as current expenses until the acquisition, construction or production activities of the asset are restarted.

(3) When the assets purchased, constructed or produced that meet the capitalization conditions reach the intended usable or salable state, the capitalization of borrowing costs ceases.

Capitalization rate and capitalization amount of borrowing costs

If a special loan is borrowed for the purpose of purchasing, constructing or producing assets that meet the capitalization conditions, the actual interest expenses incurred on the special loan in the current period (including the amortization of discounts or premiums determined in accordance with the actual interest rate method) shall be deducted from the interest income obtained from depositing the unused borrowed funds in the bank or the investment income obtained from temporary investment. The amount of interest that should be capitalized is determined based on the amount after profit; if general borrowings are occupied for the purchase, construction or production of assets that meet the capitalization conditions, the amount of interest that should be capitalized on the general borrowings is calculated and determined based on the weighted average of the cumulative asset expenditures exceeding the special borrowings multiplied by the capitalization rate of the general borrowings occupied.

Biological assets
Oil and gas assets
Intangible assets

(1) Useful life and its basis for determination, estimation, amortization method or review procedure

Intangible assets include land use rights, software, etc., which are initially measured at cost.
Intangible assets with limited service life shall be amortized systematically and reasonably within the service life according to the expected realization method of the economic benefits related to the intangible asset. If the expected realization method cannot be reliably determined, the straight-line method shall be used for amortization. The details are as follows:

Item Service life and basis for determination Amortization method Full text of the 2026 Semi-annual Report of Zhejiang Tailin Biotechnology Co., Ltd.

Land use rights 50 years, time the land is available for use Straight-line method

Software 3-5 years, service life straight line method

(2) Scope of aggregation of R&D expenditures and related accounting treatment methods

(1) Employee compensation

Employee compensation includes the wages and salaries of the company's R&D personnel, basic pension insurance premiums, basic medical insurance premiums, unemployment insurance premiums, work-related injury insurance premiums, maternity insurance premiums and housing provident funds, as well as labor costs for external R&D personnel.

If R&D personnel serve multiple R&D projects at the same time, labor costs will be recognized based on the working hours records of R&D personnel for each R&D project provided by the company's management department, and will be allocated proportionally among different R&D projects.

(2) Material consumption

Material consumption refers to the actual related expenditures incurred by the company to implement research and development activities. Including: 1) Direct consumption of materials, fuel and power costs; 2) Development and manufacturing costs of molds and process equipment used for intermediate testing and product trial production, purchase costs for samples, prototypes and general testing methods that do not constitute fixed assets, and inspection fees for trial production products; 3) Operation and maintenance, adjustment, inspection, detection, repair and other costs of instruments and equipment used for research and development activities.

(3) Depreciation expenses and long-term prepaid expenses

Depreciation expenses refer to the depreciation expenses of instruments, equipment and buildings in use used for research and development activities.

If instruments, equipment, and buildings in use are used for R&D activities and are also used for non-R&D activities, necessary records shall be made of the use of such instruments, equipment, and buildings in use, and the actual depreciation expenses incurred shall be allocated between R&D expenses and production and operating expenses in a reasonable manner based on factors such as actual working hours and usage area. Long-term deferred expenses refer to the long-term deferred expenses incurred during the reconstruction, modification, decoration and repair of R&D facilities. They are collected based on actual expenditures and amortized evenly in installments within the specified period.

(4) Design costs

Design expenses refer to the expenses incurred in conceiving, developing and manufacturing new products and new processes, and designing processes, technical specifications, procedures, operating characteristics, etc., including expenses related to creative design activities to obtain innovative, creative, and breakthrough products.

(5) Testing fee

Mainly refers to the costs incurred during a series of tests to ensure product quality and performance during the product development process.

(6) Other expenses

Other expenses refer to other expenses directly related to research and development activities in addition to the above expenses, including technical data fees, data translation fees, expert consultation fees, high-tech R&D insurance fees, retrieval, demonstration, review, identification, and acceptance fees for R&D results, intellectual property application fees, registration fees, agency fees, conference fees, travel expenses, communication fees, etc.

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Expenditures in the research phase of internal research and development projects are included in the current profits and losses when incurred. Expenditures in the development phase of internal research and development projects are recognized as intangible assets if they meet the following conditions: (1) It is technically feasible to complete the intangible asset so that it can be used or sold; (2) There is the intention to complete the intangible asset and use or sell it; (3) The way in which the intangible asset generates economic benefits includes being able to prove that there is a market for the products produced using the intangible asset or that the intangible asset itself has a market. If the intangible asset will be used internally, its usefulness can be proven; (4) It has sufficient technical, financial and other resource support to complete the development of the intangible asset and has the ability to use or sell the intangible asset; (5) Expenditures attributable to the development stage of the intangible asset can be measured reliably.
Impairment of long-term assets

For long-term assets such as long-term equity investments, investment properties measured using the cost model, fixed assets, projects under construction, and intangible assets with limited useful lives, if there are signs of impairment on the balance sheet date, the recoverable amount is estimated. Goodwill and intangible assets with indefinite useful lives formed due to business combinations are subject to impairment testing every year regardless of whether there are signs of impairment. Goodwill is tested for impairment in combination with its related asset groups or combinations of asset groups.

If the recoverable amount of the above-mentioned long-term assets is lower than its book value, the asset impairment provision shall be recognized based on the difference and included in the current profit and loss.

Long-term deferred expenses

Long-term deferred expenses are calculated as expenses that have been spent and have an amortization period of more than 1 year (excluding 1 year). Long-term deferred expenses are recorded according to the actual amount incurred, and are amortized evenly over the benefit period or a specified period. If a long-term deferred expense item cannot benefit future accounting periods, all the amortized value of the item that has not been amortized will be transferred to the current profit and loss.

Contract liabilities

The Company presents obligations to transfer goods to customers for consideration received or receivable from customers as contract liabilities.

Employee compensation

(1) Accounting treatment method for short-term compensation

During the accounting period when employees provide services to the company, the actual short-term compensation is recognized as a liability and included in the current profit and loss or related asset costs.

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

(2) Accounting treatment of post-employment benefits

Post-employment benefits are divided into defined contribution plans and defined benefit plans.

(1) During the accounting period when employees provide services to the company, the deposit amount payable calculated according to the defined contribution plan is recognized as a liability and included in the current profit and loss or related asset costs.

(2) The accounting treatment of defined benefit plans usually includes the following steps:

Based on the expected cumulative benefit unit method, use unbiased and mutually consistent actuarial assumptions to estimate relevant demographic variables and financial variables, measure the obligations arising from the defined benefit plan, and determine the period to which the relevant obligations belong. At the same time, the obligations arising from the defined benefit plan are discounted to determine the present value of the defined benefit plan obligations and the current service cost;
If there are assets in the defined benefit plan, the deficit or surplus formed by subtracting the present value of the defined benefit plan obligations from the fair value of the defined benefit plan assets is recognized as a net liability or net asset of the defined benefit plan. If a defined benefit plan has a surplus, the net assets of the defined benefit plan shall be measured at the lower of the surplus of the defined benefit plan and the asset upper limit;
At the end of the period, the employee compensation costs generated by the defined benefit plan are recognized as service costs, net interest on the net liabilities or net assets of the defined benefit plan, and changes caused by remeasurement of the net liabilities or net assets of the defined benefit plan. Among them, service costs and net liabilities or net assets of the defined benefit plan are The net interest is included in the current profit and loss or related asset costs, and the changes resulting from the remeasurement of the net liabilities or net assets of the defined benefit plan are included in other comprehensive income, and are not allowed to be transferred back to profit or loss in subsequent accounting periods, but these amounts recognized in other comprehensive income can be transferred within the scope of equity.

(3) Accounting treatment method for dismissal benefits

For dismissal benefits provided to employees, the employee compensation liabilities arising from the dismissal benefits are recognized and included in the current profit and loss at the earliest of the following two situations: (1) when the company cannot unilaterally withdraw the dismissal benefits provided due to the termination of labor relations plan or layoff proposal; (2) when the company recognizes costs or expenses related to the restructuring involving the payment of dismissal benefits.

(4) Accounting treatment methods for other long-term employee benefits

Other long-term benefits provided to employees that meet the conditions of the defined contribution plan shall be accounted for in accordance with the relevant provisions of the defined contribution plan; other long-term benefits shall be accounted for in accordance with the relevant provisions of the defined benefit plan. In order to simplify the relevant accounting treatment, the employee compensation costs incurred are recognized as service costs, net interest on other long-term employee benefit net liabilities or net assets, and the total net amount of the changes resulting from the remeasurement of other long-term employee benefit net liabilities or net assets shall be included in the current profit and loss or related asset costs.

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Estimated liabilities
Obligations resulting from contingencies such as external guarantees, litigation matters, product quality guarantees, loss-making contracts, etc., become current obligations borne by the company. When the performance of the obligation is likely to cause economic benefits to flow out of the company, and the amount of the obligation can be reliably measured, the company will recognize the obligation as an estimated liability.
The company initially measures estimated liabilities based on the best estimate of the expenditure required to fulfill relevant current obligations, and reviews the book value of estimated liabilities on the balance sheet date.
Share-based payment
Types of share-based payment

Including equity-settled share-based payments and cash-settled share-based payments.

Accounting treatments related to the implementation, modification, and termination of share-based payment plans

(1) Equity-settled share-based payment

Equity-settled share-based payments that become exercisable immediately after grant in exchange for employee services will be included in relevant costs or expenses based on the fair value of the equity instrument on the date of grant, and the capital reserve will be adjusted accordingly. For equity-settled share-based payments in exchange for employee services that are vested upon completion of services within the waiting period or upon meeting specified performance conditions, on each balance sheet date during the waiting period, based on the best estimate of the number of exercisable equity instruments and the fair value on the date of grant of the equity instrument, the services obtained in the current period are included in the relevant costs or expenses, and the capital reserve is adjusted accordingly.

For equity-settled share-based payments in exchange for services from other parties, if the fair value of the other party's services can be reliably measured, it will be measured based on the fair value of the other party's services on the date of acquisition; if the fair value of the other party's services cannot be reliably measured, but the fair value of the equity instrument can be measured reliably, it will be measured based on the fair value of the equity instrument on the date of service acquisition, and the relevant costs or expenses will be included, and the owner's equity will be increased accordingly.

(2) Cash-settled share-based payment

Cash-settled share-based payments that are exercisable immediately after grant in exchange for employee services will be included in relevant costs or expenses based on the fair value of the company's liabilities on the date of grant, with corresponding increases in liabilities. For cash-settled share-based payments in exchange for employee services that are vested upon completion of services within the waiting period or upon meeting specified performance conditions, on each balance sheet date during the waiting period, based on the best estimate of the vesting situation and the fair value of the liabilities borne by the company, the services obtained in the current period are included in the relevant costs or expenses and corresponding liabilities.

(3) Modification and termination of share-based payment plan

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

If the modification increases the fair value of the equity instruments granted, the company will recognize the increase in the services obtained according to the increase in the fair value of the equity instruments; if the modification increases the number of equity instruments granted, the company will recognize the increased fair value of the equity instruments as an increase in the services obtained accordingly; if the company modifies the vesting conditions in a way that is beneficial to employees, the company will consider the modified vesting conditions when processing the vesting conditions.

If the modification reduces the fair value of the equity instruments granted, the company will continue to recognize the amount of services obtained based on the fair value of the equity instruments on the date of grant, regardless of the decrease in the fair value of the equity instruments; if the modification reduces the number of equity instruments granted, the company will treat the reduction as the cancellation of the equity instruments granted; if the vesting conditions are modified in a way that is unfavorable to employees, the modified vesting conditions will not be considered when processing the vesting conditions.

If the company cancels the granted equity instruments or settles the granted equity instruments during the waiting period (except for cancellation due to failure to meet vesting conditions), the cancellation or settlement will be treated as accelerated vesting, and the amount originally recognized during the remaining waiting period will be immediately recognized.

Preferred shares, perpetual bonds and other financial instruments

According to relevant standards for financial instruments, for financial instruments such as convertible corporate bonds issued, the company shall classify such financial instruments or their components as financial assets, financial liabilities or equity instruments at the time of initial recognition based on the contractual terms of the financial instruments issued and the economic substance reflected therein rather than just the legal form, combined with the definitions of financial assets, financial liabilities and equity instruments.

On the balance sheet date, for financial instruments classified as equity instruments, their interest payments or dividend distributions are treated as the company's profit distribution, and their repurchases, cancellations, etc. are treated as changes in equity; for financial instruments classified as financial liabilities, their interest payments or dividend distributions are treated as borrowing costs, and the gains or losses arising from their repurchases or redemptions are included in the current profits and losses.

Income

Disclose accounting policies adopted for revenue recognition and measurement by business type

Principles of revenue recognition

On the contract commencement date, the company evaluates the contract, identifies each individual performance obligation contained in the contract, and determines whether each individual performance obligation is to be performed within a certain period of time or at a certain point in time.

When one of the following conditions is met, the performance obligation is fulfilled within a certain period of time; otherwise, the performance obligation is fulfilled at a certain point in time: (1) The customer obtains and consumes the economic benefits brought by the company's performance while the company performs the contract; (2) The customer is able to control the goods under construction during the company's performance; (3) The goods produced during the company's performance have irreplaceable uses, and the company has the right to collect payment for the cumulative performance part that has been completed so far during the entire contract period.

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

For performance obligations performed within a certain period of time, the company recognizes revenue based on the performance progress within that period of time. When the progress of contract performance cannot be reasonably determined, if the costs incurred are expected to be compensated, revenue shall be recognized based on the amount of costs incurred until the progress of contract performance can be reasonably determined. For performance obligations fulfilled at a certain point in time, revenue is recognized at the point when the customer obtains control of the relevant goods or services. When judging whether the customer has obtained control of the goods, the company considers the following signs: (1) the company has a current right to receive payment for the goods, that is, the customer has a current payment obligation for the goods; (2) the company has transferred the legal ownership of the goods to the customer, that is, the customer already has legal ownership of the goods; (3) The company has physically transferred the commodity to the customer, which means that the customer has physically taken possession of the commodity; (4) the company has transferred the main risks and rewards of ownership of the commodity to the customer, that is, the customer has obtained the main risks and rewards of ownership of the commodity; (5) the customer has accepted the commodity; (6) other indications that the customer has obtained control of the commodity.

Income measurement principles

(1) The company measures revenue based on the transaction price allocated to each individual performance obligation. The transaction price is the amount of consideration that the company expects to be entitled to receive for the transfer of goods or services to the customer, excluding amounts collected on behalf of third parties and amounts expected to be returned to the customer.

(2) If there is variable consideration in the contract, the company determines the best estimate of the variable consideration based on the expected value or the most likely amount, but the transaction price including the variable consideration shall not exceed the amount at which a significant reversal of the accumulated recognized revenue is unlikely to occur when the relevant uncertainty is eliminated.

(3) If there is a significant financing component in the contract, the company determines the transaction price based on the amount payable in cash when the customer obtains control of the goods or services. The difference between the transaction price and the contract consideration is amortized using the effective interest method during the contract period. On the contract start date, if the company expects that the interval between the customer's obtaining control of the goods or services and the customer's payment of the price will not exceed one year, it will not consider the significant financing component in the contract.

(4) If the contract contains two or more performance obligations, the company will allocate the transaction price to each individual performance obligation based on the relative proportion of the stand-alone selling price of the goods promised by each individual performance obligation on the contract commencement date.

Specific methods of revenue recognition

The company's main products are microbial detection technology series products, sterile production and pollution control equipment series products (formerly environmental control series products and sterilization technology series products), and organic matter analysis technology series products. According to the contract or agreement signed with the customer, if the contract or agreement clearly stipulates the time point for the transfer of the main risk of commodity ownership, revenue will be recognized at the agreed time point; if the contract or agreement does not clearly stipulate the time point for the main risk transfer of commodity ownership, revenue will be recognized at the following time points:

(1) The timing of recognition of domestic sales revenue is: 1) If the goods sold require acceptance, the revenue will be recognized when the goods are delivered to the other party and accepted by the customer, or the revenue will be recognized after no quality objection is raised within the time specified in the contract; 2) If the goods sold do not require acceptance, the revenue will be recognized after the customer receives the goods.

(2) The following conditions must be met for the recognition of revenue from exported products: the company has declared the products to customs in accordance with the contract, obtained the bill of lading, and the amount of product sales revenue has been determined, the payment has been recovered or the receipt voucher has been obtained, and the relevant economic benefits are likely to flow in.

Similar business adopts different business models and involves different revenue recognition methods and measurement methods.

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Contract costs

The incremental costs incurred by the company to obtain the contract are expected to be recovered and are recognized as an asset as the contract acquisition cost. If the amortization period of the contract acquisition cost does not exceed one year, it will be directly included in the current profit and loss when incurred.

If the costs incurred by the company to fulfill the contract do not apply to the scope of relevant standards such as inventory, fixed assets or intangible assets and meet the following conditions at the same time, they will be recognized as an asset as the cost of contract performance:

The cost is directly related to a current or expected contract, including direct labor, direct materials, manufacturing overhead (or similar expenses), costs expressly borne by the customer, and other costs incurred solely because of the contract;
This cost increases the company’s future resources for fulfilling performance obligations;
The cost is expected to be recovered.

The company amortizes assets related to contract costs on the same basis as the revenue recognition of goods or services related to the assets, and includes them in the current profits and losses.

If the book value of an asset related to the contract cost is higher than the remaining consideration expected to be obtained from the transfer of the goods or services related to the asset minus the estimated costs to be incurred, the company will make an impairment provision for the excess and recognize it as an asset impairment loss. If the factors of impairment in the previous period subsequently change, so that the remaining consideration expected to be obtained from the transfer of the goods or services related to the asset minus the estimated costs to be incurred is higher than the book value of the asset, the asset impairment provision that has been originally accrued will be reversed and included in the current profit and loss, but the book value of the asset after the reversion shall not exceed the book value of the asset on the date of reversal if no impairment provision is made.

Government subsidies
Government subsidies are recognized when the following conditions are met at the same time: (1) the company can meet the conditions attached to the government subsidy; (2) the company can receive the government subsidy. If the government subsidy is a monetary asset, it shall be measured according to the amount received or receivable. If the government subsidy is a non-monetary asset, it shall be measured at fair value; if the fair value cannot be obtained reliably, it shall be measured at the nominal amount.
Judgment basis and accounting treatment method for government subsidies related to assets

Government documents stipulate that government subsidies used to purchase, construct or otherwise form long-term assets are classified as asset-related government subsidies. If the government documents are unclear, the judgment will be based on the basic conditions that must be met to obtain the subsidy. If the basic condition is the acquisition, construction or other means of forming long-term assets, it will be regarded as an asset-related government subsidy. Government subsidies related to assets are offset against the book value of the relevant assets or recognized as deferred income. If government subsidies related to assets are recognized as deferred income, they shall be included in profits and losses in installments according to a reasonable and systematic method within the useful life of the relevant assets. Government subsidies measured according to the nominal amount are directly included in the current profit and loss. Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

If the relevant assets are sold, transferred, scrapped or damaged before the end of their useful life, the undistributed balance of relevant deferred income will be transferred to the profit and loss of the current period of asset disposal.

Judgment basis and accounting treatment method for government subsidies related to income

Government subsidies other than asset-related government subsidies are classified as income-related government subsidies. For government subsidies that contain both asset-related parts and income-related parts, it is difficult to distinguish whether they are asset-related or income-related, and are generally classified as income-related government subsidies. If government subsidies related to income are used to compensate for relevant costs, expenses or losses in the future period, they are recognized as deferred income. During the period when the relevant costs, expenses or losses are recognized, they are included in the current profits and losses or offset the relevant costs; if they are used to compensate for the relevant costs, expenses or losses that have already occurred, they are directly included in the current profits and losses or offset the relevant costs.

Government subsidies related to the company's daily operating activities shall be included in other income or offset related costs and expenses according to the economic business essence. Government subsidies that are not related to the company's daily activities are included in non-operating income and expenses.
Deferred income tax assets/deferred income tax liabilities
Based on the difference between the book value of assets and liabilities and their tax basis (if the tax basis of items not recognized as assets and liabilities can be determined in accordance with tax laws, the difference between the tax basis and their book amount), deferred income tax assets or deferred income tax liabilities are calculated and recognized according to the applicable tax rate during the period when the asset is expected to be recovered or the liability is settled.
Deferred income tax assets are recognized to the extent that it is probable that the taxable income will be available to offset the deductible temporary differences. On the balance sheet date, if there is conclusive evidence that sufficient taxable income is likely to be obtained in the future period to offset the deductible temporary differences, deferred income tax assets that have not been recognized in previous accounting periods will be recognized.
On the balance sheet date, the book value of the deferred tax assets is reviewed. If it is likely that sufficient taxable income will not be available in the future period to offset the benefits of the deferred tax assets, the book value of the deferred tax assets will be written down. The amount of the write-down is reversed when it is probable that sufficient taxable income will be obtained.
The company's current income tax and deferred income tax are included in the current profit and loss as income tax expenses or income, but do not include income tax arising from the following situations: (1) business merger; (2) transactions or events directly recognized in owner's equity.
When the following conditions are met at the same time, the company will present the deferred income tax assets and deferred income tax liabilities as the net amount after offsetting: (1) It has the legal right to settle the current income tax assets and current income tax liabilities on a net basis; (2) Deferred income tax assets and deferred income tax liabilities are related to the income tax levied by the same tax collection and administration department on the same taxable entity or to different taxable entities. However, in each future period when important deferred income tax assets and deferred income tax liabilities are reversed, the taxable entity involved intends to settle the current income tax assets and current income tax liabilities with a net amount or to obtain assets and pay off debts at the same time.

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Leasing

(1) Accounting treatment method for leasing as lessee

On the start date of the lease period, the company identifies leases with a lease term of no more than 12 months and that do not include a purchase option as short-term leases; leases with a low value when a single leased asset is a new asset are identified as low-value asset leases. If a company subleases or anticipates subletting a leased asset, the original lease will not be deemed a low-value asset lease.

For all short-term leases and low-value asset leases, the company includes the lease payments into the relevant asset cost or current profit and loss on a straight-line basis throughout the lease term.

In addition to the above-mentioned short-term leases and low-value asset leases that adopt simplified treatment, the company recognizes right-of-use assets and lease liabilities for leases on the start date of the lease period.

(1) Right-of-use assets

The right-of-use assets are initially measured at cost, which includes: 1) the initial measurement amount of the lease liability; 2) the lease payment amount paid on or before the start date of the lease period, and if there is a lease incentive, the amount related to the lease incentive that has been enjoyed is deducted; 3) the initial direct costs incurred by the lessee; 4) the costs expected to be incurred by the lessee to dismantle and remove the leased asset, restore the site where the leased asset is located, or restore the leased asset to the state agreed upon in the lease terms.

The company depreciates right-of-use assets on a straight-line basis. If it is reasonably certain that the ownership of the leased asset will be obtained at the expiration of the lease term, the company will accrue depreciation over the remaining useful life of the leased asset. If it is not reasonably certain that the ownership of the leased asset will be obtained at the expiration of the lease term, the company will accrue depreciation during the shorter of the lease term and the remaining useful life of the leased asset.

(2) Lease liabilities

At the beginning of the lease period, the company recognizes the present value of the unpaid lease payments as lease liabilities. When calculating the present value of lease payments, the interest rate implicit in the lease is used as the discount rate. If the interest rate implicit in the lease cannot be determined, the company's incremental borrowing rate is used as the discount rate. The difference between the lease payment and its present value is regarded as an unrecognized financing expense, and interest expenses are recognized at the discount rate used to confirm the present value of the lease payment during each period of the lease term, and included in the current profit and loss. Variable lease payments that are not included in the measurement of lease liabilities are included in the current profit and loss when they actually occur.

After the start date of the lease period, when the actual fixed payment amount changes, the estimated amount payable of the guaranteed residual value changes, the index or ratio used to determine the lease payment amount changes, the evaluation results or actual exercise of the purchase option, lease renewal option or termination option change, When a change occurs, the company remeasures the lease liability based on the present value of the changed lease payment, and adjusts the book value of the right-of-use asset accordingly. If the book value of the right-of-use asset has been reduced to zero, but the lease liability still needs to be further reduced, the remaining amount will be included in the current profit and loss.

(3) Sale and leaseback

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

As the lessee, the company evaluates and determines whether the asset transfer in the sale and leaseback transaction is a sale in accordance with the provisions of "Accounting Standards for Business Enterprises No. 14 - Revenue".

If the asset transfer in a sale and leaseback transaction is a sale, the company measures the right-of-use assets formed by the sale and leaseback based on the portion of the original asset's book value related to the right of use obtained through the leaseback, and only recognizes relevant gains or losses for the rights transferred to the lessor.

If the asset transfer in a sale and leaseback transaction does not constitute a sale, the company will continue to recognize the transferred assets, and at the same time recognize a financial liability equal to the transfer income, and perform accounting treatment on the financial liability in accordance with the "Accounting Standards for Business Enterprises No. 22 - Recognition and Measurement of Financial Instruments".

(2) Accounting treatment method for leasing as lessor

On the lease commencement date, the Company classifies leases that substantially transfer almost all risks and rewards related to the ownership of the leased assets as finance leases, and other leases as operating leases.

(1) Operating lease

The company recognizes the lease receipts as rental income according to the straight-line method in each period during the lease term. The initial direct expenses incurred are capitalized and amortized on the same basis as the rental income recognition, and included in the current profit and loss in installments. Variable lease payments obtained by the company related to operating leases that are not included in the lease receipts are included in the current profit and loss when they actually occur.

(2) Finance lease

On the start date of the lease period, the company recognizes the financial lease receivable based on the net lease investment (the sum of the unguaranteed residual value and the present value of the lease payments not yet received on the start date of the lease discounted at the interest rate implicit in the lease), and terminates the recognition of financial lease assets. During each period of the lease term, the company calculates and recognizes interest income based on the interest rate implicit in the lease.

Variable lease payments obtained by the company that are not included in the measurement of net lease investment are included in the current profit and loss when actually incurred.

(3) Sale and leaseback

As the lessor, the company evaluates and determines whether the asset transfer in the sale and leaseback transaction is a sale in accordance with the provisions of "Accounting Standards for Business Enterprises No. 14 - Revenue".

If the asset transfer in a sale and leaseback transaction is a sale, the company will account for the asset purchase in accordance with other applicable accounting standards for enterprises, and account for the asset leasing in accordance with "Accounting Standards for Business Enterprises No. 21 - Lease".

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

If the asset transfer in a sale and leaseback transaction does not constitute a sale, the company does not recognize the transferred asset, but recognizes a financial asset equal to the transfer income, and performs accounting treatment on the financial asset in accordance with the "Accounting Standards for Business Enterprises No. 22 - Recognition and Measurement of Financial Instruments".

Other important accounting policies and accounting estimates
Changes in important accounting policies and accounting estimates

(1) Changes in important accounting policies

□Applicable Not applicable

(2) Changes in important accounting estimates

□Applicable Not applicable

(3) Adjustment of relevant items in the financial statements at the beginning of the year when the new accounting standards are first implemented starting from 2026 □ Applicable  Not applicable

Others

The company determines its operating segments based on its internal organizational structure, management requirements, internal reporting system, etc. A company's operating segments refer to components that simultaneously meet the following conditions:

This component can generate income and incur expenses in daily activities;
The management can regularly evaluate the operating results of the component to decide to allocate resources to it and evaluate its performance;
Be able to obtain relevant accounting information such as the financial status, operating results and cash flow of the component through analysis.

6. Taxes

Main tax types and tax rates

Tax Type Tax Calculation Basis The tax rate is based on the sales of goods and taxable goods calculated in accordance with tax laws.

Calculate output tax based on labor service income and deduct

Value-added tax 13%, 6%, 5%, 3% [Note] After the input tax allowed to be deducted in the current period, the balance shall be

VAT payable

Urban maintenance and construction tax Actual turnover tax paid 7% Corporate income tax Taxable income 15%, 20%, 25%

If the tax is assessed on an ad valorem basis, it will be deducted once from the original value of the property.

Property tax is 1.2% of the residual value after 30%; 1.2% and 12% are levied on rent.

, calculated at 12% of rental income

Education fee surcharge Actual turnover tax paid 3% Full text of Zhejiang Tailin Biotechnology Co., Ltd. 2026 Semi-annual Report

Local education surcharge Actual turnover tax paid 2%

If there are taxpayers with different corporate income tax rates, a description of the disclosure

Name of tax payer Income tax rate

Our company 25%

Zhejiang Tailin Life Sciences Co., Ltd. (hereinafter referred to as Life Sciences) 15%

Zhejiang Tailin Medical Engineering Co., Ltd. (hereinafter referred to as Medical Engineering) 15%

Zhejiang Tailin Analytical Instrument Co., Ltd. (hereinafter referred to as Analytical Instrument) 20%

Zhejiang Tailin Science and Technology Co., Ltd. (hereinafter referred to as Science and Technology) 20%

Zhejiang Tailin Medical Equipment Co., Ltd. (hereinafter referred to as medical equipment) 25%

Zhejiang Tailin New Materials Co., Ltd. (hereinafter referred to as Tailin New Materials) 25%

Beijing WoSrDa Cell Technology Co., Ltd. (hereinafter referred to as Beijing WoSrDa) 25%

Zhejiang Tailinkoda Medical Technology Co., Ltd. (hereinafter referred to as Tailinkoda) 25%

Tax incentives
VAT

According to the "Notice of the Ministry of Finance and the State Administration of Taxation on Value-Added Tax Policies for Software Products" (Caishui [2011] No. 100), software products developed, produced and sold by the Company and its subsidiaries can enjoy the VAT refund policy after filing. The amount of tax benefits enjoyed in this period is RMB 2.6477 million.

Corporate income tax

Life Sciences was jointly recognized as a high-tech enterprise by the Zhejiang Provincial Department of Science and Technology, the Zhejiang Provincial Department of Finance, and the Zhejiang Provincial Taxation Bureau of the State Administration of Taxation on December 19, 2025. It obtained a high-tech enterprise certificate numbered GR202533009928. The certificate is valid for 3 years. The corporate income tax from 2025 to 2027 is calculated and paid at a rate of 15%.

Medical Engineering was jointly recognized as a high-tech enterprise by the Zhejiang Provincial Department of Science and Technology, the Zhejiang Provincial Department of Finance, and the Zhejiang Provincial Taxation Bureau of the State Administration of Taxation on December 19, 2025. It obtained a high-tech enterprise certificate numbered GR202533007109. The certificate is valid for 3 years. The corporate income tax from 2025 to 2027 is calculated and paid at a rate of 15%.

According to the Ministry of Finance and the State Administration of Taxation’s “Announcement on Preferential Income Tax Policies for Small and Micro Enterprises and Individual Industrial and Commercial Households” (Announcement No. 6 of 2023 of the Ministry of Finance and State Administration of Taxation), “Announcement on Further Implementing Preferential Income Tax Policies for Small and Micro Enterprises” (Announcement No. 13 of 2022 of the Ministry of Finance and State Administration of Taxation) and “Announcement on Further Supporting the Development of Relevant Tax Policies for Small and Micro Enterprises and Individual Industrial and Commercial Households” (Announcement No. 12 of 2023 of the Ministry of Finance and State Administration of Taxation), since 2023 From January 1, 2022 to December 31, 2027, the annual taxable income of small and low-profit enterprises does not exceed 1 million yuan, a reduced rate of 25% is included in the taxable income, and the corporate income tax is paid at a rate of 20%; from January 1, 2022 to December 31, 2027, the annual taxable income of small and low-profit enterprises exceeds 1 million yuan but does not exceed 3 million yuan. The portion of RMB 10,000 shall be included in the taxable income at a reduced rate of 25%, and the corporate income tax shall be paid at a rate of 20%. Analytical instruments and science and technology meet the confirmation standards for small and low-profit enterprises, and declare corporate income tax at the preferential tax rate for small and low-profit enterprises.

Others

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

7. Notes on Consolidated Financial Statement Items

Monetary funds

Unit: Yuan

Item Ending balance Beginning balance

Cash on hand 3,671.28 3,671.28Bank deposits 154,859,688.44 148,564,947.40Other monetary funds 588,505.53 519,757.96Total 155,451,865.25 149,088,376.64Other instructions

Trading financial assets

Unit: Yuan

Item Ending balance Beginning balance

Measured at fair value with changes included in current profit and loss

37,100,000.00 61,120,441.21 beneficial financial assets

Among them:

Financial products 10,100,000.00 16,120,441.21 Structured deposits 27,000,000.00 45,000,000.00 of which:

Total 37,100,000.00 61,120,441.21Other instructions:

Derivative financial assets

Unit: Yuan

Item Ending balance Beginning balance

Other notes:

Notes receivable

(1) Classified presentation of notes receivable

Unit: Yuan

Item Ending balance Beginning balance

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

(2) Classified disclosure according to bad debt accrual method

Unit: Yuan Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book price Book price provision ratio Provision ratio

Amount Ratio Amount Value Amount Ratio Amount Value Example

its

Medium:

its

Medium:

Total 0.00

If bad debt provisions for notes receivable are made according to the general expected credit loss model:

□Applicable Not applicable

(3) Bad debt provisions accrued, recovered or reversed in the current period

Bad debt provisions for the current period:

Unit: Yuan Amount of changes in the current period

Category Opening balance Ending balance Provision Recovery or transfer Write-off Others

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

□Applicable Not applicable

(4) Notes receivable pledged by the company at the end of the period

Unit: Yuan Project Amount pledged at the end of the period

(5) Notes receivable that have been endorsed or discounted by the company at the end of the period and have not yet matured on the balance sheet date

Unit: Yuan Item Amount derecognized at the end of the period Amount not derecognized at the end of the period

(6) Notes receivable actually written off in the current period

Unit: yuan item write-off amount

Among them, the important write-off of bills receivable:

Unit: Whether the Yuan amount is paid by the related unit, nature of the note receivable, write-off amount, reason for write-off, write-off procedures performed

Instructions for writing off notes receivable resulting from transactions:

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Accounts receivable

(1) Disclosure based on aging

Unit: Yuan

Aging Book balance at the end of the period Book balance at the beginning of the period

Within 1 year (including 1 year) 46,674,162.39 44,800,043.94 1 to 2 years 5,721,959.39 9,513,760.53 2 to 3 years 4,360,702.05 2,274,919.80 More than 3 years 5,035,455.22 4,402,619.41 3 to 4 years 2,565,018.80 2,904,729.61 4 to 5 years 1,854,958.62 812,520.00

More than 5 years 615,477.80 685,369.80 Total 61,792,279.05 60,991,343.68

(2) Classified disclosure according to bad debt accrual method

Unit: Yuan Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book price Book price provision ratio Provision ratio

Amount Ratio Amount Value Amount Ratio Amount Value

Example Example

By item

bad provision

740,000 740,000 740,000 740,000

Account provision 1.20% 100.00% 1.21% 100.00%

.00 .00 .00 .00

receivables

Accounts

its

Medium:

by combination

bad provision

61,052, 5,610,5 55,441, 60,251, 5,177,4 55,073, Account provision 98.80% 9.19% 98.79% 8.59%

279.05 07.24 771.81 343.68 10.91 932.77 receivables

Accounts

its

Medium:

61,792, 6,350,5 55,441, 60,991, 5,917,4 55,073, total 100.00% 10.28% 100.00% 9.70%

279.05 07.24 771.81 343.68 10.91 932.77 Category name of bad debt provision based on individual items: Individual bad debt provision combination

Unit: Yuan Beginning balance Ending balance

Name

Book balance Bad debt provision Book balance Bad debt provision Provision ratio Reason for provision Beijing Xuanzhu Kangming

The company went bankrupt and Biotechnology Co., Ltd. 280,000.00 280,000.00 280,000.00 280,000.00 100.00%

Enter a clearing company

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

The terminal project is temporarily Nanjing Woxin Instruments

240,000.00 240,000.00 240,000.00 240,000.00 100.00% Stop, no restart Equipment Co., Ltd.

room

Hunan Sanqing Pharmaceutical Company went bankrupt and has

220,000.00 220,000.00 220,000.00 220,000.00 100.00%

Co., Ltd. Total liquidation 740,000.00 740,000.00 740,000.00 740,000.00

Category name of provision for bad debts by combination: Aging combination

Unit: Yuan ending balance

Name

Book balance Bad debt provision Provision ratio

Within 1 year 46,674,162.39 2,333,708.13 5.00% 1-2 years 5,721,959.39 572,195.95 10.00% 2-3 years 4,360,702.05 872,140.41 20.00% 3-4 years 2,565,018.80 769,505.64 30.00% 4-5 years 1,334,958.62 667,479.31 50.00% More than 5 years 395,477.80 395,477.80 100.00% Total 61,052,279.05 5,610,507.24

Description of what this combination is based on:

If bad debt provisions for accounts receivable are made according to the general expected credit loss model:

□Applicable Not applicable

(3) Bad debt provisions accrued, recovered or reversed in the current period

Bad debt provisions for the current period:

Unit: Yuan Amount of changes in the current period

Category Beginning Balance Ending Balance

Provision Recovery or transfer Write-off Others

Single provision for bad debts

740,000.00 740,000.00Preparation

Bad provision based on combination

5,177,410.91 442,096.33 9,000.00 5,610,507.24 Account preparation

Total 5,917,410.91 442,096.33 9,000.00 6,350,507.24 Among them, the amount of bad debt provision recovery or reversal in the current period is important:

Unit: Yuan Determine the name of the original bad debt provision accrual unit, the amount recovered or reversed, the reason for the reverse, the method of recovery, the basis for the ratio and its reasonableness

sex

(4) Accounts receivable actually written off in the current period

Unit: Yuan Zhejiang Tailin Biotechnology Co., Ltd. Full text of 2026 semi-annual report

Item Write-off Amount

Actual write-off of accounts receivable 9,000.00 Among them, the important write-off of accounts receivable:

Unit: Yuan Whether the amount is paid by the name of the related unit Nature of accounts receivable Amount of write-off Reason for write-off The write-off procedures performed

Instructions for writing off accounts receivable arising from transactions:

(5) Accounts receivable and contract assets with the top five closing balances collected by debtors

Unit: Yuan accounts receivable and combined accounts receivable, bad debts, quasi-accounts receivable, ending balance, contract assets, ending balance, accounts receivable and contracts

Unit name Closing balance of same assets Provision and contract asset reduction amount Closing balance of assets

Proportion of total value preparation closing balance Customer one 13,829,663.71 13,829,663.71 22.38% 691,483.19 Customer two 3,105,586.92 77,450.00 3,183,036.92 5.15% 159,151.85 Customer three 3,083,141.00 3,083,141.00 4.99% 154,157.05Customer Four 1,786,295.76 494,900.00 2,281,195.76 3.69% 114,059.79Customer Five 1,713,238.94 1,713,238.94 2.77% 342,647.79Total 23,517,926.33 572,350.00 24,090,276.33 38.98% 1,461,499.67

Contract assets

(1) Contract assets

Unit: Yuan Ending balance Beginning balance

Project

Book balance Bad debt provision Book value Book balance Bad debt provision Book value Quality deposit receivable 7,307,723.00 402,815.03 6,904,907.97 5,307,733.00 340,472.15 4,967,260.85Total 7,307,723.00 402,815.03 6,904,907.97 5,307,733.00 340,472.15 4,967,260.85

(2) Amount and reasons of major changes in book value during the reporting period

Unit: Yuan

Item Amount of change Reason for change

(3) Classified disclosure according to bad debt accrual method

Unit: Yuan Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book price Book price provision ratio Provision ratio

Amount Ratio Amount Value Amount Ratio Amount Value Example

its

Medium:

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

by combination

7,307,7 402,815 6,904,9 5,307,7 340,472 4,967,2 Bad provision 100.00% 5.51% 100.00% 6.41%

23.00 .03 07.97 33.00 .15 60.85Account preparation

its

Medium:

7,307,7 402,815 6,904,9 5,307,7 340,472 4,967,2Total 100.00% 5.51% 100.00% 6.41%

23.00 .03 07.97 33.00 .15 60.85Number of bad debt provision categories by combination: 1

Category name of bad debt provisions accrued by portfolio: Quality deposit receivable portfolio

Unit: Yuan ending balance

Name

Book balance Bad debt provision Provision ratio

Quality deposit receivable portfolio 7,307,723.00 402,815.03 5.51% Total 7,307,723.00 402,815.03

Description of what this combination is based on:

Provision for bad debts based on the general expected credit loss model

□Applicable Not applicable

(4) Bad debt provisions accrued, recovered or reversed in the current period

Unit: Yuan Item Provision in the current period Recovery or transfer in the current period Write-off/write-off in the current period Reasons

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

Unit: Yuan Determine the name of the original bad debt provision accrual unit, the recovery or reversal amount, the reason for the reversal, the recovery method, the basis for the ratio and its rationality

Other instructions

Amount of changes in the current period

Item Opening amount Ending amount Provision Recovery or transfer Write-off/write-off Others

Impairment provision on a group basis

340,472.15 62,342.88 402,815.03Preparation

Total 340,472.15 62,342.88 402,815.03

(5) Contract assets actually written off in the current period

Unit: yuan item write-off amount

Among them, the important write-off of contract assets

Unit: Yuan Unit name Nature of the payment Amount written off Reason for write-off Written-off procedures performed Whether the payment is from a related party Zhejiang Tailin Biotechnology Co., Ltd. 2026 Semi-annual Report Full text

Instructions for writing off contract assets generated by transactions:

Other notes:

Accounts receivable financing

(1) Classified presentation of financing receivables

Unit: Yuan

Item Ending balance Beginning balance

Bank acceptance bill 8,764,689.34 12,778,553.43 Total 8,764,689.34 12,778,553.43

(2) Classified disclosure according to bad debt accrual method

Unit: Yuan Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book price Book price provision ratio Provision ratio

Amount Ratio Amount Value Amount Ratio Amount Value

Example Example

Among them:

by combination

8,764,6 8,764,6 12,778, 12,778, bad provision 100.00% 100.00%

89.34 89.34 553.43 553.43Account preparation

Among them:

Bank commitment 8,764,6 8,764,6 12,778, 12,778,

100.00% 100.00%

Exchange of money orders 89.34 89.34 553.43 553.43

8,764,6 8,764,6 12,778, 12,778, total 100.00% 100.00%

89.34 89.34 553.43 553.43 Provision for bad debts based on the general expected credit loss model

Unit: Yuan Phase 1 Phase 2 Phase 3

Expected credit throughout the lifetime Credit expected throughout the lifetime

Provision for bad debts Expected credit in the next 12 months Total

Loss (no credit deduction has occurred Loss (credit deduction has occurred)

loss

value) value)

Balance as of January 1, 2026

In this issue

Basis for division of each stage and provision ratio for bad debts

Explanation of significant changes in the book balance of accounts receivable financing that have experienced changes in loss provisions in the current period:

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

(3) Bad debt provisions accrued, recovered or reversed in the current period

Unit: Yuan Amount of changes in the current period

Category Opening balance Ending balance Provision Recovery or reversal Write-off or write-off Other changes

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

Other notes:

(4) Financing of the company’s pledged receivables at the end of the period

Unit: Yuan Project Amount pledged at the end of the period

(5) Financing of receivables that have been endorsed or discounted by the company at the end of the period and have not yet matured on the balance sheet date

Unit: Yuan Item Amount derecognized at the end of the period Amount not derecognized at the end of the period

Bank acceptance draft 10,167,831.59

Total 10,167,831.59

(6) Financing of receivables actually written off in the current period

Unit: yuan item write-off amount

Important financing write-offs of receivables

Unit: Whether the yuan amount is paid by the name of the related unit, nature of the amount, write-off amount, write-off reason, write-off procedures performed

transaction generated

Write-off instructions:

(7) Increases and decreases in receivables financing during the current period and changes in fair value

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

(8) Other instructions

The acceptor of the bank acceptance bill is a commercial bank with relatively high credit, and the possibility that the bank acceptance bill accepted by it will not be paid when due is low, so the company will derecognize the bank acceptance bill that has been endorsed or discounted. However, if the bills are not paid when due, the company will still be jointly and severally liable to the holders in accordance with the provisions of the Negotiable Instruments Law.

Other receivables

Unit: Yuan Item Ending balance Beginning balance

Other receivables 7,654,832.04 7,403,136.38 Total 7,654,832.04 7,403,136.38 (1) Interest receivable

Classification of interest receivable

Unit: Yuan Item Ending balance Beginning balance

Important overdue interest

Unit: Yuan Whether impairment occurs and the borrowing unit is judged. Ending balance Overdue time Reason for overdue

Judgment basis

Other notes:

Classified disclosure according to bad debt accrual method

□Applicable Not applicable

Bad debt provisions accrued, recovered or reversed in the current period

Unit: Yuan Amount of changes in the current period

Category Opening balance Ending balance Provision Recovery or reversal Write-off or write-off Other changes

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

Other notes:

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Interest receivable actually written off in the current period

Unit: yuan item write-off amount

Among them, the important write-off of interest receivable

Unit: Whether the yuan amount is paid by the name of the related unit, nature of the amount, write-off amount, write-off reason, write-off procedures performed

transaction generated

Write-off instructions:

Other notes:

(2) Dividends receivable

Classification of dividends receivable

Unit: yuan project (or invested unit) Ending balance Beginning balance

Important dividends receivable aged more than 1 year

Unit: Yuan Whether impairment occurs and the judgment item (or invested unit) Closing balance Aging Reason for non-recovery

Judgment basis

Classified disclosure according to bad debt accrual method

□Applicable Not applicable

Bad debt provisions accrued, recovered or reversed in the current period

Unit: Yuan Amount of changes in the current period

Category Opening balance Ending balance Provision Recovery or reversal Write-off or write-off Other changes

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

Other notes:

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Dividends receivable actually written off in the current period

Unit: Yuan

Item Write-off Amount

Among them, the important write-off of dividends receivable

Unit: Whether the yuan amount is paid by the name of the related unit, nature of the amount, write-off amount, write-off reason, write-off procedures performed

Instructions for writing off transactions:

Other notes:

(3) Other receivables

Classification of other receivables according to nature of payment

Unit: Yuan

Nature of payment Book balance at the end of the period Book balance at the beginning of the period

Deposit and security deposit 2,988,454.00 7,711,778.00 Temporary payment receivable 4,961,261.69 1,109,830.00 Reserve fund 369,120.00 2,000.00 Total 8,318,835.69 8,823,608.00

Disclosure based on aging

Unit: Yuan

Aging Book balance at the end of the period Book balance at the beginning of the period

Within 1 year (including 1 year) 7,292,078.27 3,303,553.58 1 to 2 years 216,667.42 237,364.42 2 to 3 years 390,540.00 4,741,425.00 More than 3 years 419,550.00 541,265.00 3 to 4 years 301,000.00 365,050.00 4 to 5 years 18,450.00 4,915.00

More than 5 years 100,100.00 171,300.00 Total 8,318,835.69 8,823,608.00

Classified disclosure according to bad debt accrual method

Applicable □Not applicable

Unit: Yuan Ending balance Beginning balance

Category Book balance Bad debt provision Book price Book balance Bad debt provision Book price

Amount Proportion Amount Provision ratio Amount Proportion Amount Provision ratio Full text of the 2026 Semi-annual Report of Zhejiang Tailin Biotechnology Co., Ltd.

Example Example

Among them:

by combination

8,318,8 664,003 7,654,8 8,823,6 1,420,4 7,403,1 Bad provision 100.00% 7.98% 100.00% 16.10%

35.69 .65 32.04 08.00 71.62 36.38Account preparation

Among them:

8,318,8 664,003 7,654,8 8,823,6 1,420,4 7,403,1Total 100.00% 7.98% 100.00% 16.10%

35.69 .65 32.04 08.00 71.62 36.38 Name of bad debt provision category by combination: Aging combination

Unit: Yuan ending balance

Name

Book balance Bad debt provision Provision ratio

Within 1 year 7,292,078.27 364,603.91 5.00% 1-2 years 216,667.42 21,666.74 10.00% 2-3 years 390,540.00 78,108.00 20.00% 3-4 years 301,000.00 90,300.00 30.00% 4-5 years 18,450.00 9,225.00 50.00% More than 5 years 100,100.00 100,100.00 100.00% Total 8,318,835.69 664,003.65

Description of what this combination is based on:

Provision for bad debts is made based on the general expected credit loss model:

Unit: Yuan Phase 1 Phase 2 Phase 3

Expected credit throughout the lifetime Credit expected throughout the lifetime

Provision for bad debts Expected credit in the next 12 months Total

Loss (no credit deduction has occurred Loss (credit deduction has occurred)

loss

value) value)

Balance on January 1, 2026 165,177.68 23,736.44 1,231,557.50 1,420,471.62 Balance on January 1, 2026

In this issue

——Transfer to the second stage -10,833.37 10,833.37

——Transfer to the third stage -39,054.00 39,054.00

Provision for the current period 210,259.60 26,150.93 -991,078.50 -754,667.97 Write-off for the current period 1,800.00 1,800.00 Remainder as of June 30, 2026

364,603.91 21,666.74 277,733.00 664,003.65 amount

Basis for division of each stage and provision ratio for bad debts

Changes in book balances with significant changes in loss provision during the current period

□Applicable Not applicable

Bad debt provisions accrued, recovered or reversed in the current period

Bad debt provisions for the current period:

Unit: Yuan Zhejiang Tailin Biotechnology Co., Ltd. Full text of 2026 semi-annual report

Amount of changes in the current period

Category Opening balance Ending balance Provision Recovery or reversal Write-off or write-off Others

Among them, the amount of bad debt provision for the current period that is reversed or recovered is important:

Other receivables actually written off in the current period

Unit: yuan item write-off amount

Important write-offs of other receivables:

Unit: Whether the Yuan amount is paid by the related unit. Nature of other receivables. Write-off amount. Reason for write-off. Write-off procedures performed.

transaction generated

Instructions for writing off other receivables:

Other receivables with the top five closing balances based on debtors

Unit: Yuan accounted for other receivable period

Name of the unit with the ending balance of bad debt provision Nature of the payment Ending balance Aging Total ending balance

Proportion

Zhejiang University Temporary payment receivable 1,700,000.00 Within 1 year 20.44% 85,000.00 Hangzhou Fuchun Bay New City

Deposit security deposit 1,500,000.00 Within 1 year 18.03% 75,000.00 Management Committee

Withholding and payment for employees 5

Temporary payment receivable 964,158.29 Within 1 year 11.59% 48,207.91 Insurance and one fund

Guangdong Province Mechanical and Electrical Equipment

Temporary payment receivable 402,280.00 Within 1 year 4.84% 20,114.00 Bidding Center

Sichuan University Deposit guarantee 226,000.00 3-4 years 2.72% 67,800.00 Total 4,792,438.29 57.62% 296,121.91

Presented in other receivables due to centralized management of funds

Unit: Yuan Other instructions:

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Advance payment

(1) Prepayments are listed based on aging

Unit: Yuan Ending balance Beginning balance

Aging

Amount Ratio Amount Ratio

Within 1 year 5,226,362.47 85.94% 3,735,345.28 91.07% 1 to 2 years 593,366.77 9.76% 198,123.40 4.83% 2 to 3 years 156,423.36 2.57% 135,001.16 3.29% More than 3 years 105,340.54 1.73% 33,384.04 0.81% Total 6,081,493.14 4,101,853.88

Explanation of the reasons why prepayments with an aging of more than 1 year and important amounts are not settled in a timely manner:

(2) Prepayments with the top five closing balances by prepayment objects

The total of the top five prepayments at the end of the period is 2,500,252.33 yuan, accounting for 41.11% of the total end of prepayments balance.

Other notes:

Inventory

Whether the company needs to comply with the real estate industry’s disclosure requirements

(1) Inventory classification

Unit: Yuan Ending balance Beginning balance

Provision for inventory decline Provision for inventory decline

Project

Book balance or contract performance costs Book value Book balance or contract performance costs Book value impairment provision

28,444,285.7 26,165,756.8 30,267,033.6 28,424,915.1 Raw materials 2,278,528.92 1,842,118.50

3 1 2 2

44,784,521.1 44,471,641.0 38,146,525.8 37,834,255.0 Products in progress 312,880.13 312,270.77

9 6 1 4

25,263,447.8 22,691,439.3 26,402,599.7 23,860,414.1 Inventory goods 2,572,008.58 2,542,185.58

9 1 0 2

42,940,140.7 42,940,140.7 36,259,147.9 36,259,147.9 Products shipped

6 6 7 7 Commissioned processing materials 183,770.16 183,770.16 156,339.38 156,339.38

141,616,165. 136,452,748. 131,231,646. 126,535,071. Total 5,163,417.63 4,696,574.85

73 10 48 63Full text of Zhejiang Tailin Biotechnology Co., Ltd. 2026 Semi-annual Report

(2) Data resources confirmed as inventory

Unit: Data resources processed by Yuan itself Data obtained through other methods

Item Outsourced data resource inventory Total

Inventory Resource Inventory

(3) Provision for inventory depreciation and provision for impairment of contract performance costs

Unit: Yuan Increase amount in this period Decrease amount in this period

Item Beginning balance Closing balance

Provision Others Reversal or write-off Others

Raw materials 1,842,118.50 787,727.00 351,316.58 2,278,528.92 Work in progress 312,270.77 6,356.53 5,747.17 312,880.13 Inventory goods 2,542,185.58 29,823.00 2,572,008.58 Total 4,696,574.85 823,906.53 357,063.75 5,163,417.63

The specific basis for determining the net realizable value and the reasons for the reversal or write-off of inventory depreciation reserves in the current period.

Determine the net realizable value, reverse inventory depreciation items, and write off inventory depreciation items.

Specific basis for preparation Reason for preparation Raw materials

The estimated selling price of the relevant finished goods is reduced to the estimated completion price

Calculate the costs and estimated sales expenses that will be incurred. Inventory depreciation provisions have been made in previous periods. In this period, inventory depreciation provisions have been made for work in progress.

The net realizable value of variable inventories is determined based on the amount after taxes and related taxes. Increase in inventory consumption/sold

Current net worth

Inventory items

Provision for inventory decline in value on a group basis

Unit: End of the period Beginning of the period

Portfolio name Provision for decline in price Provision for decline in price Provision for decline in price Closing balance Provision for decline in price Opening balance Provision for decline in price

Proportion Proportion The standard for accruing inventory depreciation provisions based on the combination

(4) Explanation that the closing balance of inventory includes the capitalized amount of borrowing costs

(5) Explanation of the amortization amount of contract performance costs for the current period

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Assets held for sale

Unit: Yuan Item Book balance at the end of the period Impairment provision Book value at the end of the period Fair value Estimated disposal costs Estimated disposal time Other instructions

Non-current assets due within one year

Unit: Yuan Item Ending balance Beginning balance

(1) Debt investments due within one year

□Applicable Not applicable

(2) Other debt investments due within one year

□Applicable Not applicable

Other current assets

Unit: Yuan Item Ending balance Beginning balance

Value-added tax input tax to be deducted 9,504,578.15 6,076,792.27 Prepaid corporate income tax 220,140.45 310,472.16 Structured deposits 99,941,635.62 122,393,876.69 Total 109,666,354.22 128,781,141.12 Information related to compensating assets

Other notes:

Debt investment

(1) Situation of debt investment

Unit: Yuan Ending balance Beginning balance

Project

Book balance Impairment provision Book value Book balance Impairment provision Book value Debt investment impairment provision Changes in the current period

Unit: Yuan Item Beginning balance Increase in the current period Decrease in the current period Ending balance

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

(2) Important debt investments at the end of the period

Unit: Yuan Ending balance Beginning balance

claims

Coupon interest Actual interest Overdue principal Coupon interest Actual interest Overdue principal Par value Maturity date Par value Maturity date Rate Rate Gold Rate Rate Gold

(3) Provision of impairment provisions

Unit: Yuan Phase 1 Phase 2 Phase 3

Expected credit throughout the lifetime Credit expected throughout the lifetime

Bad debt provision Expected total credit losses in the next 12 months (no credit deductions have occurred Losses (credit deductions have occurred)

loss

value) value)

Balance as of January 1, 2026

In this issue

Basis for division of each stage and provision ratio for bad debts

(4) Debt investment actually written off in this period

Unit: yuan item write-off amount

Among them, the important write-off of debt investment

Debt investment write-off instructions:

Changes in book balances with significant changes in loss provision during the current period

□Applicable Not applicable

Other notes:

Other debt investments

(1) Situation of other debt investments

Unit: Yuan Accumulative fair in other comprehensive income for the period Accumulative fair

Item Opening balance Accrued interest Interest adjustment Closing balance Cost Recognition in profit Remarks Value changes Value changes

provision for impairment

Transferable large 55,452,6 55,819,6

Certificate of deposit 27.40 73.98

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

55,452,6 55,819,6

total

27.40 73.98

Changes in impairment provisions for other debt investments during the current period

Unit: Yuan Item Beginning balance Increase in the current period Decrease in the current period Ending balance

(2) Other important debt investments at the end of the period

Unit: Yuan Ending balance Beginning balance

Other debts

Coupon interest Actual interest Overdue capital Coupon interest Actual interest Overdue capital item Par value Maturity date Par value Maturity date rate Gold rate Gold Hangzhou Silver

Bank unit 2028 2028 55,000, 55,000,

Large deposit 2.30% 2.30% January 26 0.00 2.30% 2.30% January 26 000.00 000.00

Single G008 Day Date

55,000, 55,000,

total

000.00 000.00

(3) Provision of impairment provisions

Unit: Yuan Phase 1 Phase 2 Phase 3

Expected credit throughout the lifetime Credit expected throughout the lifetime

Bad debt provision Expected total credit losses in the next 12 months (no credit deductions have occurred Losses (credit deductions have occurred)

loss

value) value)

Balance as of January 1, 2026

In this issue

Basis for division of each stage and provision ratio for bad debts

(4) Other debt investments actually written off in the current period

Unit: yuan item write-off amount

Among them, the write-off of other important debt investments

Changes in book balances with significant changes in loss provision during the current period

□Applicable Not applicable

Other notes:

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Investment in other equity instruments

Unit: Yuan Designated as fair value included in the current period Included in the current period Accumulated at the end of the period Accumulated at the end of the period

Recognized and measured in the current period and its other comprehensive Other comprehensive accounting is included in its Other comprehensive accounting is included in its

Item name Dividend income at the beginning of the period Dividend income at the end of the period Changes included in income Loss of income Other comprehensive income Other comprehensive income

Income Other comprehensive gains and losses Gains and losses

original income

Because

There is termination confirmation in this period

Unit: yuan Project name Accumulated gains transferred to retained earnings Accumulated losses transferred to retained earnings Reasons for derecognition

Disclosure of non-trading equity instrument investments in the current period by items

Unit: Yuan designated as fair

Other comprehensive income Dividend income measured in value and recognized in other comprehensive income

Project name Accumulated profits Accumulated losses Transfer to retained earnings Changes are included in other Transfer to retained earnings

The amount of comprehensive income is due to

Other notes:

Long-term receivables

(1) Long-term receivables

Unit: Yuan Ending balance Beginning balance

Item Discount rate range Book balance Bad debt provision Book value Book balance Bad debt provision Book value

(2) Classified disclosure according to bad debt accrual method

Unit: Yuan Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book price Book price provision ratio Provision ratio

Amount Ratio Amount Value Amount Ratio Amount Value Example

Among them:

Provision for bad debts based on the general expected credit loss model

Unit: Yuan Phase 1 Phase 2 Phase 3

Bad debt provision Expected credit for the next 12 months Expected credit for the entire duration Expected credit for the entire duration Total

Loss Loss (no credit deduction has occurred Loss (credit deduction has occurred)

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

value) value)

Balance as of January 1, 2026

In this issue

Basis for division of each stage and provision ratio for bad debts

(3) Bad debt provisions accrued, recovered or reversed in the current period

Unit: Yuan Amount of changes in the current period

Category Opening balance Ending balance Provision Recovery or reversal Write-off or write-off Others

Among them, the amount of bad debt provision for the current period that is reversed or recovered is important:

Other notes:

(4) Long-term receivables actually written off in the current period

Unit: yuan item write-off amount

Among them, the important write-off situation of long-term receivables:

Unit: Whether the yuan amount is paid by the name of the related unit, nature of the amount, write-off amount, write-off reason, write-off procedures performed

transaction generated

Instructions for writing off long-term receivables:

Long-term equity investment

Unit: Yuan Increase or decrease in the current period

Beginning of period Equity declaration End of period

Impairment Impairment investment balance Other disbursement balance under the law

Preparation Other Provisions Provision Notes (Account Addition Decrease Confirmation Comprehensive Cash (Account

Equity Impairment at the Beginning of the Period Others Ending of the Period Face Price Investment Investment Income from Investment Dividends Face Price

Balance Change Provision Balance Value) Capital Loss Adjustment or Profit Value)

profit

1. Joint ventures

2. Joint ventures

Jiangsu 10,54 555,1 11,10

Hongzhong 9,721 14.78 4,836

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Bai De .85 .63 Creature

Technology

limited

company

(With

Xia Jian

call macro

Hundreds

De Gong

Division)

10,54 11,10

555,1

Subtotal 9,721 4,836 14.78

.85 .63 10,54 11,10

555,1

Total 9,721 4,836 14.78

.85 .63 The recoverable amount is determined based on the net amount of fair value minus disposal costs.

□Applicable Not applicable

The recoverable amount is determined based on the present value of expected future cash flows.

□Applicable Not applicable

Reasons for the obvious inconsistency between the aforementioned information and the information used in impairment testing in previous years or external information

Reasons for the discrepancy between the information used in the company's impairment testing in previous years and the actual situation of that year.

Other instructions

Other non-current financial assets

Unit: Yuan

Item Ending balance Beginning balance Other instructions:

Investment real estate

(1) Investment real estate using cost measurement model

Applicable □Not applicable

Unit: Yuan

Projects Houses and buildings Land use rights Construction in progress Total

1. Original book value

Opening balance 19,180,610.55 19,180,610.55
Increase amount in this period

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

(1) Outsourcing

(2) Inventory\

Fixed assets\construction in progress transfer

enter

(3) Enterprise cooperation

and increase

Reduction amount in this period

(1) Disposal

(2) Other transfers

out

Ending balance 19,180,610.55 19,180,610.55

2. Accumulated depreciation and accumulation

Amortization

Balance at the beginning of the period 10,629,254.99 10,629,254.99 2. Increased amount in the current period 151,846.56 151,846.56 (1) Provision or

151,846.56 151,846.56 Amortization

Reduction amount in this period

(1) Disposal

(2) Other transfers

out

Ending balance 10,781,101.55 10,781,101.55

3. Impairment provision

Opening balance
Increase amount in this period

(1) Provision

Reduction amount in this period

(1) Disposal

(2) Other transfers

out

Ending balance

4. Book value

Book value at the end of the period 8,399,509.00 8,399,509.00 2. Book value at the beginning of the period 8,551,355.56 8,551,355.56 The recoverable amount is determined based on the net amount of fair value minus disposal costs □ Applicable  Not applicable

The recoverable amount is determined based on the present value of expected future cash flows □Applicable Not applicable

The reason for the obvious inconsistency between the aforementioned information and the information used in impairment testing in previous years or external information. Full text of Zhejiang Tailin Biotechnology Co., Ltd.'s 2026 Semi-annual Report

Reasons for the discrepancy between the information used in the company's impairment testing in previous years and the actual situation of that year.

Other notes:

(2) Investment real estate using fair value measurement model

□Applicable Not applicable

(3) Converted to investment real estate and measured at fair value

Unit: Accounting Section before yuan conversion Amount of other comprehensive income items Reason for conversion Approval procedure Impact on profit and loss

Benefit impact

(4) Investment real estate that has not completed the ownership certificate

Unit: Yuan Item Book value Reasons for not completing the property rights certificate

Other instructions

Fixed assets

Unit: Yuan Item Ending balance Beginning balance

Fixed assets 244,342,116.18 250,792,052.78 Total 244,342,116.18 250,792,052.78

(1) Fixed assets

Unit: Yuan Item Houses and buildings Machinery and equipment Transportation Office and electronic equipment Total

1. Original book value:

Opening balance 232,636,608.85 79,585,684.73 4,784,813.71 9,997,092.74 327,004,200.03 2. Increase in this period

1,331,131.72 136,522.09 1,467,653.81Amount

(1) Purchase

746,689.25 136,522.09 883,211.34

(2) in

584,442.47 584,442.47 Construction project transferred in

(3) Enterprise

Increase in business mergers

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Reduction in this period

1,920,555.51 619.68 1,921,175.19Amount

(1) place

1,920,555.51 619.68 1,921,175.19 Disposal or scrapping

Closing balance 232,636,608.85 78,996,260.94 4,784,813.71 10,132,995.15 326,550,678.65

2. Accumulated depreciation

Opening balance 28,722,749.34 36,277,629.60 3,537,128.43 7,674,639.88 76,212,147.25 2. Increase in this period

3,295,030.26 3,791,681.97 184,096.62 470,559.63 7,741,368.48 Amount

(1) Count

3,295,030.26 3,791,681.97 184,096.62 470,559.63 7,741,368.48

Reduction in this period

1,744,888.92 64.34 1,744,953.26Amount

(1) place

1,744,888.92 64.34 1,744,953.26 Disposal or scrapping

Closing balance 32,017,779.60 38,324,422.65 3,721,225.05 8,145,135.17 82,208,562.47

3. Impairment provision

Opening balance

2.Increase in this period

Amount

(1) Count

mention

Reduction in this period

Amount

(1) place

dispose or scrap

Ending balance

4. Book value

Closing accounts

200,618,829.25 40,671,838.29 1,063,588.66 1,987,859.98 244,342,116.18 Value

Opening accounts

203,913,859.51 43,308,055.13 1,247,685.28 2,322,452.86 250,792,052.78 value

(2) Temporarily idle fixed assets

Unit: Yuan Item Original book value Accumulated depreciation Impairment provision Book value Remarks

(3) Fixed assets leased through operating leases

Unit: Yuan Item Closing book value

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

(4) Fixed assets whose property rights certificates have not been obtained

Unit: Yuan

Item Book value Other reasons for failure to obtain property rights certificate

(5) Impairment testing of fixed assets

□Applicable Not applicable

(6) Fixed assets liquidation

Unit: Yuan

Item Ending balance Beginning balance

Other instructions

Projects under construction

Unit: Yuan

Item Ending balance Beginning balance

Construction in progress 39,161,752.01 9,259,817.63 Total 39,161,752.01 9,259,817.63

(1) Projects under construction

Unit: Yuan Ending balance Beginning balance

Project

Book Balance Impairment Allowance Book Value Book Balance Impairment Allowance Book Value High Performance Filter

34,895,619.2 34,895,619.2

and supporting functional films 4,969,177.04 4,969,177.04

0 0

Industrialization project

Medical Engineering ERP

3,076,529.07 3,076,529.07 2,697,217.00 2,697,217.00 project

Analytical instrument factory area

257,800.00 257,800.00 Decoration project

Equipment to be installed 1,189,603.74 1,189,603.74 1,335,623.59 1,335,623.59

39,161,752.0 39,161,752.0

Total 9,259,817.63 9,259,817.63

1 1

(2) Changes in important projects under construction during the current period

Unit: Yuan for the current period Project Interest Other

This issue This issue This issue

Project Budget Beginning of Period Transferred to End of Period Accumulated Project Capital Among: Funds

Add other interest

Name Number Balance Fixed Balance Investment Progress Accumulation Source Amount in the Current Period Decrease in Capital

Assets to Estimated Funds Interest

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Amount Amount Calculation ratio Amount Capitalization rate High performance of capitalization amount

Can pass

filter

Raising and matching 321,6 4,969 29,92 34,89

11.38 Capital fraud 18,80,177. 6,442 5,619 12.00

% gold, energy film 0.00 04 .16 .20

Other industries

Chemical terms

Head

321,6 4,969 29,92 34,89

Total 18,80 ,177. 6,442 5,619

0.00 04 .16 .20

(3) Provision for impairment of projects under construction in the current period

Unit: Yuan Item Beginning balance Increase in the current period Decrease in the current period Closing balance Other explanations for the reasons for provision

(4) Impairment testing of projects under construction

□Applicable Not applicable

(5) Engineering materials

Unit: Yuan Closing balance Beginning balance item

Book balance Impairment provision Book value Book balance Impairment provision Other instructions for book value:

Productive biological assets

(1) Productive biological assets using cost measurement model

□Applicable Not applicable

(2) Impairment testing of productive biological assets using the cost measurement model

□Applicable Not applicable

(3) Productive biological assets using fair value measurement model

□Applicable Not applicable

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Oil and gas assets

□Applicable Not applicable

Right-of-use assets

(1) Right-of-use assets

Unit: Yuan

Item Total

1. Original book value

Opening balance
Increase amount in this period
Reduction amount in this period
Ending balance

2. Accumulated depreciation

Opening balance
Increase amount in this period

(1) Provision

Reduction amount in this period

(1) Disposal

Ending balance

3. Impairment provision

Opening balance
Increase amount in this period

(1) Provision

Reduction amount in this period

(1) Disposal

Ending balance

4. Book value

Book value at the end of the period 2. Book value at the beginning of the period

(2) Impairment testing of right-of-use assets

□Applicable Not applicable

Other notes:

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Intangible assets

(1) Intangible assets

Unit: Yuan

Project Land use rights Patent rights Non-patented technology Software Total

1. Original book value

Opening balance 29,789,800.00 1,977,841.45 31,767,641.45 2. Increase in the current period

(1) Purchase

(2) Internal research and development

(3) Increase in business mergers

Reduction amount in this period

(1) Disposal

Closing balance 29,789,800.00 1,977,841.45 31,767,641.45

2. Accumulated amortization

Opening balance 3,475,931.70 899,206.36 4,375,138.06 2. Increase in this period

297,890.58 99,989.88 397,880.46 Amount

(1) Count

297,890.58 99,989.88 397,880.46

Reduction amount in this period

(1) Disposal

Closing balance 3,773,822.28 999,196.24 4,773,018.52

3. Impairment provision

Opening balance 2. Increase in current period

(1) Provision

Reduction amount in this period

(1) Disposal

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Ending balance

4. Book value

Closing accounts

26,015,977.72 978,645.21 26,994,622.93 value

Opening accounts

26,313,868.30 1,078,635.09 27,392,503.39 value

The proportion of intangible assets formed through the company's internal research and development at the end of the period to the balance of intangible assets is 0.00%

(2) Data resources recognized as intangible assets

Unit: Yuan Outsourced data resources are intangible Self-developed data resources Data obtained through other means

Item Total assets Intangible assets Resources intangible assets

(3) Land use rights for which property rights certificates have not been obtained

Unit: Yuan Item Book value Other explanations for reasons for not completing the property rights certificate

(4) Impairment testing of intangible assets

□Applicable Not applicable

Goodwill

(1) Original book value of goodwill

Unit: yuan Name of invested unit Increase in this period Decrease in this period

Goodwill is called or formed. Opening balance Formed by business combination Disposal of closing balance

matters of

total

(2) Goodwill impairment provision

Unit: yuan Name of invested unit Increase in this period Decrease in this period

Goodwill is called or formed. Balance at the beginning of the period. Balance at the end of the period. Provision for disposal.

matters

total

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

(3) Relevant information about the asset group or asset group combination where the goodwill is located

The composition of the asset group or portfolio to which it belongs and

Name, operating segment and basis. Is it consistent with previous years?

Basis

Changes in asset group or asset group combination

Name Composition before the change Composition after the change Objective facts and basis for the change Other explanations

(4) Specific determination method of recoverable amount

The recoverable amount is determined as the net amount after fair value minus disposal costs.

□Applicable Not applicable

The recoverable amount is determined based on the present value of expected future cash flows.

□Applicable Not applicable

Reasons for the obvious inconsistency between the aforementioned information and the information used in impairment testing in previous years or external information

Reasons for the discrepancy between the information used in the company's impairment testing in previous years and the actual situation of that year.

(5) Completion of performance commitments and corresponding impairment of goodwill

There is a performance commitment when goodwill is formed and the reporting period or the previous period of the reporting period is within the performance commitment period

□Applicable Not applicable

Other instructions

Long-term deferred expenses

Unit: Yuan

Item Beginning balance Increase in the current period Amortization amount in the current period Other decreases Closing balance Decoration expenses 29,069,749.33 1,190,471.13 2,147,909.06 28,112,311.40 Total 29,069,749.33 1,190,471.13 2,147,909.06 28,112,311.40Other instructions

Deferred income tax assets/deferred income tax liabilities

(1) Deferred income tax assets without offset

Unit: Yuan

Item Ending balance Beginning balance Full text of Zhejiang Tailin Biotechnology Co., Ltd.'s 2026 Semi-annual Report

Deductible temporary differences Deferred income tax assets Deductible temporary differences Deferred income tax assets Asset impairment provision 2,024,656.42 223,910.21 1,942,590.00 170,560.80 Unrealized profits from internal transactions 416,837.76 20,841.89 550,754.42 27,537.72 Deductible losses 1,720,354.83 149,587.62 2,665,878.91 291,416.24 Estimated liabilities 871,923.62 43,596.18 871,923.62 43,596.18 Total 5,033,772.63 437,935.90 6,031,146.95 533,110.94

(2) Deferred income tax liabilities without offset

Unit: Yuan Ending balance Beginning balance

Project

Taxable temporary differences Deferred income tax liabilities Taxable temporary differences Deferred income tax liabilities Fixed assets - accumulated depreciation 16,424,918.80 2,463,737.82 19,393,245.22 2,908,986.78 Total 16,424,918.80 2,463,737.82 19,393,245.22 2,908,986.78

(3) Deferred income tax assets or liabilities presented on a net basis after offsetting

Unit: Yuan Deferred income tax assets and liabilities Deferred income tax assets after offset Deferred income tax assets and liabilities Deferred income tax items after offset

Offset amount at the end of the debt period Ending balance of assets or liabilities Offsetting amount at the beginning of the debt period Deferred income tax assets 279,370.90 158,565.00 363,650.13 169,460.81 Deferred income tax liabilities 279,370.90 2,184,366.92 363,650.13 2,545,336.65

(4) Details of deferred income tax assets not recognized

Unit: Yuan

Item Ending balance Beginning balance

Deductible losses 136,870,081.82 123,024,767.40 Asset impairment provisions 9,684,163.51 10,432,339.53 Share-based payment expenses 1,006,391.87 2,100,124.66 Total 147,560,637.20 135,557,231.59

(5) Deductible losses that have not been recognized as deferred income tax assets will expire in the following years

Unit: Yuan

Year Ending amount Beginning amount Remarks

2027 1,935,767.66 1,935,767.66

2028 8,187,411.63 8,187,411.63

2029 26,338,004.61 26,338,004.61

2030 84,159,002.94 86,563,583.50

2031 and subsequent years 16,249,894.98

Total 136,870,081.82 123,024,767.40

Other instructions

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Other non-current assets

Unit: Yuan Ending balance Beginning balance

Project

Book balance Impairment provision Book value Book balance Impairment provision Book value Prepaid long-term assets 17,885,526.7 17,885,526.7 152,600.00 152,600.00

Purchase money 3 3

17,885,526.7 17,885,526.7Total 152,600.00 152,600.00

3 3 Information related to compensating assets

Other notes:

Assets whose ownership or use rights are restricted

Unit: End of the period Beginning of the period

Project

Book balance Book value Restriction type Restriction situation Book balance Book value Restriction type Restriction situation Letter of guarantee Guarantee deposit Deposit

577,505.5 495,826.5 588,505.5 588,505.5 1 yuan, ETC 506,826.5 506,826.5 1 yuan, ETC monetary funds Guarantee Guarantee

1 1 Margin 1 1 Margin 11,000.00 11,000.00 Yuan cannot be withdrawn at any time 588,505.5 588,505.5 506,826.5 506,826.5

total

1 1 1 1

Other notes:

Short-term borrowing

(1) Classification of short-term loans

Unit: Yuan Item Ending balance Beginning balance

Description of short-term loan classification:

(2) Overdue short-term borrowings that have not been repaid

The total amount of overdue and unpaid short-term borrowings at the end of the period was RMB, among which the important overdue and unpaid short-term borrowings are as follows:

Unit: Yuan Zhejiang Tailin Biotechnology Co., Ltd. Full text of 2026 semi-annual report

Borrowing unit Ending balance Borrowing interest rate Overdue time Overdue interest rate

Other instructions

Trading financial liabilities

Unit: Yuan Item Ending balance Beginning balance

Among them:

Other notes:

Derivative financial liabilities

Unit: Yuan Item Ending balance Beginning balance

Other notes:

Notes payable

Unit: Yuan Type Ending balance Beginning balance

The total amount of bills payable that were due but not paid at the end of the period was Yuan, and the reasons for unpaid dues were.

Accounts payable

(1) Presentation of accounts payable

Unit: Yuan Item Ending balance Beginning balance

Payment for goods 19,707,652.45 14,823,119.15 Asset purchase payment 10,666,442.29 779,747.46 Expenses 395,777.68 255,996.59 Total 30,769,872.42 15,858,863.20 (2) Important accounts payable that are aged more than 1 year or are overdue

Unit: Yuan Item Closing balance Reason for outstanding or carry-forward

Other notes:

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Other payables

Unit: Yuan

Item Ending balance Beginning balance

Other payables 13,710,705.20 30,935,912.34 Total 13,710,705.20 30,935,912.34

(1) Interest payable

Unit: Yuan

Item Ending balance Beginning balance

Important overdue and unpaid interest information:

Unit: Yuan

Borrowing unit Overdue amount Reasons for overdue

Other notes:

(2) Dividends payable

Unit: Yuan

Item Ending balance Beginning balance

Other explanations, including important dividends payable that have not been paid for more than 1 year, should disclose the reasons for non-payment:

(3) Other payables

List other payables according to the nature of the payment

Unit: Yuan

Item Ending balance Beginning balance

Deposit and security deposit 10,510,575.49 27,356,324.18 Engineering and decoration payment payable 2,032,832.40 2,464,831.75 Temporary payment payable 872,646.51 1,062,068.07 Others 294,650.80 52,688.34 Total 13,710,705.20 30,935,912.34

Important other payables aged more than 1 year or overdue

Unit: Yuan

Item Closing balance Reason for outstanding or carried forward

Other instructions

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Advance payments

(1) Presentation of advance receipts

Unit: Yuan Item Ending balance Beginning balance

(2) Important advances from customers aged more than 1 year or overdue

Unit: Yuan Item Closing balance Reason for outstanding or carry-forward

Unit: Yuan Item Amount of change Reason for change

Contract liabilities

Unit: Yuan Item Ending balance Beginning balance

Advance payments 72,340,074.77 65,727,476.61 Total 72,340,074.77 65,727,476.61 Important contract liabilities aged more than 1 year

Unit: Yuan Item Closing balance Reason for outstanding or carry-forward

Amount and reasons for significant changes in book value during the reporting period

Unit: yuan change fee

Item Reason for change

Employee compensation payable

(1) Presentation of employee benefits payable

Unit: Yuan Item Beginning balance Increase in the current period Decrease in the current period Ending balance

Short-term salary 27,290,486.63 64,445,773.11 76,129,706.78 15,606,552.96

2. Post-employment benefits-settings

709,738.48 4,711,477.41 4,603,588.84 817,627.05 Withdrawal plan

Total 28,000,225.11 69,157,250.52 80,733,295.62 16,424,180.01

(2) Presentation of short-term remuneration

Unit: Yuan Item Beginning balance Increase in the current period Decrease in the current period Ending balance

Salary, bonus, allowance

24,025,385.80 55,498,227.22 67,350,880.76 12,172,732.26 and subsidies

Employee welfare fees 3,231,601.79 3,231,601.79

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Social insurance premiums 429,437.78 2,937,125.29 2,882,232.44 484,330.63 including: medical insurance

409,726.84 2,797,313.03 2,726,545.34 480,494.53 fee

Work injury insurance

19,710.94 139,812.26 155,687.10 3,836.10 fee

Housing provident fund 413,635.00 2,290,510.77 2,215,432.52 488,713.25
Trade union funds and employee education

2,422,028.05 488,308.04 449,559.27 2,460,776.82 Education funds

Total 27,290,486.63 64,445,773.11 76,129,706.78 15,606,552.96

(3) Display of defined contribution plan

Unit: Yuan

Item Opening balance Increase in the current period Decrease in the current period Ending balance

Basic pension insurance 688,173.90 4,568,643.03 4,463,896.67 792,920.26
Unemployment insurance premium 21,564.58 142,834.38 139,692.17 24,706.79Total 709,738.48 4,711,477.41 4,603,588.84 817,627.05Other instructions:
Taxes payable

Unit: Yuan

Item Ending balance Beginning balance

Value-added tax 1,672,748.95 1,903,180.89 Corporate income tax 498,201.91

Personal income tax 453,475.13 507,351.55 Urban maintenance and construction tax 188,324.18 172,493.69 Real estate tax 202,413.79 1,601,686.01 Education surcharge 80,736.93 73,925.87 Local education surcharge 53,824.62 49,283.91Land use tax 61,095.00 673,710.00Stamp tax 87,764.15Total 3,210,820.51 5,069,396.07Other instructions

Liabilities held for sale

Unit: Yuan

Item Ending balance Beginning balance

Other instructions

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Non-current liabilities due within one year

Unit: Yuan Item Ending balance Beginning balance

Other notes:

Other current liabilities

Unit: Yuan Item Ending balance Beginning balance

Product quality assurance 3,505,835.29 3,505,835.29 Output tax to be transferred to value-added tax 4,893,648.08 3,038,110.83 Total 8,399,483.37 6,543,946.12 Increase or decrease in short-term bonds payable:

Unit: yuan per face

Overflow discount

Bond par value issuance Bond issuance Beginning of period Current period Value calculation Current period End of period Whether par value Price amortization

Name Interest Rate Date Term Amount Balance Issuance Profit Repayment Balance Default Cancellation

information

total

Other notes:

Long-term borrowing

(1) Classification of long-term loans

Unit: Yuan Item Ending balance Beginning balance

Description of long-term loan classification:

Other instructions, including interest rate ranges:

Bonds payable

(1) Bonds payable

Unit: Yuan Item Ending balance Beginning balance

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

(2) Increases and decreases in bonds payable (excluding preference shares, perpetual bonds and other financial instruments classified as financial liabilities)

Unit: yuan per face

Overflow discount

Bond par value issuance Bond issuance Beginning of period Current period Value calculation Current period End of period Whether par value Price amortization

Name Interest Rate Date Term Amount Balance Issuance Profit Repayment Balance Default Cancellation

information

total

(3) Description of convertible corporate bonds

(4) Description of other financial instruments classified as financial liabilities

Basic information on preferred shares, perpetual bonds and other financial instruments outstanding at the end of the period

Statement of changes in outstanding preferred stocks, perpetual bonds and other financial instruments at the end of the period

Unit: Yuan outstanding Issued at the beginning of the period Increased during the period Decreased during the period Financial instruments at the end of the period

Quantity Book value Quantity Book value Quantity Book value Quantity Book value instrument

Explanation of the basis for classifying other financial instruments as financial liabilities

Other instructions

Lease liabilities

Unit: Yuan Item Ending balance Beginning balance

Other instructions

Long-term payables

Unit: Yuan Item Ending balance Beginning balance

(1) List long-term payables according to the nature of the payment

Unit: Yuan Zhejiang Tailin Biotechnology Co., Ltd. Full text of 2026 semi-annual report

Item Ending balance Beginning balance

Other notes:

(2) Special accounts payable

Unit: Yuan Item Beginning balance Increase in the current period Decrease in the current period Closing balance Other explanations for the reasons:

Long-term employee benefits payable

(1) Long-term employee salary payable table

Unit: Yuan Item Ending balance Beginning balance

(2) Changes in defined benefit plans

Present value of defined benefit plan obligations:

Unit: Yuan Item Amount of the current period Amount of the previous period

Plan assets:

Unit: Yuan Item Amount of the current period Amount of the previous period

Net liabilities (net assets) of defined benefit plans

Unit: Yuan Item Amount of the current period Amount of the previous period

Description of the content of the defined benefit plan and the risks associated with it, as well as the impact on the company's future cash flows, timing and uncertainty:

Explanation of significant actuarial assumptions and sensitivity analysis results of defined benefit plans:

Other notes:

Estimated liabilities

Unit: Yuan Item Ending balance Beginning balance Other explanations of reasons, including important assumptions and estimation instructions for important estimated liabilities:

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Deferred income

Unit: Yuan Item Beginning balance Increase in the current period Decrease in the current period Closing balance Other explanations for the reasons:

Other non-current liabilities

Unit: Yuan Item Ending balance Beginning balance

Other notes:

Share capital

Unit: Yuan Increase or decrease in this change (+, -)

Balance at the beginning of the period Balance at the end of the period Issuance of new shares Bonus shares Conversion of public reserve funds Others Subtotal

121,199,21 121,199,21Total number of shares

9.00 9.00Other instructions:

Other equity instruments

(1) Basic information on preferred shares, perpetual bonds and other financial instruments outstanding at the end of the period

(2) Statement of changes in outstanding preferred stocks, perpetual bonds and other financial instruments at the end of the period

Unit: yuan outstanding. Beginning of the period. Increase in the current period. Decrease in the current period. End of the period.

financial engineering

Quantity Book value Quantity Book value Quantity Book value Quantity Book value instrument

Changes in other equity instruments during the current period, explanations of the reasons for the changes, and the basis for relevant accounting treatments:

Other notes:

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Capital reserve

Unit: Yuan Item Beginning balance Increase in the current period Decrease in the current period Ending balance

capital premium (equity premium

408,172,409.60 408,172,409.60 price)

Other capital reserves 4,331,024.30 1,945,909.80 6,276,934.10Total 412,503,433.90 1,945,909.80 414,449,343.70Other explanations, including changes in current period and reasons for changes:

Recognition of share-based payment expenses increased other capital reserves by RMB 1,905,519.20; deferred income tax assets adjusted for the portion of the estimated deductible amount of equity incentive restricted stocks that have not been unlocked in the future period exceeding the costs and expenses recognized during the waiting period increased other capital reserves by RMB 40,390.60.

Treasury stocks

Unit: Yuan Item Beginning balance Increase in the current period Decrease in the current period Ending balance

Buybacks used for employee stock ownership purposes

32,285,577.51 32,285,577.51 planned treasury shares

Total 32,285,577.51 32,285,577.51 Other explanations, including changes in increases and decreases in the current period and explanation of reasons for changes:

The company used its own funds to repurchase a total of 1,217,970 shares through centralized bidding transactions through a special securities account for share repurchases.

Other comprehensive income

Unit: Yuan Amount incurred in the current period

Less: previous period Less: previous period

Income for the current period is included in other items and is included in other items. Attribution after tax

Item Opening balance Less: Income Attribution after tax Ending balance before tax Comprehensive income Comprehensive income Attributable to minority shares

Tax expenses at the parent company

Amount transferred in the current period Transferred in in the current period

Profit and loss Retained earnings

Other explanations include adjustments to the initial recognition amount of the effective portion of cash flow hedging gains and losses converted into hedged items:

Special reserves

Unit: Yuan Item Beginning balance Increase in the current period Decrease in the current period Ending balance

Other explanations, including changes in increases and decreases in the current period and explanations of reasons for changes:

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Surplus reserve

Unit: Yuan

Item Opening balance Increase in the current period Decrease in the current period Ending balance Statutory surplus reserve 27,628,568.73 3,561,501.65 31,190,070.38 Total 27,628,568.73 3,561,501.65 31,190,070.38 Description of surplus reserve, including changes in increases and decreases in the current period and explanation of reasons for changes:

According to the company's articles of association, a statutory surplus reserve of RMB 3,561,501.65 is accrued based on 10% of the parent company's net profit from January to June 2026.

Undistributed profits

Unit: Yuan

Projects in this issue Previous issue

Adjusted opening undistributed profit 242,960,205.66 250,714,603.67 plus: net profit attributable to owners of the parent company for the period

20,372,823.69 16,485,445.79 profit

Less: Withdrawal of statutory surplus reserve 3,561,501.65

Dividends payable on ordinary shares 3,599,437.47 24,239,843.80 Undistributed profits at the end of the period 256,172,090.23 242,960,205.66 Details of adjustments to undistributed profits at the beginning of the period:

Due to the retrospective adjustment of the "Accounting Standards for Business Enterprises" and its related new regulations, the undistributed profit at the beginning of the period was affected.
Due to changes in accounting policies, the undistributed profit at the beginning of the period is affected.
Due to the correction of major accounting errors, the undistributed profit at the beginning of the period was affected.

4). Changes in the scope of consolidation due to the same control will affect the undistributed profit at the beginning of the period.

The total of other adjustments affects the opening undistributed profit yuan.

Detailed explanation of the use of capital reserves to cover losses:

According to the resolution of the company's 2025 annual shareholders' meeting held on April 16, 2026, the company will issue a dividend to all shareholders based on the total share capital of 119,981,249 shares.

A cash dividend of RMB 0.30 (tax included) was distributed for 10 shares, totaling RMB 3,599,437.47.

Operating income and operating costs

Unit: Yuan Amount of current period Amount of previous period

Project

revenue cost revenue cost

Main business 149,232,435.09 76,786,846.55 132,040,366.89 62,034,430.11 Other businesses 16,149,880.19 7,530,289.93 13,785,240.31 8,075,496.35 Total 165,382,315.28 84,317,136.48 145,825,607.20 70,109,926.46 Decomposition information of operating income and operating costs:

Unit: Yuan

Segment 1 Segment 2 Number for the current period Number for the same period last year Total contract points

Operating income Operating income Operating income Operating income Operating income Operating income Operating income Operating income Operating income Operating income Category

Enter this article Enter this article Enter this article Enter the full text of the 2026 Semi-annual Report of Zhejiang Tailin Biotechnology Co., Ltd.

Business class

Type

Among them:

Aseptic

Product and pollution

62,608, 39,626, 58,151, 31,565, dye control

294.12 987.40 780.38 511.01 Equipment Department

List of products

Microorganisms

Detection technology 69,722, 31,257, 58,629, 25,911, technology series 059.96 700.82 276.85 896.13 products

organic matter

Analytical technology 16,902, 5,902,1 15,896, 5,705,0 technology series 081.01 58.33 679.05 05.88 products

13,550, 7,410,1 9,912,9 6,788,3 Others

274.88 38.87 63.41 14.39 By operation

Regional distinction

class

its

Medium:

138,515 77,334, 120,153 52,319, domestic

,397.51 813.56 ,847.99 429.60

24,267, 6,862,1 22,436, 17,651, abroad

312.46 71.86 851.70 297.81 Market or

Customer type

Type

its

Medium:

Contract type

Type

its

Medium:

by product

transferable

time minutes

class

its

Medium:

According to contract

Deadline points

class

its

Medium:

At a certain point in time, 162,782 84,196, 142,590 69,970, 709.97 985.42, 699.69 727.41 Full text of the 2026 Semi-annual Report of Zhejiang Tailin Biotechnology Co., Ltd.

recognized income

by sales

Channel points

class

its

Medium:

total

Information related to performance obligations:

The company's pre-payments, the company's performance obligations, and the important payment terms. The company's commitment to transfer is the main responsibility.

The item will be refunded to the customer during the period. The type and time of the quantity guarantee. The nature of the goods. Anyone.

Account’s money and other explanations of related obligations

Information related to the transaction price allocated to the remaining performance obligations:

At the end of the reporting period, the amount of revenue corresponding to the performance obligations that have been signed but have not been performed or have not been completed is RMB 0.00, of which RMB is expected to be recognized in the year, RMB is expected to be recognized in the year, and RMB is expected to be recognized in the year.

Information related to variable consideration in the contract:

Major contract changes or major transaction price adjustments

Unit: Yuan

Item Accounting treatment method Amount of impact on income

Other instructions

Taxes and surcharges

Unit: Yuan

Item Amount for the current period Amount for the previous period

Urban maintenance and construction tax 648,319.18 522,469.89 Education surcharge 277,851.09 223,915.69 Property tax 373,677.00 402,670.45 Land use tax 61,095.00

Stamp duty 42,397.63 147,609.39 Local education surcharge 185,234.03 149,277.10 Total 1,588,573.93 1,445,942.52 Other notes:

Management expenses

Unit: Yuan Zhejiang Tailin Biotechnology Co., Ltd. Full text of 2026 semi-annual report

Item Amount for the current period Amount for the previous period

Employee compensation 11,013,717.32 10,505,469.03 Depreciation and amortization 2,529,999.23 2,254,752.40 Office expenses 1,703,085.37 1,733,178.95 Share-based payment expenses 751,113.18 403,887.27 Consulting fee 830,024.62 244,787.65 Loss from inventory scrapping 46,285.42

Travel expenses 137,388.46 89,721.84Business entertainment expenses 222,218.96 146,969.87Repair expenses 113,705.69 78,260.70Others 1,710,609.15 428,453.50Total 19,058,147.40 15,885,481.21

Other instructions

Sales expenses

Unit: Yuan

Item Amount for the current period Amount for the previous period

Employee compensation 12,611,904.88 11,210,698.32 Exhibition fees 1,066,853.79 2,547,169.92 Travel expenses 2,203,885.72 2,275,420.49 Promotion fees 1,153,639.48 738,112.68 Business entertainment expenses 1,048,398.91 726,949.51 Share-based payment expenses 382,523.56 199,714.71 Others 1,215,285.32 896,362.51 Total 19,682,491.66 18,594,428.14

Other notes:

Research and development expenses

Unit: Yuan

Item Amount for the current period Amount for the previous period

Employee compensation 19,330,797.14 20,379,374.68 Material consumption 1,996,279.89 5,786,418.04 Depreciation expense 1,565,478.65 1,675,308.53 Technical service fee 287,409.74 673,101.63 Testing fee 658,124.76 578,152.23Travel expenses 599,471.75 768,246.00Share-based payment expenses 451,325.94 332,560.63Design fees 55,904.54 9,504.95Others 719,841.01 774,052.90Total 25,664,633.42 30,976,719.59

Other instructions

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Financial expenses

Unit: Yuan

Item Amount for the current period Amount for the previous period

interest expense

Less: Interest income 2,062,233.89 4,462,895.95 Exchange gains and losses 674,308.37 143,592.81 Handling fees 55,100.63 36,325.62 Total -1,332,824.89 -4,282,977.52Other notes

Other income

Unit: Yuan

Sources of other income Amount incurred in the current period Amount incurred in the previous period

Government subsidies related to income 4,319,821.97 2,495,942.63 Additional deduction for value-added tax 84,173.41 Refund of withholding personal income tax fees 80,594.85 80,724.55 Total 4,400,416.82 2,660,840.59

Net exposure hedging income

Unit: Yuan

Item Amount for the current period Amount for the previous period

Other instructions

Gains from changes in fair value

Unit: Yuan

Sources of income from changes in fair value Amount incurred in the current period Amount incurred in the previous period

Other notes:

Investment income

Unit: Yuan

Item Amount for the current period Amount for the previous period

Long-term equity investment income calculated using the equity method 555,114.78 -5,502.22 Income from financial products 1,086,200.23

Total 1,641,315.01 -5,502.22Other instructions

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Credit impairment losses

Unit: Yuan

Item Amount for the current period Amount for the previous period

Bad debt losses 312,571.64 -2,090,608.33 Total 312,571.64 -2,090,608.33Other instructions

Asset impairment losses

Unit: Yuan

Item Amount for the current period Amount for the previous period

1. Inventory depreciation losses and contract performance cost deductions

-823,906.53

value loss

Impairment losses on contract assets -62,342.88 -27,112.65 Total -886,249.41 -27,112.65 Other notes:
Income from asset disposal

Unit: Yuan

Source of asset disposal income Amount incurred in the current period Amount incurred in the previous period

Non-operating income

Unit: Yuan Financial items included in non-recurring gains and losses for the current period Amount incurred in the current period Amount incurred in the previous period

No payment required 9,541.14

Others 3,141.73 9,525.68 3,141.73Total 3,141.73 19,066.82 3,141.73Other instructions:

Non-operating expenses

Unit: Yuan Financial items included in non-recurring gains and losses for the current period Amount incurred in the current period Amount incurred in the previous period

Loss from damage and scrapping of non-current assets 176,221.93 364,069.45 176,221.93 Fines and late payment fees 62,390.91 6,589.89 62,390.91 Others 27,352.22 184,079.20 27,352.22Total 265,965.06 554,738.54 265,965.06 Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Other notes:

Income tax expenses

(1) Income tax expense schedule

Unit: Yuan

Item Amount for the current period Amount for the previous period

Current income tax expense 1,546,247.64 46,905.03 Deferred income tax expense -309,683.32 -291,583.63 Total 1,236,564.32 -244,678.60

(2) Adjustment process of accounting profits and income tax expenses

Unit: Yuan

Item Amount incurred in this period

Total profit 21,609,388.01 Income tax expenses calculated according to statutory/applicable tax rates 5,402,347.00 The impact of different tax rates applicable to subsidiaries -3,590,224.49 The impact of non-deductible costs, expenses and losses 117,658.99 No deductible temporary differences or deductible temporary differences of deferred income tax assets have been recognized in the current period

Impact of loss of 3,118,316.45

Impact of super deduction of R&D expenses -3,811,533.63 Income tax expense 1,236,564.32 Other notes:

Other comprehensive income

See notes for details

Cash flow statement items

(1) Cash related to operating activities

Other cash received related to operating activities

Unit: Yuan

Item Amount for the current period Amount for the previous period

Rental income 2,599,605.31 3,234,907.51 Government subsidies 1,752,684.19 669,045.03 Interest income 587,836.18 2,326,802.79 Receipt of bill deposit and guarantee deposit 1,843,880.53 Others 699,436.81 439,492.67 Total 5,639,562.49 8,514,128.53 Description of other cash received related to operating activities:

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Other cash paid related to operating activities

Unit: Yuan

Item Amount for the current period Amount for the previous period

Payment of various expenses 10,497,879.87 14,708,445.33 Payment of bill deposit and guarantee deposit 70,672.47 975,308.53 Payment of current accounts 3,675,308.53 Others 144,837.25 303,914.79 Total 10,713,389.59 19,662,977.18 Description of other cash paid related to operating activities:

(2) Cash related to investing activities

Other cash received related to investing activities

Unit: Yuan

Item Amount for the current period Amount for the previous period

Redemption of certificates of deposit, bank financing and interest 817,940,739.86 596,652,600.71 Total 817,940,739.86 596,652,600.71 Important cash received related to investment activities

Unit: Yuan

Item Amount for the current period Amount for the previous period

Description of other cash received related to investing activities:

Other cash paid related to investing activities

Unit: Yuan

Item Amount for the current period Amount for the previous period

Purchase of certificates of deposit and bank financing 701,800,000.00 552,900,000.00Total 701,800,000.00 552,900,000.00 Important cash paid related to investment activities

Unit: Yuan

Item Amount for the current period Amount for the previous period

Description of other cash paid related to investment activities:

(3) Cash related to financing activities

Other cash received related to financing activities

Unit: Yuan

Item Amount for the current period Amount for the previous period

Description of other cash received related to financing activities:

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Other cash payments related to financing activities

Unit: Yuan

Item Amount for the current period Amount for the previous period

Stock repurchase 32,285,577.51 23,673,896.31 Total 32,285,577.51 23,673,896.31 Description of other cash paid related to financing activities:

Changes in various liabilities arising from financing activities

□Applicable Not applicable

(4) Explanation on presenting cash flow in net amount

Item Relevant facts and circumstances Basis for net presentation Financial impact

(5) Major activities and financial impacts that do not involve current cash receipts and payments but affect the company's financial status or may affect the company's cash flow in the future

Supplementary information for cash flow statement

(1) Supplementary information for cash flow statement

Unit: Yuan

Supplementary information Amount for the current period Amount for the previous period

1． Adjust net profit to cash flow from operating activities

Quantity:

Net profit 20,372,823.69 13,342,711.07 plus: asset impairment provision 886,249.41 27,112.65 Depreciation of fixed assets, depreciation of oil and gas assets

7,893,215.04 8,047,962.52 Depreciation of consumption and productive biological assets

Depreciation of right-of-use assets

Amortization of intangible assets 397,880.46 210,666.95 Amortization of long-term deferred expenses 2,147,909.06 2,030,830.27 Disposal of fixed assets, intangible assets and other

The loss of his long-term assets (the income is marked with a "-"

Fill in the column)

Loss on scrapping of fixed assets (income based on

176,221.93 364,069.45 (Fill in “-”)

Loss from change in fair value (gain based on

Fill in the column with "-" sign)

Financial expenses (revenues are filled in with "-"

-800,082.83 -2,136,093.16 columns)

Investment losses (income is filled in with "-" -1,641,315.01 5,502.22 Full text of the 2026 Semi-annual Report of Zhejiang Tailin Biotechnology Co., Ltd.

column)

Deferred tax assets decreased (increased by

10,895.81 -384.53 (please fill in the column with "-")

Deferred tax liabilities increased (decreased by

-360,969.73 -291,199.10 (Fill in “-”)

Decrease in inventory (increase marked with "-"

-11,117,465.23 2,544,825.90 fill in the column)

Decrease in operating receivables (increase in

-1,348,502.01 -6,824,903.04 (please fill in the numbers with "-")

Increase (decrease) in operating payables

2,850,370.73 -16,291,023.18 (please fill in with "-")

Others 1,633,338.16 2,090,608.33

Net cash flow generated from operating activities 21,100,569.48 3,120,686.35 2. Major investments and financing that do not involve cash receipts or payments

Activities:

debt to capital

Convertible corporate bonds due within one year

Financing leased fixed assets

3． Net changes in cash and cash equivalents:

Closing balance of cash 154,863,359.74 70,778,067.29 Less: Opening balance of cash 78,545,303.53 69,878,082.46 Add: Closing balance of cash equivalents

Less: Opening balance of cash equivalents

Net increase in cash and cash equivalents 76,318,056.21 899,984.83

(2) Net cash paid in the current period to acquire subsidiaries

Unit: Yuan

Amount

Among them:

Other notes:

(3) Net cash received from disposal of subsidiaries in the current period

Unit: Yuan

Amount

Among them:

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Among them:

Other notes:

(4) Composition of cash and cash equivalents

Unit: Yuan

Item Ending balance Beginning balance

Cash 154,863,359.74 78,545,303.53 Including: cash on hand 3,671.28 4,791.68

Bank deposits available for payment at any time 154,859,688.46 70,773,275.61

Balance of cash and cash equivalents at the end of the period 154,863,359.74 78,545,303.53 (5) Situations in which the scope of use is restricted but still classified as cash and cash equivalents

Unit: Yuan Items that are still cash and cash equivalents Amount for the current period Amount for the previous period

Reason

Raised funds account 13,045,461.36 9,955,579.84 Raised funds supervision account

Total 13,045,461.36 9,955,579.84

(6) Monetary funds that are not cash and cash equivalents

Unit: Yuan Items that are not cash and cash equivalents Amount for the current period Amount for the previous period

Reason

Cannot be withdrawn at any time and the initial deposit purpose is time deposit 126,506,363.16

investment

Guarantee deposit 577,505.51 629,730.00 Cannot be withdrawn at any time

ETC margin 11,000.00 11,000.00 Cannot be withdrawn at any time

Total 588,505.51 127,147,093.16

Other notes:

(7) Description of other major activities

Notes on items in the statement of changes in owners’ equity

Explain the names of "other" items and the amount of adjustments that were made to the closing balance of the previous year:

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Foreign currency monetary items

(1) Foreign currency monetary items

Unit: Yuan

Item Foreign currency balance at the end of the period Conversion exchange rate Monetary funds converted into RMB at the end of the period 23,349,321.35 Including: US dollars 3,428,228.48 6.8109 23,349,321.35 Euros

Hong Kong dollar

Accounts receivable 124,741.63 Including: USD 18,315.00 6.8109 124,741.63 Euros

Hong Kong dollar

long term borrowing

Of which: US dollars

Euro

Hong Kong dollar

Other notes:

(2) The nature of the lack of currency convertibility and its financial impact, the spot exchange rate used and its estimation process, and the risks faced by the enterprise due to the lack of currency convertibility

□Applicable Not applicable

(3) Description of overseas operating entities, including for important overseas operating entities, their main overseas business location, accounting standard currency and basis for selection should be disclosed. If the accounting standard currency changes, the reasons should also be disclosed.

□Applicable Not applicable

(4) Lack of convertibility between the accounting standard currency of overseas operations and the enterprise’s presentation currency

□Applicable Not applicable

Leasing

(1) The company serves as the lessee

□Applicable Not applicable

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

(2) The company as the lessor

Operating lease as lessor

□Applicable Not applicable

Finance lease as lessor

□Applicable Not applicable

Undiscounted lease payments for each of the next five years

□Applicable Not applicable

Reconciliation of undiscounted lease receipts and net lease investment

(3) Recognizing financial lease sales profits and losses as a manufacturer or distributor

□Applicable Not applicable

Data resources
Others

8. R&D expenditures

Unit: Yuan

Item Amount for the current period Amount for the previous period

R&D projects that meet capitalization conditions

Unit: Yuan Increase amount in this period Decrease amount in this period

Item Opening balance Internal development Confirmed as N/A Transferred to current period Closing balance Others

Expenditure tangible assets Profit and loss

total

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Significant Capitalized R&D Projects

Estimated economic benefits when capitalization begins Specific projects to begin capitalization R&D progress Estimated completion time

Production method Point entity based on development expenditure impairment provision

Unit: Yuan Item Beginning balance Increase in the current period Decrease in the current period Ending balance Impairment test situation

Important outsourced research projects

The criteria for judging capitalization or expense and the specific way in which economic benefits are expected to be generated based on the name of the project.

According to

Other notes:

9. Changes in consolidation scope

Business merger not under common control

(1) Business mergers not under common control that occurred during the current period

Unit: Yuan Purchase date to Purchase date to Purchase date to the purchased party Equity acquisition Equity acquisition Equity acquisition Equity acquisition Equity acquisition Purchased at the end of the period Acquired at the end of the period Acquired at the end of the period

Name Time Point Cost Proportion Method Determination Basis Buyer’s Income Buyer’s Net Buyer’s Cash Income Profit Cash Flow Other instructions:

(2) Merger costs and goodwill

Unit: Yuan combined cost

--cash

--Fair value of non-cash assets

--Fair value of debt issued or assumed

--Fair value of equity securities issued

--Fair value of contingent consideration

--The fair value of the equity held before the purchase date on the purchase date

--Others

Total combined costs

Less: Share of fair value of identifiable net assets acquired

Goodwill/merger cost is less than the fair value share of identifiable net assets acquired

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd. Method for determining the fair value of the merger cost:

Description of contingent consideration and its changes

The main reasons for the formation of large amounts of goodwill:

Other notes:

(3) The identifiable assets and liabilities of the purchased party on the purchase date. Unit: Yuan

Fair value on acquisition date Book value assets on acquisition date:

Monetary funds

Accounts receivable

Inventory

fixed assets

intangible assets

Liabilities:

borrow money

Accounts payable

Deferred income tax liability

net worth

Less: Minority interests

Net assets acquired

Method for determining the fair value of identifiable assets and liabilities:

Contingent liabilities of the purchased party assumed in a business combination:

Other notes:

(4) Is there any gain or loss arising from the remeasurement of the equity held before the acquisition date at fair value? There are transactions in which the enterprise merger is realized step by step through multiple transactions and control is obtained during the reporting period Yes  No

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

(5) Relevant explanation that the merger consideration or the fair value of the acquiree’s identifiable assets and liabilities cannot be reasonably determined on the acquisition date or at the end of the current period of merger.

(6) Other instructions

Merger of enterprises under common control

(1) Business mergers under the same control that occurred in the current period

Unit: yuan Consolidated current period Consolidated current period

constitute the same

Business combination from the beginning of the period to the merger period from the beginning of the period to the merger period Comparative period Comparative period Enterprises under the control of the merged party On the date of merger

Obtained from Merger date Merger date Merger date Merger name of merged party Determination basis of business merger

Equity ratio, merger’s acquisition, merger’s net income, basis of net profit

Other instructions for profit:

(2) Merger cost

Unit: Yuan

Merger costs

--cash

--Book value of non-cash assets

--The book value of debt issued or assumed

--The face value of the equity securities issued

--Contingent consideration

Description of contingent consideration and its changes:

Other notes:

(3) Book value of the assets and liabilities of the merged party on the merger date

Unit: Yuan

Merger date Closing assets of the previous period:

Monetary funds

Accounts receivable

Inventory

Full text of Zhejiang Tailin Biotechnology Co., Ltd. 2026 Semi-annual Report Fixed Assets

intangible assets

Liabilities:

borrow money

Accounts payable

net worth

Less: Minority interests

Net assets acquired

Contingent liabilities of the merged party assumed in a business merger:

Other notes:

Reverse purchase

Basic information of the transaction, the basis for the transaction to constitute a reverse purchase, whether the assets and liabilities retained by the listed company constitute business and the basis for it, the determination of the merger cost, the amount of equity adjustment when dealing with equity transactions and its calculation:

Disposal of subsidiaries

Is there any transaction or event that resulted in the loss of control of a subsidiary during this period Yes  No

Is there any situation where investments in subsidiaries are disposed of step by step through multiple transactions and control is lost in the current period Yes  No

Changes in the scope of consolidation due to other reasons

Explain the changes in the scope of consolidation caused by other reasons (such as the establishment of new subsidiaries, liquidation of subsidiaries, etc.) and their related circumstances:

Others

10. Interests in other entities

Interests in subsidiaries

(1) Composition of enterprise groups

Unit: Yuan Zhejiang Tailin Biotechnology Co., Ltd. Full text of 2026 semi-annual report

Shareholding ratio

Name of subsidiary company Registered capital Main place of business Place of registration Nature of business How to obtain

direct indirect

Life sciences 5,000.00 Hangzhou Hangzhou Manufacturing 100.00% Establishment of medical engineering 10,000.00 Hangzhou Hangzhou Manufacturing 100.00% Establishment of analytical instruments 1,000.00 Hangzhou Hangzhou Manufacturing 100.00% Establishment of science and technology 1,000.00 Hangzhou Hangzhou Commerce 100.00% Establishment of medical devices 1,000.00 Hangzhou Hangzhou Manufacturing 100.00% Establishment of Tailin New Materials 10,000.00 Hangzhou Hangzhou Manufacturing 100.00% Establishment of Tailin Keda 3,000.00 Hangzhou Hangzhou Manufacturing 51.00% Explanation on the difference between the proportion of shares held in subsidiaries and the proportion of voting rights:

Basis for holding half or less of the voting rights but still controlling the invested unit, and holding more than half of the voting rights but not controlling the invested unit:

For important structured entities included in the scope of consolidation, the basis for control is:

Basis for determining whether a company is agent or principal:

Other notes:

(2) Important non-wholly owned subsidiaries

Unit: Yuan Attributable to minority shareholders in this period Announcement to minority shareholders in this period Name of the company remaining in minority shareholders’ equity at the end of the period Shareholding ratio of minority shareholders

Profit and loss dividends distributed The proportion of minority shareholders’ shareholdings of the company is different from the proportion of voting rights:

Other notes:

(3) Main financial information of important non-wholly owned subsidiaries

Unit: Yuan

Ending balance Beginning balance

Zigong

Non-current non-current non-current non-current company name current assets current liabilities current assets current liabilities liquid assets liquid assets liquid assets total assets total liabilities total assets debts assets debt unit: yuan

Amount for the current period Amount for the previous period

Subsidiary name

Comprehensive Income Operating Activities Comprehensive Income Operating Activities Operating Income Net Profit Operating Income Net Profit

Total Cash Flow Total Cash Flow Other instructions:

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

(4) Significant restrictions on the use of enterprise group assets and settlement of enterprise group debts

(5) Financial support or other support provided to structured entities included in the scope of consolidated financial statements

Other notes:

Transactions in which the owner’s equity share in the subsidiary changes and the subsidiary is still controlled (1) Description of the change in the owner’s equity share in the subsidiary

(2) The impact of the transaction on minority shareholders’ equity and owner’s equity attributable to the parent company

Unit: Yuan

Purchase cost/disposal consideration

--cash

--Fair value of non-cash assets

Total purchase cost/disposal consideration

Less: Share of net assets of subsidiaries calculated based on the proportion of equity acquired/disposed of

difference

Including: Adjustment of capital reserve

Adjust the surplus reserve

Adjust undistributed profits

Other instructions

Interests in joint ventures or associated enterprises

(1) Important joint ventures or associates

Shareholding ratio Investment in joint ventures or joint ventures or associates Main place of business Registration place Nature of business

Name of operating enterprise Direct indirect accounting treatment method

Full text of the 2026 semi-annual report of French Zhejiang Tailin Biotechnology Co., Ltd.

Explanation on the difference between the proportion of shareholdings in joint ventures or associates and the proportion of voting rights:

Basis for holding less than 20% of the voting rights but having significant influence, or holding 20% or more of the voting rights but not having significant influence:

(2) Main financial information of important joint ventures

Unit: Yuan

Ending balance/amount of the current period Beginning balance/amount of the previous period

current assets

Of which: cash and cash equivalents

non-current assets

Total assets

current liabilities

non-current liabilities

Total liabilities

minority interests

Equity attributable to shareholders of the parent company

Share of net assets calculated based on shareholding ratio

Adjustments

--Goodwill

--Unrealized profits from internal transactions

--Others

Book value of equity investments in joint ventures

Fair value of equity investments in joint ventures with publicly quoted prices

operating income

financial charges

income tax expense

net profit

Net profit from discontinued operations

other comprehensive income

Total comprehensive income

Other explanations on dividends received from joint ventures during the year

(3) Main financial information of important associates

Unit: Yuan

Closing balance/Amount incurred in the current period Opening balance/Amount incurred in the previous period Full text of the 2026 Semi-annual Report of Zhejiang Tailin Biotechnology Co., Ltd.

current assets

non-current assets

Total assets

current liabilities

non-current liabilities

Total liabilities

minority interests

Equity attributable to shareholders of the parent company

Adjustments to net asset share calculated based on shareholding ratio

--Goodwill

--Unrealized profits from internal transactions

--Others

The fair value of equity investments in associates whose book value is publicly quoted

operating income

net profit

Net profit from discontinued operations

other comprehensive income

Total comprehensive income

Other explanations on dividends received from associates during the year

(4) Summary financial information of unimportant joint ventures and associates

Unit: Yuan

Ending balance/amount of the current period Beginning balance/amount of the previous period

Joint Venture:

The total of the following items calculated based on shareholding ratio

Associates:

The total of the following items calculated based on shareholding ratio

Other instructions

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

(5) Explanation of significant restrictions on the ability of joint ventures or associates to transfer funds to the company (6) Excess losses incurred by joint ventures or associates

Unit: Yuan Unrecognized losses in the current period (or names of joint ventures or associates in the current period Accumulated unrecognized losses accumulated in previous periods Accumulated unrecognized losses at the end of the period

Shared net profit) Other instructions

(7) Unconfirmed commitments related to investment in joint ventures

(8) Contingent liabilities related to investments in joint ventures or associates

Important joint operations

Shareholding ratio/share joint business name Main place of business Registration place Nature of business

Explanation on whether the proportion of direct or indirect shareholdings or shares enjoyed in a joint operation is different from the proportion of voting rights:

If the joint operation is a separate entity, the basis for classifying it as a joint operation is:

Other instructions

Equity in structured entities not included in the scope of consolidated financial statements

Relevant instructions for structured entities not included in the scope of consolidated financial statements:

Others

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

11. Government subsidies

Government subsidies recognized according to the amount receivable at the end of the reporting period

□Applicable Not applicable

Reasons for failure to receive the estimated amount of government subsidy at the estimated time

□Applicable Not applicable

Liability items involving government subsidies

□Applicable Not applicable

Government subsidies included in current profits and losses

Applicable □Not applicable

Unit: Yuan

Accounting accounts Amount for the current period Amount for the previous period

Amount of government subsidies included in other income 1,672,089.34 2,495,942.63Other instructions

12. Risks related to financial instruments

Various risks arising from financial instruments

The company's goal in risk management is to strike a balance between risks and returns, minimize the negative impact of risks on the company's operating performance, and maximize the interests of shareholders and other equity investors. Based on this risk management objective, the company's basic risk management strategy is to confirm and analyze the various risks faced by the company, establish an appropriate risk tolerance bottom line and conduct risk management, and supervise various risks in a timely and reliable manner to control risks within a limited range.

The Company faces various risks related to financial instruments in its daily activities, mainly including credit risk, liquidity risk and market risk. Management has reviewed and approved policies for managing these risks, which are summarized below.

(1) Credit risk

Credit risk refers to the risk that one party to a financial instrument cannot fulfill its obligations, causing financial losses to the other party.

Credit risk management practices

(1) Credit risk evaluation methods

The Company assesses at each balance sheet date whether the credit risk of relevant financial instruments has increased significantly since initial recognition. When determining whether credit risk has increased significantly since initial recognition, the Company considers reasonable and evidence-based information that is available without unnecessary additional cost or effort, including qualitative and quantitative analysis based on historical data, external credit risk ratings, and forward-looking information. The company uses a single financial instrument or a combination of financial instruments with similar credit risk characteristics. Full text of the 2026 Semi-annual Report of Zhejiang Tailin Biotechnology Co., Ltd.

Based on this, by comparing the risk of default of a financial instrument on the balance sheet date with the risk of default on the initial recognition date, the changes in default risk of the financial instrument during its expected duration are determined.

When one or more of the following quantitative and qualitative criteria are triggered, the company believes that the credit risk of financial instruments has increased significantly:

The quantitative standard is mainly that the default probability of the remaining duration on the balance sheet date has increased by more than a certain percentage compared with the initial recognition;
Qualitative standards mainly include major adverse changes in the debtor's operating or financial conditions, existing or expected changes in technology, market, economic or legal environment, which will have a major adverse impact on the debtor's ability to repay the company, etc.

(2) Definition of defaulted and credit-impaired assets

When a financial instrument meets one or more of the following conditions, the company defines the financial asset as having defaulted, and its standards are consistent with the definition of credit impairment:

The debtor encounters major financial difficulties;
The debtor violates the binding clauses on the debtor in the contract;
The debtor is likely to go bankrupt or undergo other financial reorganization;
The creditor grants concessions to the debtor that the debtor would not have made under any other circumstances due to economic or contractual considerations related to the debtor's financial difficulty.

Measurement of expected credit losses

Key parameters for measuring expected credit losses include probability of default, loss given default rate and exposure to default risk. The company considers quantitative analysis and forward-looking information of historical statistical data (such as counterparty ratings, guarantee methods and collateral types, repayment methods, etc.) to establish default probability, default loss rate and default risk exposure models.

For details of the reconciliation statement between the opening balance and the closing balance of financial instrument loss provisions, please refer to Notes 5(1)3, 5(1)4, 5(1)6, and 5(1)8 of this financial statement.
Credit risk exposure and credit risk concentration

The company's credit risk mainly comes from monetary funds and accounts receivable. In order to control the above-mentioned related risks, the Company has taken the following measures.

(1) Monetary funds

The Company places bank deposits and other monetary funds in financial institutions with higher credit ratings, so its credit risk is lower.

(2) Receivables and contract assets

The company regularly conducts credit assessments on customers who trade on credit. Based on the credit assessment results, the Company chooses to conduct transactions with approved customers with good credit and monitors their receivable balances to ensure that the Company does not face significant bad debt risks.

Since the company's accounts receivable risk points are distributed among multiple partners and customers, as of June 30, 2026, 38.98% of the company's accounts receivable and contract assets (June 30, 2026: 18.26%) originated from the top five customers with balances, and the company does not have significant credit concentration risk.

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

The Company's maximum exposure to credit risk is the carrying value of each financial asset on the balance sheet.

(2) Liquidity risk

Liquidity risk refers to the risk of a shortage of funds when the company fulfills its obligations to settle by delivering cash or other financial assets. Liquidity risk may arise from the inability to sell financial assets at fair value as quickly as possible; or from the counterparty's inability to repay its contractual debts; or from debts that mature prematurely; or from the inability to generate expected cash flows.

In order to control this risk, the Company comprehensively uses various financing methods such as bill settlement and bank borrowing, and adopts an appropriate combination of long-term and short-term financing methods to optimize the financing structure and maintain a balance between financing continuity and flexibility. The Company has obtained bank credit lines from a number of commercial banks to meet its working capital requirements and capital expenditures.

Financial liabilities are classified by remaining maturity

Closing amount

Project

Book value Undiscounted contract amount Within 1 year 1-3 years Bank borrowings over 3 years

Accounts payable 30,769,872.42 30,769,872.42 30,769,872.42

Other payables 13,710,705.20 13,710,705.20 13,710,705.20

Subtotal 44,480,577.62 44,480,577.62 44,480,577.62

(Continued from above table)

End of last year

Project

Book value Undiscounted contract amount Within 1 year 1-3 years Bank borrowings over 3 years

Accounts payable 15,858,863.20 15,858,863.20 15,858,863.20

Other payables 30,935,912.34 30,935,912.34 30,935,912.34

Subtotal 46,794,775.54 46,794,775.54 46,794,775.54

(3) Market risk

Market risk refers to the risk that the fair value or future cash flows of financial instruments will fluctuate due to changes in market prices. Market risks mainly include interest rate risk and foreign exchange risk.

Interest rate risk

Interest rate risk refers to the risk that the fair value or future cash flows of financial instruments will fluctuate due to changes in market interest rates. Fixed-rate interest-bearing financial instruments expose the Company to fair value interest rate risk, while floating-rate interest-bearing financial instruments expose the Company to cash flow interest rate risk. The Company determines the proportion of fixed-rate and floating-rate financial instruments based on market conditions, and maintains an appropriate portfolio of financial instruments through regular review and monitoring.

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Foreign exchange risk

Foreign exchange risk refers to the risk that the fair value or future cash flows of financial instruments will fluctuate due to changes in foreign exchange rates. The Company operates in Mainland China and its main activities are denominated in RMB. Therefore, the market risk of foreign exchange changes borne by the Company is not significant.

For details of the Company’s foreign currency monetary assets and liabilities at the end of the period, please refer to Note 5 (4) 1 of this financial statement.

Hedging

(1) The company carries out hedging business for risk management

□Applicable Not applicable

(2) The company carries out qualified hedging business and applies hedging accounting

Unit: Yuan Confirmed hedged items and hedged items as well as the hedging effectiveness and hedging included in the hedging book value. Hedging accounting has a negative impact on the company's financial items.

The related book value of period instruments and the cumulative fair effect of hedged items are partly derived from the relevant impact on financial statements.

Value Hedging Adjustment Hedging Risk Type

Hedging category

Other instructions

(3) The company carries out hedging business for risk management and expects to achieve risk management objectives but does not apply hedging accounting □ Applicable  Not applicable

Financial assets

(1) Classification of transfer methods

□Applicable Not applicable

(2) Financial assets derecognized due to transfer

□Applicable Not applicable

(3) Asset transfer financial assets that continue to be involved

□Applicable Not applicable

Other instructions

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

13. Disclosure of fair value

Closing fair value of assets and liabilities measured at fair value

Unit: Yuan Ending Fair Value

Item Level 1 fair value measurement Second level fair value measurement Third level fair value measurement

total

quantity quantity quantity

1. Sustained fair value

Measurement

(1) Trading finance

10,100,000.00 27,000,000.00 37,100,000.00 production

Measured at fair value and

The changes are included in the current profit and loss 10,100,000.00 27,000,000.00 37,100,000.00 financial assets

Financial products 10,100,000.00 10,100,000.00Structured deposits 27,000,000.00 27,000,000.00 Receivables financing 8,764,689.34 8,764,689.34

(2) Other debt investments 55,819,673.98 55,819,673.98 Continue to be measured at fair value

Total assets of 10,100,000.00 91,584,363.32 101,684,363.32

2. Non-sustainable fair price

value measurement

Basis for determining the market price of continuous and non-continuous first-level fair value measurement items
Continuous and non-continuous second-level fair value measurement items, valuation techniques used and qualitative and quantitative information on important parameters

The trading financial assets measured at the second level of fair value held by the Company are net value financial products, and the Company determines their fair value based on the net value corresponding to the holding share of the relevant products on the balance sheet date.

Continuous and non-continuous third-level fair value measurement projects, valuation techniques used and qualitative and quantitative information on important parameters

The trading financial assets measured at Level 3 fair value held by the Company are bank structured deposits, which have a short remaining term and a small difference between expected income and market interest rates. The Company determines its fair value based on the estimated recoverable amount based on its initial recognition cost.

The third-level fair value measurement receivable financing held by the Company is bank acceptance bill receivable, which has low credit risk and short remaining period. The Company determines its fair value based on its face balance.

Other debt investments held by the Company that are measured at Level 3 fair value are bank negotiable certificates of deposit. The Company estimates future cash flows based on expected yields and discounts them to determine their fair value.

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Continuous third-level fair value measurement items, reconciliation information between the opening and closing book values and sensitivity analysis of unobservable parameters
For ongoing fair value measurement items, if there is a conversion between various levels during the current period, the reasons for the conversion and the policy for determining the time of conversion
Valuation technology changes that occurred during the current period and reasons for the changes
Fair value of financial assets and financial liabilities not measured at fair value
Others

14. Related parties and related transactions

Information about the parent company of this enterprise

Parent company to this enterprise Parent company to this enterprise Parent company name Place of registration Nature of business Registered capital

The proportion of shareholding and the proportion of voting rights. Explanation of the parent company of the enterprise.

The ultimate controlling party of this enterprise is.

Other notes:

The actual controller of the company

The actual controllers of the company are Ye Dalin and Ni Weiju. Ye Dalin directly holds 37.73% of the company's shares, and Ni Weiju directly holds 15.18% of the company's shares; at the same time, Ye Dalin indirectly holds 1.16% of the company's shares through Qingdao Gaode Equity Investment Management Partnership (Limited Partnership), which he actually controls. Ye Dalin and Ni Weiju hold a total of 54.07% of the company's shares directly and indirectly.

Information about the company’s subsidiaries

For details of the company's subsidiaries, please refer to Note 7.

Information on joint ventures and associated enterprises of the enterprise

For details of the company's important joint ventures or associates, please refer to Note 7.

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

The situation of other joint ventures or associates that have related party transactions with the company in the current period, or related party transactions with the company in previous periods that resulted in balances is as follows:

Name of joint venture or associated enterprise Relationship with this enterprise

Hongzhong Baide Company Associates

Other instructions

Other related parties

Names of other related parties Relationship between other related parties and the company

Other instructions

Related transactions

(1) Related transactions related to the purchase and sale of goods, provision and receipt of services

Procurement of goods/service acceptance form

Unit: Yuan Whether it exceeds the transaction amount

Related parties Related party transaction content Amount incurred in the current period Approved transaction quota Amount incurred in the previous period

Microbial detection technology

Hongzhong Baide Company 2,101,602.93 No

Series products

List of goods sold/services provided

Unit: Yuan Related party Contents of related transactions Amount incurred in the current period Amount incurred in the previous period

Hongzhong Baide Company Microbial Detection Technology Series Products 25,663.72 124,851.34 Description of related transactions for purchasing and selling goods, providing and receiving services

(2) Related entrusted management/contracting and entrusted management/outsourcing situation

The company's entrusted management/contracting status table:

Unit: yuan trusteeship income/contract entrusted party/contractor confirmed in the current period trustee/contractor entrusted/contracting capital entrusted/contracted from entrusted/contracted end

Package revenue pricing is based on managed revenue/contractor name party name product type start date end date

According to the income-related custody/contracting situation

The company’s entrusted management/outsourcing status table:

Unit: Yuan Client/outsourcing Trustee/contracting Entrustment/outsourcing capital Starting from entrustment/outsourcing End of entrustment/outsourcing Custody fee/outsourcing Name of the entrusting party confirmed in this period Name of the party Type of product Start date Ending date Fee pricing basis Management fee/outsourcing fee Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Description of association management/outsourcing situation

(3) Related leasing situation

As a lessor, our company:

Unit: Yuan Name of the lessee Type of leased assets Lease income recognized in the current period Lease income recognized in the previous period The company, as the lessee:

Unit: Yuan Short-term simplified treatment not included in lease liabilities

Leases and low-value assets Variable leases measured Lease liabilities assumed Increased rent paid for right-of-use assets

Lessor Lease asset Rental payment (if appropriate) Interest expense Asset

Name Product Category Use (if applicable)

Issued in this period Issued in the previous period Issued in this period Issued in the previous period Issued in this period Issued in the previous period Issued in this period Issued in the previous period Issued in this period

(4) Related guarantees

The company acts as a guarantor

Unit: Yuan guarantee has been fulfilled by the guaranteed party. Guarantee amount. Guarantee start date. Guarantee expiry date.

Complete

The company as the guaranteed party

Unit: Yuan guarantee has been fulfilled by the guarantor. Guarantee amount. Guarantee starting date. Guarantee expiry date.

Complete

Description of related guarantees

(5) Fund lending from related parties

Unit: Yuan Related Party Lending Amount Start Date Maturity Date Description

dismantle

take out

(6) Asset transfer and debt restructuring of related parties

Unit: Yuan Related party Contents of related transactions Amount incurred in the current period Amount incurred in the previous period

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

(7) Remuneration of key management personnel

Unit: Yuan Item Amount of the current period Amount of the previous period

Remuneration of key management personnel 1,567,048.46 2,169,240.56 (8) Other related transactions

Accounts receivable and payable from related parties

(1) Items receivable

Unit: Yuan Ending balance Beginning balance

Project name Related parties

Book balance Bad debt provision Book balance Bad debt provision advance payment Hongzhong Baide Company 59,477.88

(2) Items payable

Unit: yuan Project name Related parties Book balance at the end of the period Book balance at the beginning of the period Accounts payable Hongzhong Baide Company 395,717.98

Related party commitments
Others

15. Share-based payment

Overall situation of share-based payment

Applicable □Not applicable

Unit: Yuan Grant object Granted in this period Exercise in this period Unlocked in this period Expiration category in this period Quantity Amount Quantity Amount Quantity Amount Quantity Amount Stock options or other equity instruments outstanding at the end of the period

Applicable □Not applicable

Category of grant objects Stock options outstanding at the end of the period Other equity instruments outstanding at the end of the period Full text of the 2026 Semi-annual Report of Zhejiang Tailin Biotechnology Co., Ltd.

Range of exercise price Remaining term of the contract Range of exercise price Remaining term of the contract Management personnel 9.25 yuan/share R&D personnel for 4, 16, and 28 months 9.25 yuan/share Sales personnel for 4, 16, and 28 months 9.25 yuan/share Production and manufacturing personnel for 4, 16, and 28 months 9.25 yuan/share Other instructions for 4, 16, and 28 months

On March 27, 2025, the company's first extraordinary shareholders' meeting in 2025 reviewed and approved the "Proposal on the Company's 2025 Employee Stock Ownership Plan Management Measures". The number of participants in this employee stock ownership plan did not exceed 117, and 1.208 million shares were actually subscribed. The price per share was 9.25 yuan, and the total subscription funds were 11.174 million yuan.

The 2025 Employee Stock Ownership Plan will be granted to senior managers, core technical personnel and key employees. The restricted stocks granted will be unlocked in three phases after 12 months from the date when the last underlying stock is transferred to the name of this Employee Stock Ownership Plan. The proportion of unlocked shares is 40%, 30% and 30% respectively. The conditions for lifting sales restrictions include company performance indicators and individual performance appraisals of incentive targets. Specific performance indicators are as follows:

Lifting the restricted sales period and performance appraisal targets

In the first phase, taking 2024 as the base, the operating income growth rate or net profit growth rate in 2025 will not be less than 10%.

In the second phase, taking 2024 as the base, the operating income growth rate or net profit growth rate in 2026 will not be less than 20%

In the third phase, taking 2024 as the base, the operating income growth rate or net profit growth rate in 2027 will not be less than 30%.

Equity-settled share-based payment

Applicable □Not applicable

Unit: Yuan Important parameters of fair value of equity instruments on grant date Closing price of A shares on grant date

Basis for determining the number of exercisable equity instruments Actual number granted

Reasons for significant differences between the current period’s estimates and the previous period’s estimates Not applicable

The cumulative amount of equity-settled share-based payment included in capital reserves 1,905,519.20 Total expenses recognized for equity-settled share-based payment in the current period 1,905,519.20 Other notes

In accordance with the relevant provisions of share-based payment in the Accounting Standards for Business Enterprises, the company will account for the above-mentioned share-based payment as equity-settled share-based payment. On each balance sheet date during the waiting period, based on the best estimate of the number of exercisable equity instruments and the fair value of the granted equity instruments on the grant date, the services obtained will be included in the corresponding costs and expenses according to the beneficiary objects, and the capital reserve (other capital reserve) will be increased at the same time. As of June 30, 2026 As of the date of the announcement, a total of RMB 1,905,519.20 of share-based payment expenses have been confirmed.

Share-based payment settled in cash

□Applicable Not applicable

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Share-based payment expenses for this period

Applicable □Not applicable

Unit: Yuan

Category of grant objects Equity-settled share-based payment expenses Cash-settled share-based payment expenses Management personnel 751,113.18 R&D personnel 451,325.94 Sales personnel 382,523.56 Manufacturing personnel 320,556.52

Total 1,905,519.20Other instructions

Modification and termination of share-based payment
Others

16. Commitments and contingencies

Important commitments

Important commitments existing at the balance sheet date

As of June 30, 2026, the balance of the performance guarantee that the company applied to the bank for issuance is still within the validity period is 1,506,610.00 yuan, and the balance of the advance payment guarantee is 2,238,050.00 yuan.

Contingent matters

(1) Important contingencies existing on the balance sheet date

As of June 30, 2026, the company has no major contingencies that need to be disclosed.

(2) If the company has no important contingencies that need to be disclosed, this should also be explained.

The company has no important contingencies that need to be disclosed.

Others

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

17. Events after the balance sheet date

Important non-adjustment matters

Unit: Yuan Impact on financial condition and results of operations

Item Contents Reasons why the impact cannot be estimated

number of rings

Profit distribution

According to the resolution of the 16th meeting of the fourth session of the Board of Directors on August 26, 2026, the company plans to use the total share capital on the equity registration date as the basis for the profit distribution plan to all

Shareholders will receive a cash dividend of 1 yuan (tax included) for every 10 shares. The above dividend plan is yet to be reviewed and approved by the second extraordinary shareholders' meeting in 2026.

Sales return
Description of other post-balance sheet events

The company held the 15th meeting of the fourth session of the board of directors on August 14, 2026, and reviewed and approved the "Proposal on Terminating the Issuance of Convertible Corporate Bonds to Unspecified Objects and Withdrawing the Application Documents", and agreed that the company would terminate the issuance of convertible corporate bonds to unspecified objects and apply to the Shenzhen Stock Exchange to withdraw the relevant application documents.

18. Other important matters

Correction of accounting errors in the previous period

(1) Retrospective restatement method

Unit: Yuan Report for each affected comparison period

Contents of accounting error correction Processing procedures Cumulative impact number

Project name

(2) Prospective applicable law

Contents of correction of accounting errors Approval process Reasons for adopting prospective application

Debt restructuring

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Asset replacement

(1) Non-monetary asset exchange

(2) Other asset swaps

Annuity plan
Termination of operations

Unit: Yuan Items attributable to the parent company Revenue Expenses Total profit Income tax expense Net profit Owner’s profit from discontinued operations Other instructions

Branch information

(1) Determination basis and accounting policies of reporting segments

(2) Financial information of reporting segments

Unit: Yuan Item Inter-segment elimination Total

(3) If the company has no reportable segments, or cannot disclose the total assets and total liabilities of each reportable segment, the reasons should be explained.

(4) Other instructions

The company's main business is the production and sales of pharmaceutical special equipment. The company regards this business as a whole to implement management and evaluate operating results. Therefore, the Company is not required to disclose segment information. For detailed information on the company's revenue breakdown, please refer to Note 5 (2) 1 of this financial statement.

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Other important transactions and matters that have an impact on investors’ decision-making
Others

19. Notes on main items of the parent company’s financial statements

Accounts receivable

(1) Disclosure based on aging

Unit: Yuan

Aging Book balance at the end of the period Book balance at the beginning of the period

Within 1 year (including 1 year) 645,200.00 277,286.73 1 to 2 years 1,350,049.49 2 to 3 years 1,143,949.49 476,510.00 More than 3 years 2,275,259.42 2,318,549.42 3 to 4 years 255,010.00 933,691.62 4 to 5 years 1,447,293.62 706,202.00

More than 5 years 572,955.80 678,655.80 Total 4,064,408.91 4,422,395.64

(2) Classified disclosure according to bad debt accrual method

Unit: Yuan Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book price Book price provision ratio Provision ratio

Amount Ratio Amount Value Amount Ratio Amount Value

Example Example

By item

bad provision

500,000 500,000 500,000 500,000

Account provision 12.30% 100.00% 11.31% 100.00%

.00 .00 .00 .00

receivables

Accounts

its

Medium:

by combination

bad provision

3,564,4 1,274,1 2,290,2 3,922,3 1,196,0 2,726,3 Account provision 87.70% 35.75% 88.69% 30.49%

08.91 55.51 53.40 95.64 35.58 60.06 receivables

Accounts

its

Medium:

Total 4,064,4 100.00% 1,774,1 43.65% 2,290,2 4,422,3 100.00% 1,696,0 38.35% 2,726,3 Full text of the 2026 Semi-annual Report of Zhejiang Tailin Biotechnology Co., Ltd.

08.91 55.51 53.40 95.64 35.58 60.06 Category name of bad debt provision for individual items: Bad debt provision for individual items

Unit: Yuan Beginning balance Ending balance

Name

Book balance Bad debt provision Book balance Bad debt provision Provision ratio Reason for provision Beijing Xuanzhu Kangming

The company went bankrupt and Biotechnology Co., Ltd. 280,000.00 280,000.00 280,000.00 280,000.00 100.00%

Enter a clearing company

Hunan Sanqing Pharmaceutical Company went bankrupt and has

220,000.00 220,000.00 220,000.00 220,000.00 100.00%

Co., Ltd. Total liquidation 500,000.00 500,000.00 500,000.00 500,000.00

Category name of provision for bad debts by combination: Aging combination

Unit: Yuan ending balance

Name

Book balance Bad debt provision Provision ratio

Within 1 year 645,200.00 32,260.00 5.00% 1-2 years

2-3 years 1,143,949.49 228,789.90 20.00% 3-4 years 255,010.00 76,503.00 30.00% 4-5 years 1,167,293.62 583,646.81 50.00% More than 5 years 352,955.80 352,955.80 100.00% Total 3,564,408.91 1,274,155.51

Description of what this combination is based on:

If bad debt provisions for accounts receivable are made according to the general expected credit loss model:

□Applicable Not applicable

(3) Bad debt provisions accrued, recovered or reversed in the current period

Bad debt provisions for the current period:

Unit: Yuan Amount of changes in the current period

Category Beginning Balance Ending Balance

Provision Recovery or transfer Write-off Others

Single provision for bad debts

500,000.00 500,000.00Preparation

Bad provision based on combination

1,196,035.58 78,119.93 1,274,155.51 Account preparation

Total 1,696,035.58 78,119.93 1,774,155.51 Among them, the amount of bad debt provision recovery or reversal in the current period is important:

sex

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

(4) Accounts receivable actually written off in the current period

Unit: Yuan

Item Write-off Amount

Important write-offs of accounts receivable:

Unit: Yuan Whether the amount is paid by the name of the related unit Nature of accounts receivable Amount of write-off Reason for write-off The write-off procedures performed

Instructions for writing off accounts receivable arising from transactions:

(5) Accounts receivable and contract assets with the top five closing balances collected by debtors

Unit: Yuan accounts receivable and combined accounts receivable, bad debts, quasi-accounts receivable, ending balance, contract assets, ending balance, accounts receivable and contracts

Unit name Closing balance of same assets Provision and contract asset reduction amount Closing balance of assets

Proportion of total amount Value provision closing balance Unit one 550,000.00 550,000.00 11.91% 441,335.00 Unit two 495,200.00 495,200.00 10.72% 99,040.00 Unit three 162,800.00 301,800.00 464,600.00 10.06% 23,230.00 Unit four 344,000.00 52,000.00 396,000.00 8.58% 19,800.00 Unit five 280,000.00 280,000.00 6.06% 280,000.00 Total 1,832,000.00 353,800.00 2,185,800.00 47.33% 863,405.00

Other receivables

Unit: Yuan

Item Ending balance Beginning balance

Other receivables 2,422,634.44 3,216,862.63 Total 2,422,634.44 3,216,862.63

(1) Interest receivable

Classification of interest receivable

Unit: Yuan

Item Ending balance Beginning balance

Important overdue interest

Unit: Yuan Whether impairment occurs and the borrowing unit is judged. Ending balance Overdue time Reason for overdue

Determine based on other instructions:

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Classified disclosure according to bad debt accrual method

□Applicable Not applicable

Bad debt provisions accrued, recovered or reversed in the current period

Unit: Yuan Amount of changes in the current period

Category Opening balance Ending balance Provision Recovery or reversal Write-off or write-off Other changes

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

Other notes:

Interest receivable actually written off in the current period

Unit: yuan item write-off amount

Among them, the important write-off of interest receivable

Unit: Whether the yuan amount is paid by the name of the related unit, nature of the amount, write-off amount, write-off reason, write-off procedures performed

transaction generated

Write-off instructions:

Other notes:

(2) Dividends receivable

Classification of dividends receivable

Unit: yuan project (or invested unit) Ending balance Beginning balance

Important dividends receivable aged more than 1 year

Unit: Yuan Whether impairment occurs and the judgment item (or invested unit) Closing balance Aging Reason for non-recovery

Judgment basis

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Classified disclosure according to bad debt accrual method

□Applicable Not applicable

Bad debt provisions accrued, recovered or reversed in the current period

Unit: Yuan Amount of changes in the current period

Category Opening balance Ending balance Provision Recovery or reversal Write-off or write-off Other changes

Among them, the amount of recovery or reversal of bad debt provisions for the current period is important:

Other notes:

Dividends receivable actually written off in the current period

Unit: yuan item write-off amount

Among them, the important write-off of dividends receivable

Unit: Whether the yuan amount is paid by the name of the related unit, nature of the amount, write-off amount, write-off reason, write-off procedures performed

transaction generated

Write-off instructions:

Other notes:

(3) Other receivables

Classification of other receivables according to nature of payment

Unit: yuan Nature of payment Ending book balance Beginning book balance

Current accounts 2,154,616.87 2,999,457.36 Deposit and security deposit 179,500.00 495,400.00 Temporary payment receivable 425,891.49 122,573.06 Total 2,760,008.36 3,617,430.42

Disclosure based on aging

Unit: Yuan Zhejiang Tailin Biotechnology Co., Ltd. Full text of 2026 semi-annual report

Aging Book balance at the end of the period Book balance at the beginning of the period

Within 1 year (including 1 year) 839,618.36 3,117,305.10 1 to 2 years 1,511,650.00 14,225.32 2 to 3 years 330,640.00

More than 3 years 78,100.00 485,900.00 3 to 4 years 346,600.00

More than 5 years 78,100.00 139,300.00 Total 2,760,008.36 3,617,430.42

Classified disclosure according to bad debt accrual method

Unit: Yuan Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book price Book price provision ratio Provision ratio

Amount Ratio Amount Value Amount Ratio Amount Value

Example Example

Among them:

by combination

2,760,0 337,373 2,422,6 3,617,4 400,567 3,216,8 Bad provision 100.00% 12.22% 100.00% 11.07%

08.36 .92 34.44 30.42 .79 62.63Account preparation

Among them:

2,760,0 337,373 2,422,6 3,617,4 400,567 3,216,8Total 100.00% 12.22% 100.00% 11.07%

08.36 .92 34.44 30.42 .79 62.63 Name of bad debt provision category by combination: Aging combination

Unit: Yuan ending balance

Name

Book balance Bad debt provision Provision ratio

Within 1 year 839,618.36 41,980.92 5.00% 1-2 years 1,511,650.00 151,165.00 10.00% 2-3 years 330,640.00 66,128.00 20.00% 3-4 years 30.00% 4-5 years 50.00% More than 5 years 78,100.00 78,100.00 100.00% Total 2,760,008.36 337,373.92

Description of what this combination is based on:

Provision for bad debts is made based on the general expected credit loss model:

Unit: Yuan Phase 1 Phase 2 Phase 3

Expected credit throughout the lifetime Credit expected throughout the lifetime

Provision for bad debts Expected credit in the next 12 months Total

Loss (no credit deduction has occurred Loss (credit deduction has occurred)

loss

value) value)

Balance on January 1, 2026 155,865.26 1,422.53 243,280.00 400,567.79 Balance on January 1, 2026

In this issue

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

——Transfer to the second stage -75,582.50 75,582.50

——Transfer to the third stage -16,532.00 16,532.00

Provision for the current period -38,301.84 90,691.97 -115,284.00 -62,893.87 Write-off for the current period 300.00 300.00 Remainder of June 30, 2026

41,980.92 151,165.00 144,228.00 337,373.92 amount

Basis for division of each stage and provision ratio for bad debts

Changes in book balances with significant changes in loss provision during the current period

□Applicable Not applicable

Bad debt provisions accrued, recovered or reversed in the current period

Bad debt provisions for the current period:

Unit: Yuan Amount of changes in the current period

Category Opening balance Ending balance Provision Recovery or reversal Write-off or write-off Others

Among them, the amount of bad debt provision for the current period that is reversed or recovered is important:

Other receivables actually written off in the current period

Unit: yuan item write-off amount

Important write-offs of other receivables:

Unit: Whether the Yuan amount is paid by the related unit. Nature of other receivables. Write-off amount. Reason for write-off. Write-off procedures performed.

transaction generated

Instructions for writing off other receivables:

Other receivables with the top five closing balances based on debtors

Unit: Yuan Unit name Nature of payment Closing balance Aging Account for other receivables period Bad debt provision closing balance Zhejiang Tailin Biotechnology Co., Ltd. 2026 Semi-annual Report Full text

Amount of total closing balance

Proportion

Medical equipment Current accounts 2,127,947.11 Within 2 years 77.10% 218,897.36 Withheld and paid to employees for five years

Temporary payment receivable 256,605.20 Within 1 year 9.30% 12,830.26 Insurance and one fund

Zhejiang Provincial Food and Drug Administration

Deposit security deposit 78,400.00 2-3 years 2.84% 15,680.00 Inspection Institute

Chongqing Tiandi Pharmaceutical Co., Ltd.

Deposit security deposit 33,000.00 More than 5 years 1.20% 33,000.00 Limited liability company

Life sciences Current accounts 26,268.67 Within 1 year 0.95% 1,313.43

Total 2,522,220.98 91.39% 281,721.05

Presented in other receivables due to centralized management of funds

Unit: Yuan Other instructions:

Long-term equity investment

Unit: Yuan

Ending balance Beginning balance

Project

Book balance Impairment provision Book value Book balance Impairment provision Book value 424,426,309. 424,426,309. 419,811,823. 419,811,823. Investment in subsidiaries

36 36 52 52 424,426,309. 424,426,309. 419,811,823. 419,811,823.Total

36 36 52 52

(1) Investment in subsidiaries

Unit: Yuan Beginning balance Increase or decrease in the current period Ending balance

Invested party Impairment provision Impairment provision (book price Impairment provision (book price

Position Opening balance Additional investment Decrease investment Others Closing balance value) Reserve value)

54,854,00 635,698.8 55,489,70

life sciences

8.54 3 7.37

7,939,222 3,146,699 11,085,92

Analytical instruments

.54 .64 2.18

226,249,5 635,698.9 226,885,2

Medical Engineering

95.13 9 94.12

10,569,03 116,728.8 10,685,76

science and technology

8.87 6 7.73

10,078,45 10,079,24

Medical devices 788.71

9.36 8.07

Tailin New Materials 110,121,4 110,200,3

78,870.81

Material 99.08 69.89

419,811,8 4,614,485 424,426,3

total

23.52 .84 09.36

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

(2) Investment in associates and joint ventures

Unit: Yuan

Increases and decreases in the current period

Beginning of period Equity declaration End of period

Impairment Impairment Balance Other Disbursement Balance Investment Provision Other Disbursement Provision (Account Addition Decrease Confirmation Comprehensive Cash (Billing Unit Beginning Equity Impairment Others Ending Face Price Investment Income from Investment Dividend Face Price

Balance Change Provision Balance Value) Capital Loss Adjustment or Profit Value)

profit

1. Joint ventures

2. Joint ventures

The recoverable amount is determined as the net amount after fair value minus disposal costs.

□Applicable Not applicable

The recoverable amount is determined based on the present value of expected future cash flows.

□Applicable Not applicable

Reasons for the obvious inconsistency between the aforementioned information and the information used in impairment testing in previous years or external information

Reasons for the discrepancy between the information used in the company's impairment testing in previous years and the actual situation of that year.

(3) Other instructions

Operating income and operating costs

Unit: Yuan

Amount for the current period Amount for the previous period

Project

Revenue Cost Revenue Cost Main business 1,858,909.91 1,710,619.46 252,848.17 294,593.67 Other business 3,452,488.27 228,173.99 4,073,268.19 143,950.26Total 5,311,398.18 1,938,793.45 4,326,116.36 438,543.93 Decomposition information of operating income and operating costs:

Unit: Yuan

Segment 1 Segment 2 Number for the current period Number for the same period last year Total contract points

Operating income Operating income Operating income Operating income Operating income Operating income Operating income Operating income Operating income Operating income Category

Enter this business enter this business category

Type

Among them:

Aseptic

1,858,9 1,710,6 252,848 294,593

Product and pollution

09.91 19.46 .17 .67

dye control

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

Equipment series products

172,600 76,327. 196,394 4,751.2 Others

.88 43 .42 1Classification by business area

its

Medium:

2,031,5 1,786,9 449,242 299,344Domestic

10.79 46.89 .59 .88Market or customer type

its

Medium:

Contract type

its

Medium:

Classification by time of transfer of goods

its

Medium:

in a certain

2,031,5 1,786,9 449,242 299,344 Point-in-time

10.79 46.89 .59 .88 Recognized income classified by contract period

its

Medium:

Classified by sales channel

its

Medium:

total

Information related to performance obligations:

The company's pre-payment, the quality provided by the company, and its performance obligations. Important payment terms. The company's commitment to transfer whether it is the main responsibility item. The type and time of the quantity guarantee will be returned to the customer. The nature of the goods. Who will be responsible?

account’s monies and related obligations

Other instructions: Full text of Zhejiang Tailin Biotechnology Co., Ltd.'s 2026 semi-annual report

Information related to the transaction price allocated to the remaining performance obligations:

Major contract changes or major transaction price adjustments

Unit: Yuan

Item Accounting treatment method Amount of impact on income

Other notes:

Investment income

Unit: Yuan

Item Amount for the current period Amount for the previous period

Investment income from disposal of long-term equity investments -2,714,606.40 Income from financial products 249,783.78

Dividends from subsidiaries 40,000,000.00

Total 40,249,783.78 -2,714,606.40

Others

R&D expenses

Item Number for the current period Number for the same period last year Employee compensation 381,738.30 517,816.61 Technical service fee 8,555.05 13,733.59 Depreciation fee 9,301.17

Others 7,820.50

Total 399,594.52 539,370.70

20. Supplementary information

Detailed statement of non-recurring profits and losses for the current period

Applicable □Not applicable

Unit: Yuan

Item Amount Description

Profit and loss from disposal of non-current assets -176,221.92

Government subsidies included in current profits and losses (related to the company’s regular

1,672,089.34

Closely related to regular business operations and in compliance with national policies

Full text of the 2026 semi-annual report of Zhejiang Tailin Biotechnology Co., Ltd.

stipulates, enjoys according to determined standards, and treats the company

Except for government subsidies that have a lasting impact on profits and losses)

Gains and losses from entrusting others to invest or manage assets 961,433.11 Other non-operating income and

-86,601.41

expenditure

Less: Income tax impact 249,911.30

Total 2,120,787.82 --Details of other profit and loss items that meet the definition of non-recurring profits and losses:

□Applicable Not applicable

The company has no other specific circumstances of profit and loss items that meet the definition of non-recurring profits and losses.

□Applicable Not applicable

Return on net assets and earnings per share

Earnings per share Profit for the reporting period Weighted average return on equity

Basic earnings per share (yuan/share) Diluted earnings per share (yuan/share) Net attributable to the company’s ordinary shareholders

2.53% 0.17 0.17Profit

After deducting non-recurring gains and losses, attributable to

2.27% 0.15 0.15 Net profit of the company’s ordinary shareholders

Differences in accounting data under domestic and foreign accounting standards

(1) Differences in net profit and net assets in financial reports disclosed in accordance with both international accounting standards and Chinese accounting standards

□Applicable Not applicable

(2) Differences in net profit and net assets in financial reports disclosed in accordance with both foreign accounting standards and Chinese accounting standards

□Applicable Not applicable

(3) Explanation of the reasons for the differences in accounting data under domestic and foreign accounting standards. If differences are adjusted for data that have been audited by an overseas audit institution, the name of the overseas institution should be indicated.

□Applicable Not applicable

Others